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AML1-ETO controls Genes involved in Apoptosis, Haemopoietic Differentiation and 
Histone Modifications  
 
KIAA0125 is the most statistically significant gene and is down regulated although its 
function is unknown. It resides in the middle of the immunoglobulin heavy chain 
gene region. C9orf89 is the second most statistically significant gene and is down 
regulated in this series. The gene contains a CARD domain that inhibits BCL10-
mediated activation of NF-kappa B (Woo et al., 2004). The down regulation of this 
gene would lead to more BCL-10 related apoptosis. SerpinB9, an anti apoptosis 
gene and involved in the regulation of granzyme B, is up regulated. GABARAPL1, 
shown to increase apoptosis, has decreased expression. GFI1B is a transcriptional 
repressor that is essential for erythroid cells and megakaryocytes, but is also 
expressed in hematopoietic stem cells and early myeloid progenitors. It is usually 
up-regulated in AML but is down regulated in this series suggesting that t(8;21) does 
not necessarily need to work through this pathway to establish leukaemia (Vassen et 
al., 2009). NFE2, down regulated in t(8;21) patients, encodes for a transcription 
factor with an important role in erythroid and megakaryocyte differentiation being 
regulated by the ligase Itch (Lee et al., 2008). TBL1X is part of the SMRT complex 
and also binds Wnt target genes (Li and Wang, 2008). TRERF1 encodes a zinc-
finger transcriptional regulating protein that interacts with CBP/p300. Both these 
genes are up regulated in t(8;21) and could play a key role in the regulation of 
histone acetylation. Histone transcripts, as they lack poly-A tails, are not usually well 
represented on standard array platforms but HIST1H2BM is up regulated using the 
exon array platform thus highlighting the extra information that exon arrays provide.  
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UHRF1 & CD82 may be Key Genes Regulated by AML1-ETO 
 
UHRF1 is up regulated in many carcinomas including breast and bladder cancer and 
its expression is regulated by E2F-1. Although initially discovered through binding 
topoisomerase gene promoter it appears to have a greater affinity for methylated 
CpG islands of various promoters. It is able to recruit HDAC1, suggesting that it 
might suppress expression of tumour suppressor genes through histone 
deacetylation (Unoki et al., 2004). Furthermore, it is also able to recruit DNMT1 to 
hemimethylated sites, allowing DNA methylation. Thus, UHRF1 appears to be a key 
molecule regulating cross-talk between DNA methylation and histone modifications 
(Hashimoto et al., 2009) (Figure 24).   
 
CD82 encodes for a tetraspanin and was identified as a tumour metastasis 
suppressor gene in many types of cancer. Tetraspanins regulate migration, 
adhesion and proliferation at the cellular level. CD82 is often down regulated in 
many human malignancies but its expression has been noted to be up regulated in 
leukaemia cells. Interestingly it is down regulated in t(8;21) samples. Furthermore, 
CD82 appears to work through Rho GTPases (Liu and Zhang, 2006). CD82 can be 
activated by p53 and its expression and that of p53 are strongly correlated (Smith 
and Theodorescu, 2009) (Figure 25). 
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Figure 24 Box plot of expression signals for UHRF from t(8;21) patients in blue and NK patients in red. 
 
 
 
Figure 25 Box plot of expression signals for CD82 from t(8;21) patients in blue and NK patients in red. 
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Further Comparisons & Validation of Exon Array Data 
 
The comparison of the ABI and Human Exon expression arrays had 58% similarity 
in the gene lists generated. Some of these differences, as discussed, maybe related 
to the experimental design whilst others to non-overlapping annotation files. 
Nevertheless, the high concordance rate between the two lists appears to justify the 
use of the exon array for use in gene expression profiling.  
 
To further validate the exon array platform, gene lists generated on the exon array 
platform were compared to additional gene lists derived from similar experiments 
conducted on standard expression arrays in both primary samples and cell lines. 
Data sets from primary AML samples collected from this laboratory using the ABI 
system, Kasumi cell line data from Illumina (Kasumi I), Affymetrix U133 plus 2.0 
array (Kasumi A) and Exon array (Kasumi E) platforms and a data set from stem 
cells from Gene Expression Omnibus (Krejci) were used for comparisons with the 
exon array data (Table 14). This analysis described in detail below validates the 
platform but also suggests that investigation using the Kasumi cell line does not 
result in robust data. 
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Table 14 Summary of the comparison of the main features from gene expression experiments performed: 
Expression data derived from the ABI platform (ABI); published Krejci reference (Krejci); Kasumi cell line 
performed on Affymetrix platform (KASUMI A); Kasumi cell line performed on Illumina platform 
(KASUMI I) and Kasumi cell line on Exon array platform (KASUMI E) respectively. (see text below for 
further details) 
 
 ABI KREJCI KASUMI A KASUMI I KASUMI E 
SAMPLE Patients Stem Cells  Cell lines Cell lines Cell lines 
NUMBERS 9 vs 7 9 vs 3 1 vs 1 unknown 1 vs 1 
PLATFORM ABI Affy 3’ Affy 3’ Illumina Exon 
ANALYSIS Partek Partek Partek unknown Partek 
 
 
Using the same ABI data set and the same analysis methodology as described 
above a further analysis was performed to more closely mimic the exon array 
experiment. The previously identified 9 t(8;21) primary samples were compared to 7 
M2 normal karyotype primary samples from this data set. This generated only 46 
differentially expressed probesets of which 46% (21) were up regulated and 54% 
(25) were down regulated. Only 33 probesets were annotated making meaningful 
comparison difficult. However, comparison with the exon data (223 genes) showed 
19 (58%) concordant genes. Of specific interest, a total of 12 HOX genes were 
present in the exon array data set of which 4 HOX genes were also present in the 
ABI gene list. A further 2 HOX genes were present in the ABI data set alone. 
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Data sets from the gene expression publication by Krejci (Krejci et al., 2008) were 
obtained from the Gene Expression Omnibus. In this study an AML1-ETO vector 
was introduced into stem cells and the expression profiles compared to control stem 
cells with mock transfections. A total of 9 sets of CD34+ cells treated with AML1-
ETO vector and 3 controls were obtained. The .cel files were imported into the 
Partek software and gene lists were constructed using a FDR of p <0.05 and fold 
change +2 to -2. 5638 probesets passed the above criteria. Of these 2047 (36%) 
were up-regulated and 3591 (64%) were down regulated. Of the 5638 probesets, 
4532 had annotations. Comparison with exon data (229 probesets and 223 genes) 
showed 120 probesets representing 90 (40%) genes were concordant. 
Expression profiling of Kasumi cell line correlates poorly with primary samples 
 
Kasumi Cell line data was available form three sources; previously published gene 
expression profiling data from our laboratory using the Illumina platform (Dunne et 
al., 2006); previously performed standard 3’ Affymetrix profiling from this laboratory 
by J. Dunne (unpublished) and finally Kasumi cell line experiments performed by the 
author on the exon array platform. In all these experiments Kasumi cells had the 
AML1-ETO gene knocked down with si-RNA and were compared to Kasumi cell with 
mock transfection (Table 15). [All knockdown experiments were performed by J. 
Dunne]  
 
The published gene list generated from Illumina platform data was used for 
comparison (Dunne et al., 2006). Data from the Illumina platform generated 294 
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probesets of which 133 were up regulated and 161 down regulated. Of the 294 
probesets 223 genes were annotated. Comparison with the patient exon data 
showed that 29 (12%) genes were present in both lists.  
 
Gene lists from the Affymetrix data were generated using Partek with parameters of 
p<0.05 and FC +/-2. This experiment generated a 125 probesets of which 52 (42%) 
were up regulated and 73 (58%) down regulated. Of the 125 probesets, 122 had 
annotations. Comparison to the patient exon data showed that 14 (11%) genes were 
present in both data sets.  
 
Data from the exon arrays for the Kasumi experiments using a FC criteria of +/- 2 
and p <0.05 revealed 103 probesets differentially expressed with 67 down regulated 
and 36 up-regulated. Comparison of this Kasumi exon data to the patient exon data 
demonstrated only one common gene. 
 
The expression analysis from Kasumi cell line studies appears to be poorly 
reproducible. They do not appear to correlate well with primary samples results. 
However the number of replicates performed was limited and care needs to be taken 
with this interpretation.  
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Table 15 Summary of Comparisons between Exon Array and other experiments. Experiments:  Exon1 – exon 
array with Fold Change +/-1; Exon 2 exon array with Fold Change+/-2; Kas A – Kasumi cell line using 
Affymetrix platform; Kas I- Kasumi cell line using Illumina platform; Kas E- Kasumi cell line using exon 
array platform.  
 
 PROBESETS 
(PS) 
UP 
REGULATED PS 
DOWN 
REGULATED PS 
GENES CONCORD
-ANCE 
Exon 1 448 234 214 436 N/A 
Exon 2 229 113 116 223 N/A 
ABI 46 21 25 33 59% 
Krejci 5638 2047 3591 4532 40% 
Kas A 125 52 73 122 11% 
Kas I 294 133 161 223  12% 
Kas E 103 36 67 101 1% 
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Experimental Validation 
 
RQ-PCR correlates with expression results 
 
RQ-PCR on 8 genes was performed to experimentally validate the array profiles 
(See Chapter 2 p63). RNA from all primary t(8;21) and four NK samples were tested. 
(Figure 26) 
 
 
 
Figure 26 A representative sample of RQ PCR. Amplification of the BRN3a gene. The Kasumi cell line and 
Molt4 cell lines are used as positive and negative controls. Ten t(8;21) and four normal karyotpe (NK) 
patients have been tested. Tested samples have been plotted on the x-axis. The delta delta Ct relative to 18S 
relative to Kasumi is plotted on the y-axis. Experiments were tested in triplicate. Error bars are shown. 
Further details on methodology as described as in chapter 2 p63. 
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Values were compared to expression data values (Chapter 2 p63). Seven of the 
eight genes had a statistically significant correlation (p<0.05) and validated our 
experiment (Table 16).  
 
Table 16 Correlation of RQ with expression for 8 genes.  
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Gene Ontology Functional Analysis 
 
For a global assessment of the generated gene list, gene ontology functional 
analysis, using three sources of commercial software, GeneGo Inc., Ingenuity 
Pathway Analysis (IPA) from Ingenuity SystemsTM and Gene Ontology (GO) was 
performed by collaborator P Chakraverty.  
 
Using the IPA software, 448 genes derived from the exon array were interrogated for 
enrichment for processes. The top process was “cellular growth and proliferation” 
which validated this type of approach to interrogate our gene list (Table 17).  
 
Table 17 Top process generated by IPA showing the network members and p value. 
 
Process p-value Network members 
Cellular Growth and 
Proliferation 
1.32E-05 TPM1, TRH, RECK, MBP, TBXA2R, 
ELA2, MEIS1, PALM, HOXA9, DEF6, 
VEGFA, ELF4, TGFB1, CAV1, ITGB4, 
TSPAN32, TNFRSF21, LST1, FGFR1, 
MPO, GFI1B, RUNX1T1, HSPG2 
(includes EG:3339), NFE2, PRKCD, 
RCBTB1, CAT, VAV1, ITGAX 
 
 
Further detailed functional data mining was performed using the GeneGo software. 
The same gene list consisting of 448 genes was tested for enrichment of canonical 
pathways (Table 18) and processes (Table 19) using the GeneGo metacore tool.  
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Table 18 Enriched Pathways using GeneGO 
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G-Protein coupled receptors & cell adhesion pathways are enriched 
 
Table 14 suggests there are two groups of molecules: those related to pathways 
through the use of G-protein coupled receptors and G-protein intermediaries 
including via beta-arrestins, EDG and MAPK pathways; and those involved in cell 
adhesion and cytoskeleton remodelling, including through WNT and TGFb pathways 
 
Beta-arrestin-1 and beta-arrestin-2 act as scaffolds linking GPCR to a variety of 
signalling cascades. It was initially shown the beta2 adrenegic receptor induced 
activation of MAPK’s through an Src/beta-arrestin complex. Subsequently other 
pathways requiring beta-arrestins for activation were identified and included the 
small GTPase RhoA, Ral GDP dissociation factor and the actin filament severing 
protein cofilin (Defea, 2008). EDG3, EDG5 and EDNRA are all G-protein coupled 
receptors (GPCR). EDG3 and EDG5 can regulate the activity of the Rho family 
GTPase Rac (Takuwa, 2002). 
 
TGFb and the WNT pathways have been established to play a role in t(8;21) 
leukaemia; AML1 interacts with SMAD proteins and TGFb and AML1-ETO interacts 
with plakoglobin inducing the Wnt pathways (Pardali et al., 2000) (Muller-Tidow et 
al., 2004). The canonical Wnt pathways control the stability of b-catenin. Recent 
evidence shows evidence of Rho GTPase mediating in both the canonical and non-
canonical Wnt pathways (Schlessinger et al., 2009). Similarly, non-Smad pathways, 
including the Rho-like GTPase signalling pathways, have also been implicated in 
TGFb signalling (Zhang, 2009). 
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Signal transduction & cell adhesion processes are enriched 
 
The top two enriched processes identified by GeneGo are “cell adhesion” which is 
up regulated and “signal transduction” which is down regulated (Table 19). Network 
members involved in cell adhesion are displayed in Figure 27. (drawn by P 
Chakreverty using the GeneGo software) 
 
Table 19 Top 2 processes using GeneGo and their network members 
 
Cell Adhesion Molecules,  
integrin mediated cell-matrix adhesion  
(p-value 3.15E-06; network objects 21/210) 
Signal Transduction (TGF beta & 
activin signalling)  
(p-value 6.31E-05; network objects 15/146) 
Beta-catenin C/EBPalpha 
CD82 Cyclin D1 
CAV-1 DOK1 
CAV-2 Integrin 
Collagen IV MEK6 
Cyclin D1 Mixl1 
Filamin B (TABP) PKC 
Galectin-1 PLC-2 
ITGA9 PLC-beta2 
ITGB4 PLC-beta3 
ITGB7 SMAD3 
Leupaxin Sno-N 
PI4-kinase TGF-beta 
PI4Kalpha VAV-1 
PLC-gamma KIT 
PLC gamma1  
TRIO  
Tetraspanin  
VAV-1  
Integrin  
Chapter 3  Results Exon Arrays 
 138 
Figure 27 Interactions for molecules related to cell adhesion. Nodes in list are circled 
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G-Protein signal transduction pathways are enriched 
 
To confirm the findings using the GeneGo software, a further functional data mining 
analysis was performed using the Gene Ontology (GO) software. The GO software 
is a multi-level hierarchy categorising functions into biological function, molecular 
process and cellular location. There was enrichment of genes involved in regulation 
of signal transduction. The top two enriched subgroups were noted to involve genes 
related to GTP protein signal transduction pathways thus, confirming the analysis 
using the GeneGO metacore tool. The genes involved in these subgroups and their 
interactions are demonstrated in Figure 28 (drawn by P. Chakraverty using the 
GeneGo software). These findings confirm the implications that G-protein coupled 
receptors play a key role t(8;21) leukaemogenesis. This observation may have 
implications in finding novel treatment targets and strategies. 
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Figure 28 Interactions of molecules associated with G-proteins. Nodes in list are circled 
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Further Exon Array Analysis 
In contrast to standard expression arrays, exon arrays in addition to global gene 
expression profiling can be analysed in a number of alternative ways. The design 
advantage enables interrogation for alternative exons and discovery of novel exons, 
some of which may represent miRs.  
 
microRNA Discovery  
The exon array has 190 probes to detect microRNAs as part of the extended 
metaprobeset file. On standard expression profiling using the extended and full 
metaprobeset files no microRNAs from the 190 interrogated on the array were noted 
to have differential expression. However, using these metaprobeset files, containing 
hypothetical exons, a number of probesets were detected which are differentially 
expressed but not part of any known annotated genes. These probesets may 
potentially represent important undiscovered genes and were therefore investigated 
as recently annotated microRNAs.  
 
At the gene level using the full and extended metaprobeset files no “un-annotated” 
probesets corresponding to recently annotated microRNAs were discovered. 
However, at the exon level and using parameters of FDR p<0.05 and FC +/-1 a list 
of differentially expressed probesets was generated and inspection showed five 
probesets that are differentially expressed and part of microRNA genes. The five 
probesets identified are part of miR-155hg (BIC), miR-29c, miR22, miR-194-2 and 
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miR-223.  The BIC gene is up regulated in this dataset while the other four are all 
down regulated.  
 
Previous reports have shown silencing of miR-223 by AML1-ETO (Fazi et al., 2007). 
More recently both miR-29c and miR-223 were found to be down regulated in CLL 
and associated with a poor prognosis (Stamatopoulos et al., 2009). miR-29c targets 
include DNMT, which potentially can revert abnormal DNA methylation. miR-155 is 
up-regulated in a host of cancers including lymphomas and in bone marrow blasts of 
primary AML samples with FAB M4 and M5 subtypes. Furthermore, over expression 
of miR-155 in murine models resulted in a myeloproliferative disorder with 
preleukaemic aspects (O'Connell et al., 2008). Potential targets include CSF1R, Pu1 
and CEBPA. As AML1-ETO also has direct interactions with these molecules it 
suggests a complex level of regulation.  
 
These reports are consistent with our array data validating our approach. However, 
it is noted that although there is differential expression at the individual probeset 
level, at gene/transcript level the differences are not statistically significant (Table 
20).  
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Table 20 Summary of details of probesets which show a greater than twofold differential expression and are 
part of known microRNAs  
 
 
 
 
Analysis by RQ PCR for miR-155, miR-29c and miR-223 on a series of primary 
samples has been previously performed in this laboratory and were used for 
validation (Dixon-McIver). Therefore, RQ values for 10 t(8;21) FAB M2 and 8 NK 
FAB M2 samples were selected and compared. There was no significant difference 
between the two groups and therefore did not validate the changes in microRNA 
expression between the two groups detected on the array.  
Probeset Transcript ID Gene p-value Fold Change 
2453234 2453230 miR-29c 0.020 -2.85 
3377262 3377258 miR-194-2 0.038 -2.93 
3740673 3740664 miR-22 0.005 -2.37 
3916516 3916508 miR-155hg 0.015 +2.42 
3979749 3979745 miR-223 0.126 -2.04 
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Alternative Splicing 
 
One of the aims for using the exon array platform was to discover genes whose 
splicing is regulated by AML1-ETO and to discover if the function of these genes is 
switched by alternative splicing. The hypothesis would be to discover genes involved 
in myeloid differentiation whose splicing is regulated by AML1-ETO and thus give a 
plausible rationale for the development of leukaemia. 
 
Partek uses an alternative transcript algorithm from the exon level data to generate 
lists of differentially expressed probesets. Lists generated also contained a p-value 
score for the splicing index. Visual inspection of 500 genes with the lowest splicing 
index p-value was performed to detect genes whose exons were differentially 
expressed. Strikingly, two genes were noted to have a true differential exon usage 
unlike the other 498 genes, which only showed a degree of differential gene 
expression, but not differential individual exon usage. (Figures 29 & 30).  
 
An RQ PCR strategy was used to attempt to confirm these changes. Primers on 
either side of the potentially alternatively spliced exon were designed. Primers 
between exons 6 & 7, 7 & 8 and 6 & 8 for the DHRS2 gene and between exons 18 & 
19 and 18 & 20 were devised. cDNA from four t(8;21) and four NK primary samples 
were tested. The above observations of alternative splicing could not be confirmed 
by this method.  
 
Chapter 3  Results Exon Arrays 
 145 
 
 
Figure 29 Representation of expression values for DHRS2 gene. The gene annotations with filled boxes 
representing exons are at the top of figure. The expression values representing each probeset are depicted as a 
dot plot in the middle portion of the figure. Blue represents patients with t(8;21) and red with NK. The bottom 
of the figure is a heat map. On the left of the map are the individual patients with blue representing t(8;21) 
and red NK. The heat map for each of the samples for each probeset is represented with blue representing low 
expression and red high expression. One pair of probesets corresponding to the seventh exon from the 5’ end 
shows differential expression between the two subsets of patient groups. 
 
DHRS2 (Hep27) is a reductase involved in inactivation of carbonyls. It is expressed 
in hepatocellular carcinoma cells (Pellegrini et al., 2002) and monocytic derived 
dendritic cells (Heinz et al., 2002). 
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Figure 30 Representation of expression values for WNK2 gene. The format is as described in figure 29. One 
of the probesets representing an exon near the middle of the gene is clearly demonstrated to show differential 
expression between the two subsets of patients. 
 
WNK2 (with no K = lysine) is a lysine deficient protein kinase 2. It has been found in 
brain, liver, heart and gut and is involved in colon cancer and glial tumours (Moniz et 
al., 2007). Interestingly, WNK2 appears to modulate ERK1/2 activity through Rho 
GTPase intermediaries (Moniz et al., 2008). In glial tumours WNK2 undergoes 
marked DNA methylation and subsequent silencing, suggesting that this gene acts 
to suppress cell growth (Hong et al., 2007). 
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Discussion  
 
Exon arrays can be used to profile individual exons for each gene. Studying the 
AML1-ETO gene specifically, it is noted that the ETO is transcriptionally silent in 
haemopoietic cells. Furthermore, the genomic breakpoint on ETO varies between 
patient samples. The ETO breakpoint has previously been reported to occur in three 
breakpoint regions (BCRs) in intron 1b (Zhang et al., 2002). A further breakpoint 
region has been identified in intron 1a (Buchholz et al., 2000). These reports appear 
consistent with the identification of at least 4 BCRs in our dataset. More samples 
may identify further breakpoint regions. Similarly, exon arrays may be able to identify 
genomic breakpoint locations in other translocations. 
 
The exon array also detects a whole range of signals from putative exons, 
suggesting that novel exons may be identified using this platform. We were unable 
to detect these by RT-PCR methods, despite attempts to optimise the conditions. As 
described in the Materials and Methods the Affymetrix Human Exon 1.0 ST array 
uses a whole transcript assay. RNA is used as starting material and ribosomal RNA 
is removed. However, there is no attempt made to remove pre-messenger RNA in 
the RNA processing procedure. Therefore signal values generated may result from 
the intronic sequences of the unspliced pre-messenger RNA rather than the true 
exons from messenger RNA. In this case, the signal values associated with 
probesets against the putative exons may simply represent intronic signals 
explaining the negative result in these experiments. 
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Exon arrays were also used for global gene expression profiling. We confirm 
findings of previous expression data that AML1-ETO not only causes transcriptional 
repression but also activation. The most significant genes generated on these arrays 
appear to be similar to previous array data from t(8;21) primary samples validating 
the use of this platform for expression analysis. 
 
Detailed comparison of exon array with ABI platform derived gene lists using primary 
samples, showed a degree of concordance. However, discrepancies were noted. 
The experiments that were compared used different controls. The exon array 
experiment used, the normal karyotype AML but with the same phenotype, in order 
to assess for specific AML1-ETO differences. The gene lists derived from the ABI 
platform compared t(8;21) to all other subtypes of AML. The resulting discordant 
genes may be as a result of this difference in controls. Using this control attempts to 
avoid detecting genes associated with differentiation stage of leukaemogenesis and 
highlight genes, which may play a key role in the early steps of leukaemia. Thus, 
genes that demonstrated differential expression on the exon array but not the ABI 
platform, may be more specific to the mechanisms of t(8;21) induced 
leukaemogenesis.  
 
However, this supposition assumes that the platforms used for expression profiling 
are analogous and the only difference in the results is due to the experimental 
variation of the controls used. However, this notion may not be valid for a number of 
reasons. Platforms differ in their sets of genes arrayed, have their own bias in the 
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design of their probes and often have incorrect or incomplete annotation files. 
Experiments performed by different people can also affect results, with the most 
variable part of the exon array protocol being the ribosomal removal step. Using a 
whole transcript assay results in a different pool of amplified mRNA, with the 3’ 
arrays omitting genes, such as histone genes, which lack a poly-A tail. Normalisation 
protocols, such as the use of RMA or PLIER can also result in differences. 
Furthermore, Partek uses different summarisation methods for expression data and 
exon data.  
 
Despite these highlighted differences, the exon array platform has been validated for 
gene expression analysis in previous reports (Bemmo et al., 2008). An established 
dataset was compared on three platforms: Illumina, Affymetrix Hu133 plus 2.0 and 
Human Exon ST1.0. Generally all three platforms coincided well with over 90% 
concordance although the comparisons between the Illumina and Hu133 platforms 
were more robust then with the Exon platform.  
 
Thus, comparison of gene lists between different experiments on different platforms 
is a valid method of highlighting differential gene expression. Specific genes have 
been highlighted which may play a key role in the oncogenic mechanisms of t(8;21) 
AML. 
 
Comparing gene expression data from different platforms it was noted that data from 
Kasumi cell lines was poorly reproducible. In addition, there was poor concordance 
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between gene lists derived between primary samples and Kasumi cell lines on both 
the exon array platform and other platforms. Some of this variance is due to lack of 
replicates, which would give a greater confidence to the results and indeed previous 
work has suggested that many cell lines are faithful model systems (Rucker et al., 
2006). However, primary samples are often quite biologically different to 
manipulated cell lines or stem cells. For example the Kasumi cell line has p53 and 
Kit mutations. It is recognised that some genes, such as POU4F1, which are highly 
over expressed in primary samples, are minimally altered in the Kasumi cell line 
(Dunne et al., 2006). Subsequently, Kasumi cell line expression data from this study 
should be interpreted with a degree of caution. As Kasumi cell line investigation was 
not the focus of this study, replication of samples and further analysis was not 
performed to confirm these findings. 
 
One of the main observations using the functional mining tools was the enrichment 
for G-protein coupled receptors and G protein related pathways in the t(8;21) set of 
patients, suggesting that expression changes in GPCR play an important role in 
AML1-ETO leukaemogenesis. Malignant cells can hijack the normal physiological 
functions of G-proteins and commonly stimulate G-proteins to be over expressed. 
Furthermore, the other main enriched pathway was that related to cytoskeletal 
remodelling through TGF beta and WNT. G-proteins are intermediaries in a number 
of pathways including those involving TGFb and WNT. These observations provide 
further insights into the mechanisms that the t(8;21) utilises leading to cancer. 
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Exploring these pathways may lead to development of specific drug targets, such as 
GPCR targeting agents, for the treatment of t(8;21) leukaemia. 
 
Interestingly, it is noted that “cell adhesion” was the top process using the GeneGo 
metacore tool and was up regulated. The clinical observation that t(8;21) is 
associated with the development of granulocytic sarcoma (i.e. extramedullary AML) 
may be relevant in this context. 
 
In addition to expression profiling, exon arrays are able to provide further 
information. Using extended and full metaprobeset lists in the analysis at exon or 
gene level, a number of probesets are identified which are differentially expressed 
but have no known annotations. These regions may be important and require further 
exploration. Some of these genes may code for microRNAs. Our findings suggested 
that at least at the probeset level there are important changes in expression of some 
microRNAs some of which have been implicated in AML. Although we observed 
differential expression at the exon level, the gene expression of these microRNAs on 
the array was not shown to be significantly different. Similarly, we were unable to 
detect significant gene expression changes of some these microRNAs by RQ 
analysis. The exon array although containing probesets to interrogate microRNAs 
has not been validated for microRNA analysis. The exon array does not attempt to 
remove pre-messenger RNA (mainly nuclear) and therefore the expression values 
might represent pre-microRNAs rather than the mature forms. Furthermore, for such 
small molecules the IVT amplification method used in the exon array protocol may 
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not be suitable. Some of the putative exons suggested by the array may not 
represent true exons and therefore mask true gene expression changes, which may 
have a significant effect for small genes. However, as microRNAs are relatively new 
and only recently being confirmed, mainly by computational models, the use of exon 
arrays using the full probeset list appears a justifiable way to attempt to identify 
them. Other annotations currently not classified as microRNAs may eventually result 
in being designated and thus exon arrays may give valuable information on 
microRNA expression as annotations become exhaustive. 
 
Using the alternative splice algorithm in Partek the exon array data was used to 
detect differentially expressed exons between the groups. However, the use of exon 
arrays to detect differentially spliced exons, unlike their use for expression analysis, 
has been problematic. While many algorithms have been used to detect differentially 
spliced exons, no specific algorithm has been demonstrated to be robust and 
accurate. One of the main drawbacks is the lack of a gold standard to compare 
against a particular analysis model. The arrival of next-generation sequence 
technologies such as RNA-Seq that give further information about the transcriptome, 
may overcome this limitation and provide an accurate gold standard as alternative 
transcripts are discovered and analysed.  
 
Alternative splicing analysis algorithms have to overcome a number of issues. 
Comparing probeset intensities across samples does not take into account the 
expression of the transcript across the sample; therefore probeset measurements 
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would reflect gene expression rather than differential exon usage. Use of algorithms 
such as the Splicing Index (SI) suggested by Affymetrix or Partek ANOVA method 
used in this analysis have been used to address this issue with both methods having 
the same limitations. The SI is calculated by dividing probe set intensity by the 
metaprobeset intensity i.e. exon-expression / gene-expression. However, using the 
SI many artefacts and false positives are generated. In these calculations the 
assumption is made that all probesets across a gene have a uniform response to 
changes in gene levels, which is often false. Probesets particularly affected by this 
are probesets at 3’ and 5’ ends, probesets that have low levels or levels similar to 
background, such as probesets identifying skipped exons (i.e. alternatively spliced 
but not differentially spliced exons) and probesets within highly expressed genes so 
that the detection range is saturated. The basis for the intensity variables at the 3’ 
and 5’ ends (termed edge bias effect) has been hypothesised. (Bemmo et al., 2008). 
The lower readings at the 3’ end are thought to be simply due to reduced priming 
potential as it is at the end of the template. This results in values for these probesets 
being nearer background and having a high SI. Another consequence of this effect 
is that smaller genes appear to have lower expression than longer genes. The 
rationale for the low levels seen at the 5’ end is believed to be due to the high GC 
content of the probesets, related to CpG islands. In addition, it has been 
demonstrated that genes showing strong changes in gene expression have an 
increased splice index (Gaidatzis et al., 2009). Whilst the gene expression levels 
appear to be robust the identification of alternative splicing is a technical artefact and 
probably reflects the original design of the arrays. Exon measurements are obtained 
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from the readings of only 4 probes, which are quite often overlapping whilst gene 
expression values are obtained from all probesets on a gene and quite often for 
many genes the number of probes used to detect measurements is vast. Another 
potential pitfall for detecting alternative splicing is that some probes may contain 
polymorphisms and when comparing different patient samples may lead to errors. 
Finally, the platform used does not detect alternative splice mRNA variants but only 
differences in exon usage so limiting the scope of the analysis available. 
 
As a result of these limitations, all algorithms produce many false positives and 
therefore it is important to visually inspect highlighted genes to detect true 
alternative splicing events. We identified two genes, WNK2 and DHRS, to have a 
high splicing index, which on visual inspection were confirmed as having differential 
exon expression. The assumption is that AML1-ETO controls the splicing of these 
genes resulting in variable exon usage. The alternative transcripts of these genes 
may play a significant role in leukaemogenesis. However, although these genes 
were implicated it was unable to be experimentally validated using RQ techniques. 
This negative result may have arisen due to limitations of the RQ-PCR technique. 
The expression of the relevant exons, although different in the patient groups, was 
low and RQ PCR was perhaps not sensitive enough to detect these changes in 
expression between the groups at such low levels. The use of mRNA-seq may allow 
a more comprehensive and robust analysis of alternatively spliced genes involved in 
this particular disease and validate some these findings. 
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In summary, exon arrays are more complex to perform and analyse. The use of 
more patients may allow even more robust interpretation. It is noted that samples for 
analysis were chosen based on number of vials available and generally samples 
which, were collected by leucopheresis or had a high white count had more vials. 
These samples, associated with a high WCC, maybe associated with poorer 
prognosis and introduce bias. We were careful to avoid the bias of batch effect 
(experimental variation on a single processing batch) by ensuring that our arrays 
were performed in small, varied cohorts. 
 
Using this platform for gene expression a robust dataset for differentially expressed 
genes specific to AML1-ETO has been produced. Both novel differentially expressed 
genes and key functional pathways and processes that are involved through AML1-
ETO have been identified. Furthermore, exon arrays were able to identify alternative 
splicing of certain key molecules under the control of AML1-ETO.  
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Introduction 
 
Alternative transcripts are likely to play a key role in increasing the diversity of the 
human genome. Recent developments in identifying alternative transcripts in the 
fusion gene AML1-ETO have highlighted the importance of this phenomenon. 
 
An initial observation noted that a truncated AML1-ETO protein of 552 amino acids, 
produced as a result of the loss of the C-terminal part of the AML1-ETO protein, led 
to the promotion of leukaemia in mice (Yan et al., 2004). A subsequent report 
identified an alternative exon of ETO, exon 9a, whose utilisation resulted in 
alternative transcript of AML1-ETO. This results in an early stop codon at the end of 
ETO exon 8 and a truncated AML1-ETO product of 575 aa lacking the NHR3 and 
NHR4 domains. This product was found co-expressed with full length AML1-ETO in 
t(8;21) patients. Remarkably, in mouse models the expression of AML1-ETO 9a 
transcript leads to the development of a rapidly developing leukaemia. Furthermore, 
co-expression of this mutant with the full length AML1-ETO in mice resulted in an 
earlier onset of leukaemia (Yan et al., 2006). These observations suggest that firstly 
loss of repressor domains may confer leukaemogenic properties to AML1-ETO and 
secondly that alternative spliced transcripts may co-operate with the full-length 
protein in promoting leukaemogenesis. 
 
Utilisation of yet another alternative exon, exon 11a, gives rise to an alternative 
truncated transcript that is also co-expressed with full length AML1-ETO transcript. 
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The resulting product of 688aa lacking the NHR4 domain, which is required for 
recruiting the co-repressors NCoR/SMRT, lost repressor activity. However, co-
expression with the full length AML1-ETO restored this transcriptional repressor 
activity. It was shown that the variants formed multimers unlike wild type AML1-ETO 
that formed dimers. The interaction between the wild-type ETO and the variant were 
increased compared to homo-dimerisation of wild type (Kozu et al., 2005). The 
variant forms produced by dysregulated splicing may become the core of the ETO 
repressor complexes and stimulate further oligomerisation. Oligomerisation of 
transcriptional factors imposes altered interaction with transcriptional co-regulators 
and leads to the oncogenic conversion of transcription factors in leukaemia. 
 
Other spliced forms of AML1-ETO have also been described (Figure 31). A further 3 
transcripts have been identified which contain introns 2, 4 and 5 of ETO and result in 
in-frame stop codons occurring after exons 2, 4 and 5 respectively (Era et al., 1995, 
Kozu et al., 1993, Nisson et al., 1992). The later 2 variants have been shown to co-
exist with full length AML1-ETO. In one sample, a variant with a 50-nucleotide 
deletion of exon 2 has been recognised as the only transcript. This caused a 
disruption of the reading frame and a premature stop codon resulting in only 31aa of 
ETO remaining (Lasa et al., 2002). This transcript lead to the characteristic t(8;21) 
with an M2 phenotype suggesting that very little of the ETO transcript is required for 
it to be leukaemogenic. AML1-ETO transcripts with insertions between exon 5 of 
AML1 and exon 2 of ETO have also been detected and result in out of frame 
transcript causing a stop codon and a truncated AML1-ETO with only the RHD 
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domain of AML1 translated (Tighe and Calabi, 1994, van de Locht et al., 1994). The 
roles of all these transcripts in leukaemogenesis have not been investigated. 
 
 
Figure 31 Alternative transcripts of AML1-ETO (Peterson et al., 2007a). See text for full details. 
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In addition to these isolated observations a further report identified a remarkable 
heterogeneity of AML1-ETO transcripts in 13 paediatric t(8;21) AML patients as a 
result of alternative transcripts and deletions (LaFiura et al., 2008). This suggests 
the fusion gene produces a whole range of proteins. 
 
Further understanding of the roles of alternative splice variants has focussed on 
understanding the various roles of the NHR domains.  
 
The NHR2 and NHR4 domains, containing the sites to bind co-repressors have 
been the most investigated. It was demonstrated that double deletion of NHR2 and 
NHR4 domains resulted in loss of the activity of the fusion protein in inhibiting 
differentiation and proliferation as well as promoting self-renewal of primary cells. 
However, the individual deletions of NHR2 and NHR4 domains did not cause this 
effect (Hug et al., 2002). In contrast, by introducing mutations specifically in the 
oligomerisation sequence of the NHR2 domain, AML1-ETO’s ability to sustain 
clonogenic activity of stem cells in vitro was impaired. Disrupting oligomerisation 
eliminated AML1-ETO’s ability to interact with other ETO molecules. However, 
oligomerisation was not required for interaction with co-repressors. Oligomerisation 
forming tetramers have the potential to increase recruitment by x4-fold repressor 
molecules (Liu et al., 2006). A polypeptide against the NHR2 domain disrupted high 
molecular weight complex formation, restored the expression of AML1-ETO target 
genes and reversed block in differentiation (Wichmann et al., 2007). Furthermore, it 
was shown that a heterologous dimerisation motif could rescue NHR2 deletions 
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suggesting that NHR2 plays a key role in homodimerisation and heterodimerization 
by bringing together NHR4 polypeptides (Zhang et al., 2001). Also contrary to the 
reports by Hug, it was shown that certain key mutations introduced in the NHR4 
resulted in the development of a rapidly growing leukaemia (Ahn et al., 2008). 
 
The NHR1 has been shown to interact with the activation domains of E-proteins, 
which are involved in cell cycle regulation (Zhang et al., 2004). Consequently, 
focussing further investigations on the leukaemic potential of this domain becomes 
an attractive strategy. 
 
In this chapter the leukaemic potential of the NHR1 of ETO is further investigated. I 
report on the discovery of a novel exon, ETO exon 6a, whose utilisation can result in 
at least two further AML1-ETO transcripts. One of these transcripts contains the 
NHR1 and lacks the remaining three NHRs. I have assessed this transcript using a 
retroviral transduction assay and demonstrated that the NHR1 is not leukaemogenic 
on its own but may negatively influence the effect of the full-length transcript. 
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Results 
 
In chapter 3, an attempt to detect novel exons of ETO using a PCR based strategy 
was performed. As a positive control for these experiments, RT-PCR to amplify the 
previously described exon 9a transcript was performed, using the primers for ETO 
exon 9a and AML1 exon 4, for three primary samples with t(8;21) (see Chapter 2 
p65). Bands at the appropriate size (1699bp) in two patients were detected (Figure 
32).  
 
 
Figure 32 Agarose Gel of PCR experiments of three samples from patients with AML t(8;21). Primers to ETO 
exon 9a and AML1 exon 4 were used, detecting a product of 1699bp corresponding to the 9a transcript. 
Bands are detected in patients 1 and 3 but not 2. 
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The PCR products obtained from these two patients were cloned and sequenced to 
confirm the presence of AML1-ETO exon 9a transcript. Product A retained the 
expected sequence and is schematically represented in figure 33. Product B, in 
contrast, despite being an almost identical size, actually proved to be a novel 
transcript, which is represented in figure 34. The novel transcript has ETO exon 3 
spliced out and an unidentified sequence inserted between ETO exons 5 and 6, 
giving a product of approximately similar size. 
 
 
  
Figure 33 Schematic representation of product A derived from the sequence analysis. AML-ETO exons are 
shown with AML1 on the left and ETO on the right. The thick vertical bar represents the fusion site. The 
arrows represent primers to AML1 and ETO exon 9a. The forward sequence is initiated by the AML1 exon 4 
primer and continues without interruption through AML exon 5, ETO exons 2, 3, 4 and part of 5. The reverse 
sequence is initiated by ETO exon 9a primer and continues through exons 8, 7, 6 and part of 5. The two 
sequences overlap in ETO exon 5. This confirms that product A is the AML-ETO exon 9a product. 
 
 
Figure 34 Schematic representation of product B derived from the sequence analysis. Layout is as figure 33. 
This shows that the ETO exon three is spliced out but a novel sequence is identified between the ETO exons 5 
and 6. 
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A blat search (http://genome.ucsc.edu/cgi-bin/hgBlat) confirmed that the unidentified 
sequence is part of the ETO gene and corresponds to part of the extended probeset 
on the Affymetrix Human Exon ST1.0 array between exon 5 and 6 (Figure 35). This 
new exon is referred to as ETO exon 6a. 
 
 
Figure 35 The reverse strand of ETO showing most of the sequence of exon 6a, illustrated on the IGB. The 
genomic location and base sequence of most of the exon 6a gene is shown at the top of the figure. The 
Affymetrix probeset for the 6a exon is represented by the blue and white bars. Signal estimates are low in the 
two controls and high in the t(8;21) patient. 
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To confirm the presence of the ETO exon 6a, RT-PCR on primary samples and the 
Kasumi cell line were performed, using the AML1 exon 4 and newly designed ETO 
exon 6a primers, specifically to amplify AML1-ETO 6a transcripts (Figure 36) 
 
 
 
 
Figure 36 Agarose electrophoresis of RT-PCR products derived from amplifications using primers to AML1 
exon 4 and ETO exon 6a on the following templates: negative controls (lanes 1 and 2), three different t(8;21) 
patient samples (lanes 3 to 5) and Kasumi cells (lane 6). Products of the expected 971 bp are seen. In addition 
three other fainter bands are seen in these samples – one just below the main band at 900bp, one at 
approximately 700bp and one at 500bp 
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These products were cloned and sequenced to confirm the exon 6a transcripts. A 
transcript with exon three spliced out was confirmed on a patient sample (Figure 37). 
However, a different transcript incorporating the new exon but retaining exon 3 was 
detected using the Kasumi cell line (Figure 38). 
 
 
 
Figure 37 Schematic representation of a product derived from the sequence analysis using AML1 and ETO 
exon 6a primers in a second patient. The layout is as figure 33. This shows a transcript with ETO exon 3 
spliced out and the new exon 6a retained. 
 
 
 
 
Figure 38 Schematic representation of a product derived from the sequence analysis using AML1 and ETO6a 
primers in the Kasumi cell line.  The layout is as figure 33. This shows a transcript with both ETO exon 3 and 
the new exon 6a retained. 
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ETO exon 6a has 137 base pairs and is located at 93075890-930760270 (version 
hg18 Mar 2006). It is flanked by base pairs AG and GT, which are consensus motifs 
characteristic of splice donor and acceptor sites in eukaryotic genes (Shapiro and 
Senapathy, 1987). The full ETO exon 6a sequence is as follows: 
 
ATGAATAAACTGAGGTCCAGAGAGGTTAAGTGACTTGACCAAGGTCACACAGC
TAGTCATGGAAGAGCCAGGACTAGATCTCAGGTCTCTTGATTCCCAGTCCAGT
GCTCTTTCCACTACACCACAATGCCAGTAAG. 
 
The incorporation of exon 6a was found in at least two AML1-ETO transcripts 
potentially giving rise to two truncated forms of the AML1-ETO protein. In the shorter 
transcript (AML1-ETO 6a-sh), the splicing out of ETO exon 3 and retention of ETO 
exon 6a leads to disruption of the reading frame and the introduction of a premature 
stop codon at the end of exon 2. In the longer transcript (AML1-ETO 6a), both exon 
3 and exon 6a from the primary transcript are retained, resulting in the introduction 
of a premature stop codon at the end of ETO exon 5. The protein generated by this 
transcript is predicted to be 395aa, retaining the NHR1 domain but lacking the NHR 
2, 3 and 4 domains. AML1-ETO transcripts predicted to yield identical 395aa 
sequences have been previously described, although in these reports the 
termination of the transcripts were as a result of the introduction of other intronic 
sequences and not the novel exon described here (Era et al., 1995, Kozu et al., 
1993). 
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Next, the presence of the exon 6a-containing transcripts in further t(8;21) patient 
samples was confirmed by RQ-PCR. A total of ten t(8;21) patients were identified 
and RNA obtained as previously described in Chapter 2 p63 (Table 21). 
 
Table 21 Patient samples used in this study.  Age in years,  CR- Complete remission, TRM- transplant related 
mortality, O/S – Overall survival, DFS – Disease free survival 
AGE SEX BLAST 
% 
RESPONSE 
TO 1ST 
LINE RX 
O/S 
(YEARS) 
DFS 
(YEARS) 
KARYOTYPE 
24 F 98 Fail/ 
Resistant 
disease 
0.49 0 46,XX,t(1;6)(p36;p23),t(8;21) 
(q22;q22)/46,idem,der(22) 
t(1;22)(q23;p11.2)/47, 
idem,+8 
38 F 70 CR 15.79 0.82 46,XX,t(8;21)(q22;q22) 
51 M 51 CR 1.00 0.65 46,XY,del(7)(q32q36), 
t(8;21)(q22;q22) 
68 M 50 CR 5.63 5.6 45,X,-Y,t(8;21)(q22;q22) 
20 M 60 CR 0.65 0.7 45,X,-Y,t(8;21),add(14q32)  
27 F 88 CR 11.06 11.1 46,XX,t(8;21)(q22;q22) 
49 F NA CR 5.07 5.1 46,XY,t(8;21)(q22;q22) 
67 M 30 TRM 0.16 0 46,XY,t(8;21)(q22;q22) 
34 M NA CR 7.09 7.1 45,X,-Y,t(8;21)(q22;q22) 
18 M 50 CR 14.81 11.6 45,X,-Y,t(8;21)(q22;q22) 
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RQ primers were designed to amplify across the ETO exon 6a boundaries. 
Transcripts containing the ETO exon 6a were identified in all patient samples. The 
expression level of each isoform differs between patients, for example patient 5 has 
high levels and patient 6 low levels (Figure 39).  
 
 
 
Figure 39 Bar charts showing the ΔΔCt (threshold cycle) results of real time PCR assays for ten AML patients 
and Kasumi cell line. Results, from probes designed to detect AML1-ETO 6a, 9a and full-length transcripts 
(A-E), relative to 18S ribosomal RNA normalized for Kasumi are shown. (Details Chapter 2 p66) 
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Comparisons of transcript levels within each patient demonstrate that 6a transcripts 
are generally but not always less abundant than the 9a transcript and consistently 
five- to ten-fold less abundant than the full length AML1-ETO transcript (Figure 40). 
 
 
 
Figure 40 Expression of AML1-ETO isoforms in ten primary samples and Kasumi cell line determined by 
real-time PCR. The ΔΔCt value for each isoform relative to 18S and normalised to that of the AML1-ETO 6a 
isoform for each individual patient is represented as a dot-plot. The median value is shown for each isoform. 
One value for the full-length isoform is very high and outside the axis limit and not represented. (An 
assumption is made that the reaction efficiencies for the amplification of the three isoforms are comparable.) 
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To investigate the role of the NHR1 domain in AML1-ETO induced leukaemogenesis 
the AML1-ETO 6a transcript was used for further functional assessment. Initially, a 
pMSCV AML1-ETO 6a-iresGFP (pMiG-A-E6a) and pMSCV AML1-ETO-ires hCD2 
(pMihC-A-E) vectors were constructed and the cDNA insertions were confirmed by 
sequencing. (Appendix B, performed by author) The AML1-ETO 9A vector was 
provided by D. Gascoyne for use in some of the following experiments. 
 
The plasmids were then incorporated into retrovirus using a packaging cell line. 
(performed by D. Gascoyne) Protein expression of cDNA, in packaging cell lines, 
was confirmed by Western blotting using lysates obtained from packaging cell lines 
(Figures 41 & 42). (see Chapter 2 p82) 
 
 
Figure 41 Western blot to confirm expression from the pMiG A-E6a vector. Lysates from cells transfected 
with full length, 9a or 6a AML1-ETO vectors (2 separate clones of the 6a vector were used) are run in lanes 1, 
2, 3 and 4 respectively. The AML1 antibody detects products of the expected molecular weights: 85kDa, 
65kDa and 45kDa respectively. Re-probing with anti-GAPDH showed equal loading. 
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Figure 42 Western blot to confirm expression from the pMihC-A-E vector. Lysates are from cell transfected 
with pMihC-A-E (1 and 2), pMSCV-ires-hCD2 without transcript (pMihC) (3 and 4) and Kasumi (5). The 
ETO antibody detects products at the expected weight of 85K in lanes 1, 2 and 5 but not in lanes 3 and 4. The 
faint non-specific bands in lanes 3 and 4 correspond to similar bands in lanes 1 and 2 just above the main 
band corresponding to AML1-ETO. 
 
 
 
To examine the effect of the truncated protein, murine haemopoietic stem cells were 
infected with AML1-ETO vectors and subjected to methylcellulose re-plating assays 
(See chapter 2 p89 assay performed by D. Gascoyne with transfection efficiencies 
of greater than 90%). The AML1-ETO 6a cDNA appears to have minimal affect on 
colony numbers (Figures 43 & 47) or colony morphology in first round 
methylcellulose plates. Similarly, cells transduced with this retrovirus did not re-plate 
beyond the third round, unlike the full-length and 9a vectors, indicating a lack of 
immortalization capacity (Figure 44). 
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Figure 43 FACS analysis of GFP+ cells. Murine progenitor c-Kit+/Ter119- cells were transduced with 
retroviruses containing cDNAs for GFP alone, full length AML1-ETO, AML1-ETO exon 9a or AML1-ETO 
exon 6a. Experiments were performed twice and representative sample is shown. Suppression of cell numbers 
by A-E and 9a retrovirus are suggested although actual cell counts are shown in figure 48. 
 
 
 
Figure 44 Effect of AML1-ETO 6a in murine methylcellulose re-plating assays - photos of three representative 
plates at second round/week of re-plating. (Cells transduced as Figure 43) Photos provided by D. Gascoyne. 
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Next dual transfection experiments, with full-length and 6a AML1-ETO vectors, were 
performed to more closely mimic in-vivo activity. Murine haemopoietic stem cells 
were co-infected with pMihC-A-E plus pMiG-A-E6a; pMihC-A-E plus pMiG; pMIG-A-
E6a plus pMihC; or pMiG plus pMihC. Cells were analysed by FACS analysis of 
CD2 and GFP expression (Figure 45).  
 
 
Figure 45 Representative figure of flow cytometric analysis of infection marker expression at fourth round 
replating. Murine progenitor cells have been co-infected with pMihC-A-E plus pMiG A-E6a; pMihC A-E 
plus pMiG; pMIG-A-E6a plus pMihC; or pMiG plus pMihC. Cells from the two former dual infections were 
analysed by FACS analysis of GFP expression and of CD2 expression (CD2 expression was performed with 
and without 2nd antibody resulting in both stained and unstained analysis – see Chapter 2 p84).   
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In contrast to the above observations, the expression of the 6a vector appears to 
have a suppressive effect on the ability of the full-length AML1-ETO transcript to 
propagate colony formation and cell proliferation (Figure 46 & 47).  
 
 
 
 
Figure 46 Graphs from methylcellulose re-plating assays. Experiments were performed twice and results of a 
representative sample shown. Murine progenitor cells were transduced with pMiG A-E6a and pMihC (6a) or 
pMihC A-E and pMiG (A-E) or pMiG A-E6a and pMihC A-E (6a+A-E) or both pMiG and pMihC 
retroviruses (neg). Total numbers of colonies on a plate were counted at weekly intervals and plotted against 
time. For details of methodology see chapter 2 p83. 
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Figures 47 Graphs from methylcellulose re-plating assays. Experiments were performed twice and results of a 
representative sample shown. Murine progenitor cells were transduced with pMiG A-E6a and pMihC (6a) or 
pMihC A-E and pMiG (A-E) or pMiG A-E6a and pMihC A-E (6a+A-E) or both pMiG and pMihC 
retroviruses (neg). Cells were counted at weekly intervals prior to re-plating. FACS analysis of cell markers 
was performed to identify the percentage of dual positive cells. Dual positive cell counts are plotted against 
time. 
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Discussion 
 
I have described a novel in-vivo AML1-ETO transcript, containing the NHR1 domain 
and lacking the other NHR domains, and have demonstrated that it lacks clonogenic 
potential in AML1-ETO induced leukaemogenesis. As the 9a transcript containing 
the NHRs1 and 2 domains can induce leukaemia unlike the 6a transcript, which 
lacks the NHR2 domain, it can be deduced that the NHR2 domain of ETO is 
essential in the leukaemogenic capacity of the AML1-ETO fusion protein. The homo-
oligomerisation function imparted by the NHR2 domain appears to be the key 
mechanism for leukaemogenesis in the pathogenesis of AML with t(8;21) (Kwok et 
al., 2009).  
 
By introducing specific mutations into the regions coding for the NHR1 and NHR2 
domains of AML1-ETO transcripts, three recent reports have confirmed a limited role 
of the NHR1 domain. Although our results are in keeping with these findings, we 
further demonstrate that the novel 6a-containing transcript may influence the 
clonogenic potential of the full-length transcript. This observation highlights another 
potential failsafe mechanism by which cells may be able to regulate uncontrolled 
leukaemic growth.  
 
In addition, the AML1-ETO 6a-sh transcript, although giving rise to a protein lacking 
all 4 NHR domains, may still have a role in leukaemogenesis through a dominant 
negative effect, competing with native AML1 or full-length AML1-ETO for DNA 
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binding sites. These observations provide further insights into both the genomic 
structure of ETO (Figure 48) and the role of alternative transcripts in 
leukaemogenesis. As a result of alternative exon usage a whole range of minor 
alternative transcripts are produced concurrently in t(8;21) leukaemic samples.  
These transcripts encode for proteins that lack the various NHR domains (Figure 
49). The interactions of these proteins with each other appear to be complex 
affecting the leukemic potential of the main full-length AML1-ETO product.  The key 
to these interactions may involve the role played by the NHR2 domain and the ability 
of the AML1-ETO molecule to form tetramers through this domain. AML1-ETO 
tetramers bind preferentially to DNA containing 2 AML1 binding sites (Okumura et 
al., 2008). In contrast AML1-ETO dimers have reduced DNA binding. It can be 
hypothesised that the ratio of the different proteins produced by the AML1-ETO 
oncogene can result in varying amounts of dimerisation and tetramer formation. This 
may then affect the binding ability of the AML1-ETO complex. Thus, disrupting the 
ability of the NHR2 domain gives a basis for a drug target.  
 
In the clinical setting, the detection and quantification of 6a transcripts may result in 
prognostic implications where the amount of transcript may correlate with prognosis. 
This cohort has ten patients of which four survived less than 1 year while the 
remaining six survived over 5 years. Although there was no correlation between 
survival and transcript levels, larger numbers are required to draw any firm 
conclusions.   
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Figure 48 Schematic diagram summarising the exons of ETO involved in the AML1-ETO gene 
 
 
 
 
 
Figure 49 Schematic summary of predicted AML1-ETO proteins (highlighting the NHRs) from reported 
AML1-ETO transcripts resulting from alternative exon usage.  The left of the line represents the region 
encoded by the DNA binding domain of AML1, while the right represents the region encoded by ETO and its 
NHR domains and the thick vertical bar represents the fusion junction between AML1 and ETO. In addition to 
the major full-length AML1-ETO product containing for all four NHRs, truncated proteins lacking NHRs as 
result of alternative exon usage of 11a, 9a and 6a respectively are summarized. Utilization of the 6a exon can 
result in at least two transcripts with a short form coding for a protein lacking all four NHRs (6a sh) 
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In summary, a novel exon of ETO has been detected, which is utilized to form 
further alternative transcripts of AML1-ETO. This transcript, giving rise to a protein of 
395aa and lacking NHRs 2, 3 and 4 domains is not clonogenic on its own but 
appears to have a negative effect on the clonogenic potential of the full-length 
AML1-ETO transcript.  
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Introduction 
 
The advent of high throughput sequencing has opened up new ways to investigate 
the genome. One of the most popular techniques is the use of chromatin-immuno 
precipitation followed by high throughput sequencing (ChIP-Seq) to investigate 
global binding of transcription factors. As the onco-protein AML1-ETO acts as a 
transcription factor, ChIP-Seq becomes a very attractive strategy to investigate DNA 
binding by AML1-ETO.  
ChIP  
 
DNA and histone interactions are usually transient in nature. However, in the 1960’s 
it was observed that applying formaldehyde to living cells covalently cross-linked 
DNA to histones in-situ and furthermore, these cross-links could be reversed. (Kuo 
and Allis, 1999) Thus, the basis for ChIP methodology began to take shape. (Figure 
50) However, ChIP only became established as major technique decades later with 
the development of highly specific antibodies allowing identification of where on the 
genome specific proteins could bind. Particular interest has focused on the direct 
physical interaction between transcription factors and DNA, which has further 
increased with the development of high throughput technologies allowing global 
identification of immunoprecipitated DNA. 
 
ChIP-Chip, where DNA obtained through ChIP is used to interrogate a series of 
probes on a tiling array, has been quickly superseded by Chip-Seq with its 
numerous advantages: arrays require prior knowledge of the genome; due to 
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constraints of hybridisation chemistry much of the DNA is not accessible for 
interrogation by arrays and the amount of DNA required for an array-based 
investigation is high especially considering the low yield of DNA produced by ChIP.  
 
 
 
 
Figure 50 The three main steps required for ChIP methodology: covalently cross-linking DNA-protein 
interactions; using antibodies to precipitate these interactions and uncross-linking the interactions to 
investigate the isolated DNA. In this technique DNA must be compared to a control consisting of DNA 
collected without antibody addition or non-specific antibody. This is due to random protein–DNA cross-
linking resulting in non-specific DNA being pulled down in the immunoprecipitation step. (Mardis, 2007). 
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High Throughput Sequencing 
 
For the last 30 years the “Sanger sequencing method” has been the main tool for 
sequencing, proving to be powerful enough to decipher complete genomes. 
However, the introduction of next-generation sequencing technologies appears to be 
even more potent. By omitting the need to clone DNA fragments this technique is 
able to generate a vast of amount of sequencing data in a relatively short time 
frame. 
 
Three companies have commercially introduced their systems: the 454 from Roche, 
Illumina genome analyser and SOLid from Applied Biosystems. All three use 
different technologies and have different advantages but all require a high degree of 
IT support and are currently expensive. The Illumina system used in this project 
uses a bridge amplification technique followed by sequencing-by-synthesis. There 
are three phases; DNA is prepared into a library suitable for applying to the 
sequencer, followed by cluster generation and finally sequence reading. (Figure 51) 
The end result is the generation of a series of reads whose DNA sequence at one 
end has been deciphered and tagged. These tags allow identification on the genome 
of the location of the DNA read (See Chapter 2 p86 for further details). 
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Figure 51 Illustrating the 3 phases of Sequencing. Initially DNA is prepared by adding adaptors at each end of 
small piece of DNA. Cluster formation allows bridge amplification and finally the ends of these reads are 
sequenced. (figure from www.illumina.com) 
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Summary 
 
AML1-ETO acts as transcription factor binding to DNA, through its Runt domain. 
AML1-ETO is then able to regulate the transcription of its target genes. Identification 
of these target genes have traditionally been discovered through ChIP experiments 
followed by pull down of candidate genes using specific antibodies. Global analysis 
of the ChIP DNA has been more complex and most of the work regarding 
transcriptional control of AML1-ETO has focused on differential gene expression 
related to t(8;21) (Nimer and Moore, 2004). This however, does not reveal details on 
whether direct binding of the gene by AML1-ETO controls expression of genes. 
ChIP followed by high throughput sequencing overcomes these limitations enabling 
identification of all the sites on the genome to which AML1-ETO binds.  
 
Using this technique on primary samples, genes that bind the oncoprotein AML1-
ETO have been identified and discussed. The visualisation of binding sites on these 
genes provides information on the location of these binding sites. Using functional 
annotation software, a global assessment of the genes has identified enrichment of 
specific pathways that are implicated in the pathogenesis of AML-ETO. Furthermore, 
using the expression data provided by the exon array experiments in chapter 3 
details are provided of not only which genes AML1-ETO bind but also discover if this 
binding controls its expression thus providing new insights into control of genes of 
AML1-ETO. 
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Patients and Methods used for ChIP-Seq Analysis 
 
 
ChIP was performed using an antibody to ETO. As the ETO gene is transcriptionally 
silent in haemopoietic cells, the choice of this antibody, as opposed to using an 
antibody to AML1, results in pull down of DNA bound to AML1-ETO specifically. The 
initial control was an antibody to IgG but subsequently input DNA was used as DNA 
yields using the IgG antibody were unreliable. In order to establish the ChIP 
methodology initial experiments were performed using the Kasumi cell line. 
Subsequently, three AML patient samples harbouring the t(8;21) were selected for 
analysis by ChIP-Seq methodology. (Table 22) 
 
Table 22 Patient samples used for ChIP-Seq 
Patient Sex Age Cytogenetics 
1 M 18 45,X,Y,t(8;21)(q22;q22) 
2 M 68 45,X,-Y,t(8;21)(q22;q22) 
3 M 34 45,X,-Y,t(8;21)(q22;q22) 
 
 
Sonication Experiments 
 
Initial experiments were performed with Kasumi cell lines to optimise sonication 
cycles and to verify enrichment of ChIP DNA (Chapter 2 p88). 24 cycles of 
sonication were required to obtain the correct size of DNA fragments of 200-500bp. 
(Figure 52).  
Chapter 5  Results Chip-Seq 
 188 
A) 12x 
 
 
B) 18x 
 
 
C) 24x 
 
 
Figure 52 A,B & C -DNA was extracted from Kasumi cell lines and sonicated with protocols of 12, 18 and 24 
cycles respectively. DNA was analysed on bioanalyser to analyse DNA fragment size and displayed above. 
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RQ experiments 
 
To verify that the DNA enriched was specific to AML1-ETO RQ experiments were 
performed using the c-fms gene and beta 2 microglobulin as the negative control 
(Follows et al., 2003) (Chapter 2 p65). Threefold enrichment was used as the 
threshold to confirm the success of the ChIP technique. Unfortunately, there was 
loss of enrichment with sonication after 18 cycles (Figure 53 & 54). As this yields 
suboptimal DNA sized fragments for the sequencing technology the ChIP protocol 
was amended so that initial sonication was performed with limited number of cycles 
(x18) and subsequently an extra sonication step (x3 further cycles) was incorporated 
after the enrichment step to ensure 200-500bp DNA fragments. 
 
Patient samples were then used to perform ChIP experiments using this amended 
protocol and enrichment for c-fms was verified. (Figure 55) There was no 
enrichment with the negative control beta 2 microglobulin gene (Figure 56).  
 
Library Preparation  
 
Enriched ChIP DNA was then prepared into libraries ready for sequencing on the 
Illumina system (Chapter 2 p86). Furthermore, libraries for input DNA for each 
patient sample were also prepared. All but one of the libraries was run on two lanes 
of the sequencer.  
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Figure 53 Initial RQ experiments on Kasumi cell lines. Kasumi (K) and the negative control U937 (U) cell 
lines have been used. ChIP was performed with antibodies to ETO (e) and IgG (g). Sonication cycles of 6, 12, 
15, 18 and 24 have been performed. RQ to amplify c-fms has been performed and presented relative to Input  
relative to U937-IgG (negative control). Enrichment appeared to be less robust with cycles greater than 18. 
Identical negative control experiments were performed in parallel amplifying the beta 2 microglobulin gene 
and are represented in figure 54 below. 
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Figure 54 RQ experiments on Kasumi cell lines amplifying the beta microglobulin gene. Conditions and 
samples as in figure 53.  
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Figure 55  RQ analysis for three patients respectively. ChIP DNA was obtained using antibody to ETO 
(E/S19) and 18 cycles on the sonicator and then amplified for c-fms gene. Graphs presented relative to input 
(I) relative to IgG, showing samples had a greater than threefold enrichment relative to input.  
Chapter 5  Results Chip-Seq 
 193 
 
 
 
Figure 56 RQ analysis amplifying the beta2 microglobulin gene for the same three patients  respectively using 
identical parameters as in figure 55. 
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Sequencing Data 
 
Sequence reads for each patient was obtained. Alignment, quality control 
assessment and filtering were performed as described in materials and methods and 
the summaries for each primary sample tested are represented in the tables 23-25 
below. 
 
Table 23 
Patient 1 RUN Raw Reads Filtered reads 
1 18 million 14.2 million ChIP 
2 18 million 14.7 million 
1 9 million 7.5 million Input 
2 23 million 8.2 million 
Table 24 
Patient 2 RUN Raw Reads Filtered reads 
1 34 million 26.2 million ChIP 
2 34million 25.8 million 
1 26 million 20.6 million Input 
2 25 million 19.9 
Table 25 
Patient 3 RUN Raw Reads Filtered reads 
1 24 million 18.6 million ChIP 
2 13 million 10 million 
Input 1 15 million 11.3 million 
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Gene List Generation 
 
For each separate sample, the total filtered reads obtained from both the ChIP and 
input libraries were imported into Partek. Peaks were detected by Partek, which also 
produced a p-value by comparing the peaks form the input and ChIP sample. Peaks 
detected were filtered by using an FDR of 0.05. These regions containing the peaks 
were used to detect genes using a Ref seq annotation file and by extending the 
regions by 1000bp either side of the peak. Some genes had more than one peak 
identified. The gene was only included once using the peak with lowest p-value and 
the three gene lists were obtained (Table 26) 
 
Table 26 Numbers of genes detected from each patient obtained from Partek analysis.   
Patient Numbers of Genes 
1 377 
2 15,229 
3 8,862 
 
 
Table 26 shows a marked variation in the number of genes obtained for each 
patient. Initially, the three individual gene lists were compared and 338 genes 
common to all lists obtained. (Table 31 Appendix C).  
 
Although using a filter of FDR p<0.05 allowed a more inclusive initial gene list to be 
generated, this obviously results in a large number of false positives as, for example 
for patient 2, it is unlikely that 15,229 genes bind AML1-ETO. Therefore a further 
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more stringent criterion was set using visual inspection. By individually inspecting 
the shape and the location of the peaks for all these 338 common genes on the 
visualisation browser I was able to refine and rationalise the list to include only the 
top 86 genes with the largest p-value of 1x10-20. (Table 27)  
 
Subsequently, the top individual genes were then inspected and their function 
analysed through PUBMED searches. (http://www.ncbi.nlm.nih.gov/pubmed) This 
enabled us to confirm that some of these genes had been previously associated with 
AML1-ETO, giving confidence to our methodology, whilst novel gene associations 
were made. For a global assessment of the gene lists the gene ontology tool, 
GeneGo was used to identify enriched pathways. Finally the gene list was compared 
to the expression data obtained previously in chapter 3 (Table 30 Appendix A). This 
further validates the experiments and gives an insight into the relationship between 
DNA binding and effects on gene expression.  
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Results 
 
Primary assessment of the sequencing data was performed using the visualisation 
browser on Partek. Reads obtained from the sequencer are mapped to the genome 
and depicted as peaks in the following figures. These figures visualise the location of 
the peaks for the top genes and validate the methodology.  
 
 
 
 
Figure 57 MX2 gene showing peaks at the 5’end of gene. At the top is a schematic picture of the gene. The 
next two tracks depict the reads mapping to that genomic location – the upper red track for input DNA and the 
lower yellow track for enriched DNA. (note different scales for each track) The genomic location marker is at 
the bottom of the figure. Subsequent figures all have the same configuration.  
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Figure 58 MX2 gene. This focuses in on the peak detected in figure 57. 
 
 
Figure 59 TRIM8 gene showing peaks at the 5’end of gene. 
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Figure 60 CDH23 gene showing peaks at the 3’end of gene 
 
 
 
Figure 61 CDH23 gene This focuses in on the peak detected on figure 60 
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Figure 62 CCND3 gene showing peaks at the 5’end of gene 
 
 
 
Figure 63 PTCH1 gene showing peaks in the middle of gene 
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Visual inspection of the binding sites for these top genes shows conclusively high 
numbers of reads at specific sites on the genome compared to the control sample. 
This gives confidence that enrichment by ChIP and peak detection is a feasible 
technique and to an extent validates our data, especially for genes that had low p-
values. Conversely, for some binding sites with higher p-values there was less 
confidence that these results represent true binding sites. As non-stringent criteria of 
FDR of p<0.05 was deliberately used in the initial analysis to generate these 
inclusive lists, the use of this visual analysis was used to produce a more stringent 
criterion, omitting genes whose p-value was higher than 1x10-20. Using this p-value 
to limit the numbers of genes generated resulted in a definitive list of 86 genes 
(Table 27).  
Most AML1-ETO Binding sites are at 5’ end of Genes 
 
Inspection of the above figures demonstrates that the main AML1 binding sites for 
the genes depicted in the above figures are located at the 5’ end. This would be 
consistent with the concept that AML1-ETO binds to promoter sites, which are 
normally located at this end of the gene. However, this does not appear to be 
exclusive with some binding regions located at the 3’ end and some located in 
introns in the middle of the gene suggesting that control elements of genes can be 
found anywhere along the gene. 
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Gene List  
 
Table 27 Top 86 Genes ordered by lowest p-values from ChIP-Seq experiments 
GENE  CHROMOSOME PEAKS INPUT PEAKS CHIP p-VALUE 
MX2 21 121 776 0 
CDH23 10 74 651 0 
TRIM8 10 125 714 0 
CCND3 6 141 1123 0 
PTCH1 9 77 576 0 
STAB1 3 99 974 0 
PRKCD 3 129 709 0 
HCCA2 11 71 636 0 
RPS6KA1 1 126 1011 0 
INPP5A 10 74 617 0 
GFOD1 6 110 693 0 
ZBTB16 11 56 459 0 
NEK8 17 88 602 0 
MAP2K2 19 29 420 0 
BAHCC1 17 117 936 0 
USP20 9 30 356 9.81E-45 
SH3BP5 3 70 482 7.26E-43 
KIAA0427 18 83 519 1.89E-42 
LOC374443 12 29 338 3.63E-42 
FAM129B 9 22 310 3.92E-42 
PTTG1IP 21 80 507 5.35E-42 
GALNT6 12 104 567 1.50E-40 
BCL3 19 86 512 4.44E-40 
ADCY4 14 72 470 4.70E-40 
HIP1 7 69 459 8.93E-40 
LMNA 1 108 564 1.48E-38 
SULF2 20 71 452 8.99E-38 
LAPTM5 1 108 558 1.01E-37 
C6orf103 6 64 417 1.13E-35 
HNRNPM 19 99 517 1.74E-35 
CXXC5 5 177 711 2.07E-34 
PPP4R1L 20 72 431 3.54E-34 
CYP51A1 7 88 474 9.30E-34 
GLIPR2 9 70 419 2.86E-33 
KIAA0652 11 56 376 3.93E-33 
VAV1 19 95 485 1.38E-32 
JMJD6 17 84 452 3.09E-32 
GRK7 3 165 661 5.52E-32 
GNB5 15 110 520 7.40E-32 
TADA3 3 98 485 1.80E-31 
ACSL1 4 71 407 4.40E-31 
RASSF2 20 73 411 7.87E-31 
TPM4 19 63 374 1.19E-29 
RAI1 17 77 414 1.21E-29 
Chapter 5  Results Chip-Seq 
 203 
EEPD1 7 54 347 1.29E-29 
RARA 17 173 659 1.72E-29 
LAT2 7 43 306 1.60E-28 
HSH2D 19 32 269 2.47E-28 
MSI2 17 105 473 1.90E-27 
SLC2A1 1 120 507 6.61E-27 
SH3BP2 4 67 364 1.53E-26 
TSPAN32 11 103 460 1.90E-26 
ZFYVE28 4 98 446 2.59E-26 
KIAA0182 16 75 384 3.13E-26 
NHSL2 X 14 190 5.31E-26 
ALDH16A1 19 50 310 7.87E-26 
RASSF5 1 119 494 1.27E-25 
C5orf56 5 121 497 2.21E-25 
ABCG1 21 33 254 2.53E-25 
GPR114 16 99 437 7.84E-25 
TOX2 20 77 377 1.55E-24 
CD276 15 75 371 1.87E-24 
TBC1D14 4 120 486 2.33E-24 
SPNS3 17 38 263 3.20E-24 
SMG6 17 154 561 1.43E-23 
MBP 18 171 599 2.15E-23 
STARD9 15 20 198 2.35E-23 
PKIB 6 80 376 2.44E-23 
MAX 14 66 337 3.74E-23 
FNTB 14 66 337 3.74E-23 
IL21R 16 55 305 5.82E-23 
CCDC135 16 48 283 1.09E-22 
TK2 16 134 504 1.68E-22 
LOC100130987 11 84 380 1.69E-22 
IL17RA 22 101 423 1.86E-22 
SORBS1 10 68 335 3.87E-22 
ADORA2A 22 92 396 6.34E-22 
C22orf45 22 92 396 6.34E-22 
MGAT1 5 198 646 6.38E-22 
COL23A1 5 52 287 1.33E-21 
SIK3 11 152 538 1.41E-21 
CNIH3 1 82 365 3.07E-21 
SIPA1L3 19 82 362 7.39E-21 
LST1 6 100 407 8.11E-21 
CD82 11 109 429 8.32E-21 
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AML1-ETO binds Genes involved in Cell Growth 
 
Many of these genes appear to play a key role in cell cycle or tumour suppressor 
functions. MX2 encodes for a protein that is part of the dynamin and GTPase family 
(Melen et al., 1996). CDH23 encodes a cadherin and involved in cell-cell adhesion 
(Di Palma et al., 2001). TRIM8 is thought to be a tumour-suppressor gene working 
through enhancement of the Stat3 pathway (Okumura et al.). CCND3 encodes for a 
cyclin involved in cell cycle and mutations in this gene have been implicated in the 
pathogenesis of AML (Smith et al., 2005). PTCH1 encodes for the receptor for sonic 
hedgehog and functions as tumour suppressor gene (Katoh and Katoh, 2009). 
PRKCD is involved in the regulation of cell growth and apoptosis (Brodie and 
Blumberg, 2003). RPS6KA1 encodes for a kinase involved in cell growth, 
differentiation and apoptosis (Frodin and Gammeltoft, 1999). PLZF (ZBTB16) has 
been shown to interact with AML1-ETO, which causes its repression (Yeyati et al., 
1999). CXXC5 is involved in Wnt pathway and p53 regulation (Kim et al.). These 
molecules may have a key role to play in the pathogenesis of t(8;21) related acute 
myeloid leukaemia. 
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Gene Ontology Functional Analysis 
 
Further analysis to inspect the gene list on a global rather than individual basis uses 
commercial software designed to look for canonical pathways. GeneGo was used to 
inspect the initial list of 338 genes as previously generated, with the data 
summarised in table 28. 
Table 28 Significant processes as detected by GeneGo generated from the definitive gene list of 86. Genes 
involved in the processes are referred to as network objects. 
 
 NAME p-VALUE NETWORK 
OBJECTS 
1 Signal transduction_CREM pathway 2.60E-04 5/98 
2 Reproduction_FSH-beta signaling pathway 3.14E-04 6/159 
3 Development_Hemopoiesis, Erythropoietin 
pathway 
1.13E-03 5/135 
4 Cell cycle_G2-M 1.20E-03 6/205 
5 Inflammation_MIF signaling 1.33E-03 5/140 
6 Signal transduction_ESR1-nuclear pathway 1.57E-03 6/216 
7 Inflammation_Neutrophil activation 1.85E-03 6/223 
8 Immune response_IL-5 signaling 2.17E-03 3/44 
9 Reproduction_Male sex differentiation 3.04E-03 6/246 
10 Apoptosis_Anti-Apoptosis mediated by external 
signals via MAPK and JAK/STAT 
3.12E-03 5/170 
11 Signal Transduction_Cholecystokinin signaling 3.43E-03 4/106 
12 Inflammation_Interferon signaling 3.92E-03 4/110 
13 Cell cycle_G1-S Growth factor regulation 5.60E-03 5/195 
14 Reproduction_Gonadotropin regulation 6.10E-03 5/199 
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AML1-ETO binds genes related to cell cycle and apoptosis 
 
Notable pathways from table 24 include CREM (cAMP response-element modulator) 
pathway, genes involved in cell cycle and apoptosis. Although the CREB and CREM 
pathways are associated with spermatogenesis it has been shown that there is 
increased expression of genes encoding CREB in AML cells (Shankar et al., 2005).  
These observations once again offer glimpses of the pathways that appear to be 
dysregulated in the pathogenesis of AML with t(8;21). 
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ChIP-Seq correlation with Gene Expression 
 
The initial list of 338 genes obtained from the ChIP-seq analysis was compared to 
the 448 genes obtained from the expression data from the exon arrays. This results 
in a list of 30 genes that are common to both lists. Similarly, comparisons of the 
expression data to the ChIP-Seq list of 86 genes generated using the stricter criteria, 
resulted in 15 common genes. (Table 29) The probability of randomly obtaining 
these common genes from two lists is small. For example, using appropriate 
consideration of permutation and combinatorial theory and assuming the presence 
of 25,000 genes in the human genome, the likelihood of randomly generating more 
than 30 matches from the initial comparison is 7x10-13. This statistical analysis 
provides further evidence of the robustness of the ChIP-Seq technique.  
 
Many of the genes that have been detected, by the ChIP-Seq methodology, to bind 
AML1-ETO do not have an effect on gene expression as detected by the exon array 
data. However, there are some genes that are enriched in both expression and 
ChIP-Seq methodologies with the majority of these genes appearing to be 
repressed. (Table 29) This suggests that the traditional hypothesis that AML1-ETO 
acts by binding to genes and causing their down-regulation due to its repressor 
domains of ETO are valid. In contrast, this data suggests that the up regulation of 
genes associated with AML1-ETO occurs through indirect associations.  
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Table 29 Table of Genes common to Expression and ChIP-Seq analysis (List 1).  The top15 genes are derived 
when the more stringent Chip-Seq list of 86 is used for comparison. 
GENE  CHROMOSOME INPUT CHIP p-VALUE EXPRESSSION 
TRIM8 10 125 714 0 -2.62267 
CCND3 6 141 1123 0 -2.17201 
PRKCD 3 129 709 0 -2.75581 
LAPTM5 1 108 558 1.01E-37 -2.34841 
VAV1 19 95 485 1.38E-32 -1.66865 
GNB5 15 110 520 7.40E-32 -1.98786 
LAT2 7 43 306 1.60E-28 -6.46607 
SH3BP2 4 67 364 1.53E-26 -1.72992 
TSPAN32 11 103 460 1.90E-26 -4.58844 
GPR114 16 99 437 7.84E-25 -2.49612 
TBC1D14 4 120 486 2.33E-24 1.45898 
SPNS3 17 38 263 3.20E-24 -4.40062 
MBP 18 171 599 2.15E-23 -1.77519 
LST1 6 100 407 8.11E-21 -2.69105 
CD82 11 109 429 8.32E-21 -2.15598 
 
HSPG2 1 70 319 2.54E-19 2.3495 
FUT7 9 93 376 3.56E-19 -2.65019 
KIAA0513 16 81 324 1.70E-16 -2.12616 
ZC3H3 8 82 323 4.35E-16 1.46274 
MTSS1 8 4 83 8.35E-14 3.70334 
NTNG2 9 43 198 9.80E-13 2.08723 
C9orf89 9 99 326 4.41E-12 -2.1954 
PPCDC 15 15 112 9.61E-12 -1.58971 
UHRF1 19 18 121 1.09E-11 3.08633 
SMAD3 15 60 217 5.52E-10 -1.65456 
PI4KA 22 20 115 6.91E-10 -1.4591 
FGD3 9 4 53 4.28E-08 -1.50351 
SIPA1 11 118 320 7.47E-08 -1.6328 
MAN1A1 6 297 650 5.97E-07 4.82998 
WIPF1 2 11 59 2.04E-05 1.40696 
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AML1-ETO controls genes that regulate haemopoiesis 
 
Whilst many of these genes in this list have not been extensively investigated others 
have been shown to play a role in haemopoiesis. The VAV1 proto-oncogene 
encodes a protein that is a guanine nucleotide exchange factor for the Rho family of 
GTP binding proteins and has an important role in T-cell and B-cell development 
and activation. It is also able to affect JNK/SAPK signalling cascade (Katzav, 2007). 
The LAPTM5 gene encodes a transmembrane receptor, also known as E3 protein, 
that plays a role in haematopoiesis (Scott et al., 1996). The protein encoded by 
SH3BP2 binds to the SH3 domains of several proteins including the ABL1 and SYK 
protein tyrosine kinases, and functions as a cytoplasmic adaptor protein to positively 
regulate transcriptional activity in T, natural killer (NK), and basophilic cells (Chen et 
al., 2007). TSPAN32 is a member of the tetraspanin superfamily and behaves as 
tumour suppressor gene. It is also involved in hematopoietic cell function (Robb et 
al., 2001). These findings give a rational hypothesis that AML1-ETO binds to and 
represses the transcription of genes involved in haemopoietic control leading to 
dysregulation of normal haemopoiesis. 
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Discussion 
 
ChIP-Seq although relatively new appears to be a very powerful method to locate 
transcription factor binding to the genome. Using an antibody to ETO, DNA that is 
enriched for genes that bind AML1-ETO is pulled down. A number of novel genes 
that bind AML1-ETO are identified. It appears that AML1-ETO binding does not lead 
to differential gene transcription in all cases. However, where it does have a direct 
effect on gene expression it appears, as has traditionally been thought, to cause 
transcriptional repression. Conversely, the up-regulation of genes through AML1-
ETO appears to be an indirect effect in most cases. 
 
AML1-ETO binds to genes involved in cell cycle and apoptosis as well as down 
regulating genes related to control of haemopoiesis. These observations validate our 
approach to investigate AML1-ETO. Some specific pathways implicated include the 
WNT, Notch and Hedgehog pathways suggesting that these pathways may be 
appropriate targets for further treatment strategies.  
 
The ChIP-methodology whilst being very powerful does result in a vast amount of 
data. There are further possibilities for both analysing and interrogating the data. 
Due to time constraints only limited analysis has been performed and there are 
many areas that have been left unexplored.  
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More primary AML samples may be used to give more confidence to the validity of 
the data. The sample preparation methodology needs to be optimised to enrich for 
DNA at sonication levels to produce 500bp lengths. To obtain more data, further 
runs on the sequencer for the 3 samples already obtained would deliver more 
sequence reads. This would be particularly useful for sample 1 which resulted in low 
numbers of genes discovered and out of keeping with the other samples. Inspection 
of this sequence run revealed that its quality was poor and consequently affected 
the data obtained from the sequencer. In fact, a further run of good quality has been 
subsequently performed with excellent quantities and quality of reads but not yet 
analysed. This may be particularly pertinent as this sample drastically limited the 
numbers of common genes and it was felt that this might have introduced bias 
excluding some important genes. In fact comparing only genes obtained from the 
analysis of samples 2 and 3 and then using the strict p-value criteria of p<1x10-20 
resulted in 186 common genes. (Appendix C Table 28) GeneGo analysis of this list 
highlighted the enrichment of molecules involved in the WNT, Notch and Hedgehog 
pathways. (Appendix C Table 29) Re-analysing sample 1 with data from the new 
sequencing run may confirm these findings. 
 
Analysis of the data can also be altered by changing some of the statistical 
parameters used in setting peak detection to deliver more stringent criteria. The use 
of different software for analysis would also provide greater confidence if similar 
gene lists were produced. In this analysis each patient sample was analysed 
separately and only then compared to detect common genes to all three lists. A 
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more robust analysis may be obtained if the peaks detection were performed with all 
samples concurrently.  
 
Due to the extra sonication step in the ChIP methodology used here it is difficult to 
perform a motif analysis. This analysis would be invaluable to confirm some of the 
findings by detecting the recognised AML1 binding motifs at sites of peak detection. 
Motif analysis can also be used to identify novel AML1-ETO binding motifs. In this 
analysis genes that may have more than one peak detected were only recognised 
once and other peaks ignored so that only one binding site for each gene was 
detected. It is known that AML1-ETO tetramers preferentially bind genes with 2 
AML1 binding sites . Motif analysis analysis would aid in confirming this observation. 
A further analysis that is outstanding is comparing this ChIP-Seq data to data 
obtained in our laboratory regarding methylation status in t(8;21) samples, 
particularly as epigenetics are a key feature of the pathogenesis in t(8;21). 
Furthermore, current work to confirm some of these enriched genes by ChIP 
followed by RQ-PCR is ongoing. 
 
In summary, ChIP-Seq appears a very powerful technique and produces a vast 
amount of data. Our analysis is preliminary and further work is required to confirm 
our findings. However, the data appears valid and interesting observations have 
been made giving further clues on the mechanisms of the pathogenesis of AML1-
ETO. 
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AML is characterised by the occurrence of non-random translocations. The 
commonest is the t(8;21)(q22;p22). The pathogenesis of this form of AML has been 
extensively investigated. The t(8;21) results in the AML1 gene being placed 
alongside most of the ETO gene. AML1 acts as a master regulator of haemopoiesis 
while ETO through its four nervy domains is involved in recruiting co-repressors. The 
first five exons of AML1 containing the DNA binding domain are involved in the 
translocation while nearly the whole of ETO is involved. The t(8;21) occurs early in 
stem cells and gives rise to a product of 752aa with the RHD at the NH2 end and the 
ETO domains at the C-terminal end. AML1-ETO loses the activation domains of 
AML1 that recruit HATs, and gains repressor domains associated with ETO, which 
are involved in recruiting HDACs. Deacetylation of histones causes a closed 
chromatin structure and repression of transcription of a number of genes. In cell 
lines AML1-ETO blocks differentiation and proliferation and increases apoptosis. In 
stem cells it causes cell proliferation and renewal. Self-renewal may occur through 
down regulation of lineage-programming transcription factors such as GATA1 or 
through up-regulation of pathways such as Wnt or Notch. In mouse models 
introduction of AML1-ETO does not lead to the development of leukaemia on its own 
but can be seen when mice are treated with alkylating agents. This suggests that 
leukaemogenesis follows a multi-hit model with t(8;21) being an early and necessary 
mutation but requiring a second hit such as Kit mutations. AML1-ETO favours 
genetic instability through repression of genes involved in DNA excision repair. 
Alternative splice variants, which may themselves result from dysregulated splicing 
of AML1-ETO, also aid in loss or gain of genetic material by deregulating the mitotic 
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checkpoint. In addition to the acquisition of further mutations, the alternative splice 
variants on their own or with co-operation of full length AML1-ETO may themselves 
act as the “second hit” which results in leukaemia. 
 
The observations in this study adds further knowledge to the current understanding 
of AML1-ETO induced leukaemia as well as providing a description of how the 
newer high throughput technologies may be used to investigate the genome. The 
results also highlight the importance of the role that alternative transcripts play in the 
pathogenesis of leukaemia, which may also be extrapolated to genomics of cancer 
in general.  
 
The number of genes in the human genome is less than anticipated. Alternative 
transcripts have a function in increasing the diversity of the products the genome 
produces. Here, further evidence is provided for the key role alternative transcripts 
have in leukaemogenesis. The AML1-ETO gene has alternative exons and together 
with alternative splicing results in a number of transcripts all produced concurrently. 
These transcripts are translated into different sized protein products, which appear 
to have different roles and may affect the overall balance of the function of the 
oncogene. This mechanism may play a role in other malignancies and may even 
explain the different prognosis in patients with essentially the same disease. 
Specifically in the t(8;21) the key region appears to be the NHR2 domain of ETO. Its 
ability to interact with other ETO proteins through its dimerisation function is crucial 
to the pathogenesis of the t(8;21) in a similar mechanism seen in AML with t(15;17). 
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The shorter proteins produced by alternative transcripts of AML1-ETO may be more 
susceptible to produce tetramers of AML1-ETO which result in more effective 
function of AML1-ETO protein in its role as a transcription factor. 
 
AML1-ETO regulates the transcription of a number of genes as evidenced by 
expression arrays. Many of these genes are related to key molecules in G-protein 
pathways as well as molecules in involved in cell adhesion pathways suggesting that 
AML1-ETO disrupts cell control through these pathways and may offer targets for 
intervention. The effect of AML1-ETO on transcription results in both up and down 
regulation of its target gene. ChIP-Seq experiments highlight the different 
mechanisms for this differential gene regulation. Down regulation of genes result 
from a direct effect of AML1-ETO binding to its target gene and causing gene 
repression through its ETO domains as traditionally hypothesised. Up regulation of 
genes is likely in many cases to result from an indirect effect of AML1-ETO rather 
directly binding of AML1-ETO to these genes. In addition, AML1-ETO binds to a 
number of genes without having an effect on transcriptional control. This observation 
may simply stem from the limitations of expression arrays. Alternatively the effects in 
transcription are not detected because of negative feedback or through pleiotropy of 
transcriptional control.  
 
Expression arrays appear to be a very robust method for obtaining expression data. 
Its use for detecting alternative transcripts however, is more limited currently but 
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may become more useful as we build up our understanding of alternative transcripts 
particularly through sequencing technologies.  
 
The ChIP-Seq technology is extremely powerful and generates vast amounts of 
data. The output we have generated remains incredibly exciting and regarding 
transcriptional control will provide a potent way to unravel key pathways. Our 
analyses due to time constraints have been limited and require further analysis. In 
this regard a great deal of future work is possible. 
 
Future Work 
 
The data from the ChIP-Seq needs further mining and validating to ensure 
robustness of the data. As discussed in chapter 5 further samples, further analysis 
of the sequence runs already performed and using different software other than 
Partek would give more confidence to the gene list produced. Furthermore ChIP 
experiments to optimise enrichment at appropriate sonication parameters without 
the need to add additional sonication steps allows for analysis of binding motifs, both 
to confirm that discovered peaks have recognised AML1 binding motifs as well as 
discovering new motifs. RQ PCR for enrichment of specific genes that are 
highlighted from the ChIP-Seq experiments should be performed. While the ChIp-
Seq data has been compared to my own expression data I would also compare it 
with published AML expression data available from the GEO omnibus. This analysis 
would also highlight further any specific genes, which may be a suitable candidate 
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for further functional assessment. In this regard the expression data did highlight two 
genes UHRF1 and CD82 that are potential candidates for further assessment. 
Intriguingly the work investigating differential exon usage revealed two genes WNK2 
and DHRS2 that provide further avenues for additional analysis. In this regard work 
with mRNA-Seq techniques investigating transcriptomes may be appropriate to 
clarify the significance of this observation. 
 
The underlying drive to unravel the genomics of this heterogeneous disease is 
initially to understand the genomic mechanisms of disease states but also eventually 
to produce treatments, which are more effective for our patients. Modern technology 
has made designer drugs aimed at a molecular target a possibility and in some 
diseases a reality. For most malignancies a single targeted therapy is unlikely to 
prove a cure due to the pleiotropy and redundancy in biological systems that makes 
it possible for many cancer cells to circumvent one specific form of attack. However, 
the current global analysis techniques provided, gives us insights on multiple and 
global targets that appear to work simultaneously.  
 
Since Velpeau published the first case of leukaemia almost 200 years ago there 
have been huge advances in the understanding of the pathogenesis of AML. The 
newer techniques, exploring the genome, offer even greater potential to unravel the 
mysteries of human biology and may eventually provide safe and effective treatment 
for our patients.  
  References 
 219 
References 
 
"GROUPEFRANCAIS" 1990. Acute myelogenous leukemia with an 8;21 
translocation. A report on 148 cases from the Groupe Francais de 
Cytogenetique Hematologique. Cancer Genet Cytogenet, 44, 169-79. 
ABU-DUHIER, F. M., GOODEVE, A. C., WILSON, G. A., PEAKE, I. R. & REILLY, 
J. T. 2003. c-FMS mutational analysis in acute myeloid leukaemia. Br J 
Haematol, 123, 749-50. 
AHN, E. Y., YAN, M., MALAKHOVA, O. A., LO, M. C., BOYAPATI, A., OMMEN, H. 
B., HINES, R., HOKLAND, P. & ZHANG, D. E. 2008. Disruption of the 
NHR4 domain structure in AML1-ETO abrogates SON binding and 
promotes leukemogenesis. Proc Natl Acad Sci U S A, 105, 17103-8. 
AHN, M. Y., HUANG, G., BAE, S. C., WEE, H. J., KIM, W. Y. & ITO, Y. 1998. 
Negative regulation of granulocytic differentiation in the myeloid precursor 
cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, 
and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci U S A, 
95, 1812-7. 
ALCALAY, M., MEANI, N., GELMETTI, V., FANTOZZI, A., FAGIOLI, M., ORLETH, 
A., RIGANELLI, D., SEBASTIANI, C., CAPPELLI, E., CASCIARI, C., 
SCIURPI, M. T., MARIANO, A. R., MINARDI, S. P., LUZI, L., MULLER, H., 
DI FIORE, P. P., FROSINA, G. & PELICCI, P. G. 2003. Acute myeloid 
leukemia fusion proteins deregulate genes involved in stem cell 
maintenance and DNA repair. J Clin Invest, 112, 1751-61. 
AMANN, J. M., NIP, J., STROM, D. K., LUTTERBACH, B., HARADA, H., LENNY, 
N., DOWNING, J. R., MEYERS, S. & HIEBERT, S. W. 2001. ETO, a target 
of t(8;21) in acute leukemia, makes distinct contacts with multiple histone 
deacetylases and binds mSin3A through its oligomerization domain. Mol 
Cell Biol, 21, 6470-83. 
APPELBAUM, F. R., KOPECKY, K. J., TALLMAN, M. S., SLOVAK, M. L., 
GUNDACKER, H. M., KIM, H. T., DEWALD, G. W., KANTARJIAN, H. M., 
PIERCE, S. R. & ESTEY, E. H. 2006. The clinical spectrum of adult acute 
myeloid leukaemia associated with core binding factor translocations. Br J 
Haematol, 135, 165-73. 
ARONSON, B. D., FISHER, A. L., BLECHMAN, K., CAUDY, M. & GERGEN, J. P. 
1997. Groucho-dependent and -independent repression activities of Runt 
domain proteins. Mol Cell Biol, 17, 5581-7. 
ASOU, H., TASHIRO, S., HAMAMOTO, K., OTSUJI, A., KITA, K. & KAMADA, N. 
1991. Establishment of a human acute myeloid leukemia cell line (Kasumi-
1) with 8;21 chromosome translocation. Blood, 77, 2031-6. 
ASOU, N. 2003. The role of a Runt domain transcription factor AML1/RUNX1 in 
leukemogenesis and its clinical implications. Crit Rev Oncol Hematol, 45, 
129-50. 
ASOU, N., YANAGIDA, M., HUANG, L., YAMAMOTO, M., SHIGESADA, K., 
MITSUYA, H., ITO, Y. & OSATO, M. 2007. Concurrent transcriptional 
  References 
 220 
deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 
chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood, 109, 
4023-7. 
BACHER, U., HAFERLACH, C., SCHNITTGER, S., KOHLMANN, A., KERN, W. & 
HAFERLACH, T. 2010. Mutations of the TET2 and CBL genes: novel 
molecular markers in myeloid malignancies. Ann Hematol, 89, 643-52. 
BACHER, U., HAFERLACH, T., SCHOCH, C., KERN, W. & SCHNITTGER, S. 
2006. Implications of NRAS mutations in AML: a study of 2502 patients. 
Blood, 107, 3847-53. 
BAE, S. C., YAMAGUCHI-IWAI, Y., OGAWA, E., MARUYAMA, M., INUZUKA, M., 
KAGOSHIMA, H., SHIGESADA, K., SATAKE, M. & ITO, Y. 1993. Isolation 
of PEBP2 alpha B cDNA representing the mouse homolog of human acute 
myeloid leukemia gene, AML1. Oncogene, 8, 809-14. 
BAKSHI, R., ZAIDI, S. K., PANDE, S., HASSAN, M. Q., YOUNG, D. W., 
MONTECINO, M., LIAN, J. B., VAN WIJNEN, A. J., STEIN, J. L. & STEIN, 
G. S. 2008. The leukemogenic t(8;21) fusion protein AML1-ETO controls 
rRNA genes and associates with nucleolar-organizing regions at mitotic 
chromosomes. J Cell Sci, 121, 3981-90. 
BEMMO, A., BENOVOY, D., KWAN, T., GAFFNEY, D. J., JENSEN, R. V. & 
MAJEWSKI, J. 2008. Gene expression and isoform variation analysis using 
Affymetrix Exon Arrays. BMC Genomics, 9, 529. 
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. 
A., GRALNICK, H. R. & SULTAN, C. 1976. Proposals for the classification 
of the acute leukaemias. French-American-British (FAB) co-operative group. 
Br J Haematol, 33, 451-8. 
BLOOMFIELD, C. D., LAWRENCE, D., BYRD, J. C., CARROLL, A., PETTENATI, 
M. J., TANTRAVAHI, R., PATIL, S. R., DAVEY, F. R., BERG, D. T., 
SCHIFFER, C. A., ARTHUR, D. C. & MAYER, R. J. 1998. Frequency of 
prolonged remission duration after high-dose cytarabine intensification in 
acute myeloid leukemia varies by cytogenetic subtype. Cancer Res, 58, 
4173-9. 
BOYAPATI, A., YAN, M., PETERSON, L. F., BIGGS, J. R., LE BEAU, M. M. & 
ZHANG, D. E. 2007. A leukemia fusion protein attenuates the spindle 
checkpoint and promotes aneuploidy. Blood, 109, 3963-71. 
BRITOS-BRAY, M. & FRIEDMAN, A. D. 1997. Core binding factor cannot 
synergistically activate the myeloperoxidase proximal enhancer in immature 
myeloid cells without c-Myb. Mol Cell Biol, 17, 5127-35. 
BRODIE, C. & BLUMBERG, P. M. 2003. Regulation of cell apoptosis by protein 
kinase c delta. Apoptosis, 8, 19-27. 
BRUHN, L., MUNNERLYN, A. & GROSSCHEDL, R. 1997. ALY, a context-
dependent coactivator of LEF-1 and AML-1, is required for TCRalpha 
enhancer function. Genes Dev, 11, 640-53. 
BUCHHOLZ, F., REFAELI, Y., TRUMPP, A. & BISHOP, J. M. 2000. Inducible 
chromosomal translocation of AML1 and ETO genes through Cre/loxP-
mediated recombination in the mouse. EMBO Rep, 1, 133-9. 
  References 
 221 
BULLINGER, L., RUCKER, F. G., KURZ, S., DU, J., SCHOLL, C., SANDER, S., 
CORBACIOGLU, A., LOTTAZ, C., KRAUTER, J., FROHLING, S., GANSER, 
A., SCHLENK, R. F., DOHNER, K., POLLACK, J. R. & DOHNER, H. 2007. 
Gene-expression profiling identifies distinct subclasses of core binding 
factor acute myeloid leukemia. Blood, 110, 1291-300. 
BYRD, J. C., DODGE, R. K., CARROLL, A., BAER, M. R., EDWARDS, C., 
STAMBERG, J., QUMSIYEH, M., MOORE, J. O., MAYER, R. J., DAVEY, 
F., SCHIFFER, C. A. & BLOOMFIELD, C. D. 1999. Patients with 
t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and 
overall survival when repetitive cycles of high-dose cytarabine are 
administered. J Clin Oncol, 17, 3767-75. 
CHEN, G., DIMITRIOU, I. D., LA ROSE, J., ILANGUMARAN, S., YEH, W. C., 
DOODY, G., TURNER, M., GOMMERMAN, J. & ROTTAPEL, R. 2007. The 
3BP2 adapter protein is required for optimal B-cell activation and thymus-
independent type 2 humoral response. Mol Cell Biol, 27, 3109-22. 
CHOU, W. C., CHOU, S. C., LIU, C. Y., CHEN, C. Y., HOU, H. A., KUO, Y. Y., 
LEE, M. C., KO, B. S., TANG, J. L., YAO, M., TSAY, W., WU, S. J., 
HUANG, S. Y., HSU, S. C., CHEN, Y. C., CHANG, Y. C., KUO, Y. Y., KUO, 
K. T., LEE, F. Y., LIU, M. C., LIU, C. W., TSENG, M. H., HUANG, C. F. & 
TIEN, H. F. 2011. TET2 mutation is an unfavorable prognostic factor in 
acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 
118, 3803-10. 
DAVIS, J. N., MCGHEE, L. & MEYERS, S. 2003. The ETO (MTG8) gene family. 
Gene, 303, 1-10. 
DAVIS, J. N., WILLIAMS, B. J., HERRON, J. T., GALIANO, F. J. & MEYERS, S. 
1999. ETO-2, a new member of the ETO-family of nuclear proteins. 
Oncogene, 18, 1375-83. 
DE GUZMAN, C. G., WARREN, A. J., ZHANG, Z., GARTLAND, L., ERICKSON, 
P., DRABKIN, H., HIEBERT, S. W. & KLUG, C. A. 2002. Hematopoietic 
stem cell expansion and distinct myeloid developmental abnormalities in a 
murine model of the AML1-ETO translocation. Mol Cell Biol, 22, 5506-17. 
DEBERNARDI, S., LILLINGTON, D. M., CHAPLIN, T., TOMLINSON, S., AMESS, 
J., ROHATINER, A., LISTER, T. A. & YOUNG, B. D. 2003. Genome-wide 
analysis of acute myeloid leukemia with normal karyotype reveals a unique 
pattern of homeobox gene expression distinct from those with translocation-
mediated fusion events. Genes Chromosomes Cancer, 37, 149-58. 
DEFEA, K. 2008. Beta-arrestins and heterotrimeric G-proteins: collaborators and 
competitors in signal transduction. Br J Pharmacol, 153 Suppl 1, S298-309. 
DEGOS, L. 2001. John Hughes Bennett, Rudolph Virchow... and Alfred Donne: the 
first description of leukemia. Hematol J, 2, 1. 
DI PALMA, F., HOLME, R. H., BRYDA, E. C., BELYANTSEVA, I. A., 
PELLEGRINO, R., KACHAR, B., STEEL, K. P. & NOBEN-TRAUTH, K. 
2001. Mutations in Cdh23, encoding a new type of cadherin, cause 
stereocilia disorganization in waltzer, the mouse model for Usher syndrome 
type 1D. Nat Genet, 27, 103-7. 
  References 
 222 
DOWTON, S. B., BEARDSLEY, D., JAMISON, D., BLATTNER, S. & LI, F. P. 1985. 
Studies of a familial platelet disorder. Blood, 65, 557-63. 
DUNNE, J., CULLMANN, C., RITTER, M., SORIA, N. M., DRESCHER, B., 
DEBERNARDI, S., SKOULAKIS, S., HARTMANN, O., KRAUSE, M., 
KRAUTER, J., NEUBAUER, A., YOUNG, B. D. & HEIDENREICH, O. 2006. 
siRNA-mediated AML1/MTG8 depletion affects differentiation and 
proliferation-associated gene expression in t(8;21)-positive cell lines and 
primary AML blasts. Oncogene, 25, 6067-78. 
ELAGIB, K. E. & GOLDFARB, A. N. 2007a. Oncogenic pathways of AML1-ETO in 
acute myeloid leukemia: multifaceted manipulation of marrow maturation. 
Cancer Lett, 251, 179-86. 
ELAGIB, K. E. & GOLDFARB, A. N. 2007b. Regulation of RUNX1 transcriptional 
function by GATA-1. Crit Rev Eukaryot Gene Expr, 17, 271-80. 
ELSASSER, A., FRANZEN, M., KOHLMANN, A., WEISSER, M., SCHNITTGER, 
S., SCHOCH, C., REDDY, V. A., BUREL, S., ZHANG, D. E., UEFFING, M., 
TENEN, D. G., HIDDEMANN, W. & BEHRE, G. 2003. The fusion protein 
AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-
jun protein expression via the proximal AP-1 site of the c-jun promoter in an 
indirect, JNK-dependent manner. Oncogene, 22, 5646-57. 
ERA, T., ASOU, N., KUNISADA, T., YAMASAKI, H., ASOU, H., KAMADA, N., 
NISHIKAWA, S., YAMAGUCHI, K. & TAKATSUKI, K. 1995. Identification of 
two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and 
expression of wild-type ETO gene in hematopoietic cells. Genes 
Chromosomes Cancer, 13, 25-33. 
ERICKSON, P., GAO, J., CHANG, K. S., LOOK, T., WHISENANT, E., RAIMONDI, 
S., LASHER, R., TRUJILLO, J., ROWLEY, J. & DRABKIN, H. 1992. 
Identification of breakpoints in t(8;21) acute myelogenous leukemia and 
isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila 
segmentation gene, runt. Blood, 80, 1825-31. 
ERICKSON, P. F., DESSEV, G., LASHER, R. S., PHILIPS, G., ROBINSON, M. & 
DRABKIN, H. A. 1996. ETO and AML1 phosphoproteins are expressed in 
CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis 
and monitoring residual disease. Blood, 88, 1813-23. 
FALINI, B., MECUCCI, C., TIACCI, E., ALCALAY, M., ROSATI, R., 
PASQUALUCCI, L., LA STARZA, R., DIVERIO, D., COLOMBO, E., 
SANTUCCI, A., BIGERNA, B., PACINI, R., PUCCIARINI, A., LISO, A., 
VIGNETTI, M., FAZI, P., MEANI, N., PETTIROSSI, V., SAGLIO, G., 
MANDELLI, F., LO-COCO, F., PELICCI, P. G., MARTELLI, M. F. & PARTY, 
G. A. L. W. 2005. Cytoplasmic nucleophosmin in acute myelogenous 
leukemia with a normal karyotype. N Engl J Med, 352, 254-66. 
FAZI, F., ZARDO, G., GELMETTI, V., TRAVAGLINI, L., CIOLFI, A., DI CROCE, L., 
ROSA, A., BOZZONI, I., GRIGNANI, F., LO-COCO, F., PELICCI, P. G. & 
NERVI, C. 2007. Heterochromatic gene repression of the retinoic acid 
pathway in acute myeloid leukemia. Blood, 109, 4432-40. 
FENSKE, T. S., PENGUE, G., MATHEWS, V., HANSON, P. T., HAMM, S. E., 
RIAZ, N. & GRAUBERT, T. A. 2004. Stem cell expression of the AML1/ETO 
  References 
 223 
fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad 
Sci U S A, 101, 15184-9. 
FOLLOWS, G. A., TAGOH, H., LEFEVRE, P., HODGE, D., MORGAN, G. J. & 
BONIFER, C. 2003. Epigenetic consequences of AML1-ETO action at the 
human c-FMS locus. EMBO J, 22, 2798-809. 
FRANK, R., ZHANG, J., UCHIDA, H., MEYERS, S., HIEBERT, S. W. & NIMER, S. 
D. 1995. The AML1/ETO fusion protein blocks transactivation of the GM-
CSF promoter by AML1B. Oncogene, 11, 2667-74. 
FRODIN, M. & GAMMELTOFT, S. 1999. Role and regulation of 90 kDa ribosomal 
S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol, 151, 65-77. 
GAIDATZIS, D., JACOBEIT, K., OAKELEY, E. J. & STADLER, M. B. 2009. 
Overestimation of alternative splicing caused by variable probe 
characteristics in exon arrays. Nucleic Acids Res, 37, e107. 
GAIDZIK, V. I., BULLINGER, L., SCHLENK, R. F., ZIMMERMANN, A. S., ROCK, 
J., PASCHKA, P., CORBACIOGLU, A., KRAUTER, J., 
SCHLEGELBERGER, B., GANSER, A., SPATH, D., KUNDGEN, A., 
SCHMIDT-WOLF, I. G., GOTZE, K., NACHBAUR, D., PFREUNDSCHUH, 
M., HORST, H. A., DOHNER, H. & DOHNER, K. 2011. RUNX1 mutations in 
acute myeloid leukemia: results from a comprehensive genetic and clinical 
analysis from the AML study group. J Clin Oncol, 29, 1364-72. 
GAMOU, T., KITAMURA, E., HOSODA, F., SHIMIZU, K., SHINOHARA, K., 
HAYASHI, Y., NAGASE, T., YOKOYAMA, Y. & OHKI, M. 1998. The partner 
gene of AML1 in t(16;21) myeloid malignancies is a novel member of the 
MTG8(ETO) family. Blood, 91, 4028-37. 
GELMETTI, V., ZHANG, J., FANELLI, M., MINUCCI, S., PELICCI, P. G. & LAZAR, 
M. A. 1998. Aberrant recruitment of the nuclear receptor corepressor-
histone deacetylase complex by the acute myeloid leukemia fusion partner 
ETO. Mol Cell Biol, 18, 7185-91. 
GIESE, K., KINGSLEY, C., KIRSHNER, J. R. & GROSSCHEDL, R. 1995. 
Assembly and function of a TCR alpha enhancer complex is dependent on 
LEF-1-induced DNA bending and multiple protein-protein interactions. 
Genes Dev, 9, 995-1008. 
GILLILAND, D. G. 2002. Molecular genetics of human leukemias: new insights into 
therapy. Semin Hematol, 39, 6-11. 
GOEMANS, B. F., ZWAAN, C. M., MILLER, M., ZIMMERMANN, M., HARLOW, A., 
MESHINCHI, S., LOONEN, A. H., HAHLEN, K., REINHARDT, D., 
CREUTZIG, U., KASPERS, G. J. & HEINRICH, M. C. 2005. Mutations in 
KIT and RAS are frequent events in pediatric core-binding factor acute 
myeloid leukemia. Leukemia, 19, 1536-42. 
GOETZ, T. L., GU, T. L., SPECK, N. A. & GRAVES, B. J. 2000. Auto-inhibition of 
Ets-1 is counteracted by DNA binding cooperativity with core-binding factor 
alpha2. Mol Cell Biol, 20, 81-90. 
GOLLING, G., LI, L., PEPLING, M., STEBBINS, M. & GERGEN, J. P. 1996. 
Drosophila homologs of the proto-oncogene product PEBP2/CBF beta 
regulate the DNA-binding properties of Runt. Mol Cell Biol, 16, 932-42. 
  References 
 224 
GOLUB, T. R., BARKER, G. F., BOHLANDER, S. K., HIEBERT, S. W., WARD, D. 
C., BRAY-WARD, P., MORGAN, E., RAIMONDI, S. C., ROWLEY, J. D. & 
GILLILAND, D. G. 1995. Fusion of the TEL gene on 12p13 to the AML1 
gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A, 
92, 4917-21. 
GONCALVES, J. E., J.D. 2007. Use of an Exon Software Package to Identify 
Global Gene Splicing and Gene Expression Regulation. American 
Biotechnolog Laboratory, 24-26. 
GREEN, C. L., EVANS, C. M., ZHAO, L., HILLS, R. K., BURNETT, A. K., LINCH, 
D. C. & GALE, R. E. 2011. The prognostic significance of IDH2 mutations in 
AML depends on the location of the mutation. Blood, 118, 409-12. 
GRIMWADE, D., HILLS, R. K., MOORMAN, A. V., WALKER, H., CHATTERS, S., 
GOLDSTONE, A. H., WHEATLEY, K., HARRISON, C. J. & BURNETT, A. K. 
2010. Refinement of cytogenetic classification in acute myeloid leukemia: 
determination of prognostic significance of rare recurring chromosomal 
abnormalities among 5876 younger adult patients treated in the United 
Kingdom Medical Research Council trials. Blood, 116, 354-65. 
GRIMWADE, D., WALKER, H., OLIVER, F., WHEATLEY, K., HARRISON, C., 
HARRISON, G., REES, J., HANN, I., STEVENS, R., BURNETT, A. & 
GOLDSTONE, A. 1998. The importance of diagnostic cytogenetics on 
outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 
trial. The Medical Research Council Adult and Children's Leukaemia 
Working Parties. Blood, 92, 2322-33. 
GRISOLANO, J. L., O'NEAL, J., CAIN, J. & TOMASSON, M. H. 2003. An activated 
receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to 
induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A, 100, 
9506-11. 
GU, T. L., GOETZ, T. L., GRAVES, B. J. & SPECK, N. A. 2000. Auto-inhibition and 
partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate 
DNA binding by CBFalpha2 (AML1). Mol Cell Biol, 20, 91-103. 
GUERRASIO, A., ROSSO, C., MARTINELLI, G., LO COCO, F., PAMPINELLA, M., 
SANTORO, A., LANZA, C., ALLIONE, B., RESEGOTTI, L. & SAGLIO, G. 
1995. Polyclonal haemopoieses associated with long-term persistence of 
the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia 
in continous clinical remission. Br J Haematol, 90, 364-8. 
HARRISON, C. J., HILLS, R. K., MOORMAN, A. V., GRIMWADE, D. J., HANN, I., 
WEBB, D. K., WHEATLEY, K., DE GRAAF, S. S., VAN DEN BERG, E., 
BURNETT, A. K. & GIBSON, B. E. 2010. Cytogenetics of childhood acute 
myeloid leukemia: United Kingdom Medical Research Council Treatment 
trials AML 10 and 12. J Clin Oncol, 28, 2674-81. 
HASHIMOTO, H., HORTON, J. R., ZHANG, X. & CHENG, X. 2009. UHRF1, a 
modular multi-domain protein, regulates replication-coupled crosstalk 
between DNA methylation and histone modifications. Epigenetics, 4, 8-14. 
HEINZ, S., KRAUSE, S. W., GABRIELLI, F., WAGNER, H. M., ANDREESEN, R. & 
REHLI, M. 2002. Genomic organization of the human gene HEP27: 
  References 
 225 
alternative promoter usage in HepG2 cells and monocyte-derived dendritic 
cells. Genomics, 79, 608-15. 
HIEBERT, S. W., LUTTERBACH, B. & AMANN, J. 2001. Role of co-repressors in 
transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and 
inv(16) fusion proteins. Curr Opin Hematol, 8, 197-200. 
HIEBERT, S. W., REED-INDERBITZIN, E. F., AMANN, J., IRVIN, B., DURST, K. & 
LINGGI, B. 2003. The t(8;21) fusion protein contacts co-repressors and 
histone deacetylases to repress the transcription of the p14ARF tumor 
suppressor. Blood Cells Mol Dis, 30, 177-83. 
HONG, C., MOOREFIELD, K. S., JUN, P., ALDAPE, K. D., KHARBANDA, S., 
PHILLIPS, H. S. & COSTELLO, J. F. 2007. Epigenome scans and cancer 
genome sequencing converge on WNK2, a kinase-independent suppressor 
of cell growth. Proc Natl Acad Sci U S A, 104, 10974-9. 
HROMAS, R., BUSSE, T., CARROLL, A., MACK, D., SHOPNICK, R., ZHANG, D. 
E., NAKSHATRI, H. & RICHKIND, K. 2001. Fusion AML1 transcript in a 
radiation-associated leukemia results in a truncated inhibitory AML1 protein. 
Blood, 97, 2168-70. 
HUANG, G., SHIGESADA, K., ITO, K., WEE, H. J., YOKOMIZO, T. & ITO, Y. 
2001. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-
proteasome-mediated degradation. Embo J, 20, 723-33. 
HUG, B. A. & LAZAR, M. A. 2004. ETO interacting proteins. Oncogene, 23, 4270-
4. 
HUG, B. A., LEE, S. Y., KINSLER, E. L., ZHANG, J. & LAZAR, M. A. 2002. 
Cooperative function of Aml1-ETO corepressor recruitment domains in the 
expansion of primary bone marrow cells. Cancer Res, 62, 2906-12. 
IIZUKA, M. & SMITH, M. M. 2003. Functional consequences of histone 
modifications. Curr Opin Genet Dev, 13, 154-60. 
IMAI, Y., KUROKAWA, M., TANAKA, K., FRIEDMAN, A. D., OGAWA, S., MITANI, 
K., YAZAKI, Y. & HIRAI, H. 1998. TLE, the human homolog of groucho, 
interacts with AML1 and acts as a repressor of AML1-induced 
transactivation. Biochem Biophys Res Commun, 252, 582-9. 
JAKUBOWIAK, A., POUPONNOT, C., BERGUIDO, F., FRANK, R., MAO, S., 
MASSAGUE, J. & NIMER, S. D. 2000. Inhibition of the transforming growth 
factor beta 1 signaling pathway by the AML1/ETO leukemia-associated 
fusion protein. J Biol Chem, 275, 40282-7. 
KAMACHI, Y., OGAWA, E., ASANO, M., ISHIDA, S., MURAKAMI, Y., SATAKE, 
M., ITO, Y. & SHIGESADA, K. 1990. Purification of a mouse nuclear factor 
that binds to both the A and B cores of the polyomavirus enhancer. J Virol, 
64, 4808-19. 
KANIA, M. A., BONNER, A. S., DUFFY, J. B. & GERGEN, J. P. 1990. The 
Drosophila segmentation gene runt encodes a novel nuclear regulatory 
protein that is also expressed in the developing nervous system. Genes 
Dev, 4, 1701-13. 
KATOH, Y. & KATOH, M. 2009. Hedgehog target genes: mechanisms of 
carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol 
Med, 9, 873-86. 
  References 
 226 
KATZAV, S. 2007. Flesh and blood: the story of Vav1, a gene that signals in 
hematopoietic cells but can be transforming in human malignancies. Cancer 
Lett, 255, 241-54. 
KELLER, G., LACAUD, G. & ROBERTSON, S. 1999. Development of the 
hematopoietic system in the mouse. Exp Hematol, 27, 777-87. 
KIM, M. S., YOON, S. K., BOLLIG, F., KITAGAKI, J., HUR, W., WHYE, N. J., WU, 
Y. P., RIVERA, M. N., PARK, J. Y., KIM, H. S., MALIK, K., BELL, D. W., 
ENGLERT, C., PERANTONI, A. O. & LEE, S. B. A novel Wilms tumor 1 
(WT1) target gene negatively regulates the WNT signaling pathway. J Biol 
Chem, 285, 14585-93. 
KIM, W. Y., SIEWEKE, M., OGAWA, E., WEE, H. J., ENGLMEIER, U., GRAF, T. & 
ITO, Y. 1999. Mutual activation of Ets-1 and AML1 DNA binding by direct 
interaction of their autoinhibitory domains. Embo J, 18, 1609-20. 
KITABAYASHI, I., IDA, K., MOROHOSHI, F., YOKOYAMA, A., MITSUHASHI, N., 
SHIMIZU, K., NOMURA, N., HAYASHI, Y. & OHKI, M. 1998a. The AML1-
MTG8 leukemic fusion protein forms a complex with a novel member of the 
MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol, 18, 846-58. 
KITABAYASHI, I., YOKOYAMA, A., SHIMIZU, K. & OHKI, M. 1998b. Interaction 
and functional cooperation of the leukemia-associated factors AML1 and 
p300 in myeloid cell differentiation. Embo J, 17, 2994-3004. 
KLAMPFER, L., ZHANG, J., ZELENETZ, A. O., UCHIDA, H. & NIMER, S. D. 1996. 
The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl 
Acad Sci U S A, 93, 14059-64. 
KLISOVIC, M. I., MAGHRABY, E. A., PARTHUN, M. R., GUIMOND, M., 
SKLENAR, A. R., WHITMAN, S. P., CHAN, K. K., MURPHY, T., ANON, J., 
ARCHER, K. J., RUSH, L. J., PLASS, C., GREVER, M. R., BYRD, J. C. & 
MARCUCCI, G. 2003. Depsipeptide (FR 901228) promotes histone 
acetylation, gene transcription, apoptosis and its activity is enhanced by 
DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. 
Leukemia, 17, 350-8. 
KOHZAKI, H., ITO, K., HUANG, G., WEE, H. J., MURAKAMI, Y. & ITO, Y. 1999. 
Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) 
but not by highly expressed Bcl-2. Oncogene, 18, 4055-62. 
KOJIMA, K., OMOTO, E., HARA, M., SASAKI, K., KATAYAMA, Y., NAWA, Y., 
KIMURA, Y., AZUMA, T., TAKIMOTO, H. & HARADA, M. 1998. 
Myelodysplastic syndrome with translocation (8;21): a distinct 
myelodysplastic syndrome entity or M2-acute myeloid leukemia with 
extensive myeloid maturation? Ann Hematol, 76, 279-82. 
KOTTARIDIS, P. D., GALE, R. E., FREW, M. E., HARRISON, G., LANGABEER, S. 
E., BELTON, A. A., WALKER, H., WHEATLEY, K., BOWEN, D. T., 
BURNETT, A. K., GOLDSTONE, A. H. & LINCH, D. C. 2001. The presence 
of a FLT3 internal tandem duplication in patients with acute myeloid 
leukemia (AML) adds important prognostic information to cytogenetic risk 
group and response to the first cycle of chemotherapy: analysis of 854 
patients from the United Kingdom Medical Research Council AML 10 and 12 
trials. Blood, 98, 1752-9. 
  References 
 227 
KOZU, T., FUKUYAMA, T., YAMAMI, T., AKAGI, K. & KANEKO, Y. 2005. MYND-
less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in 
leukemia with t(8;21). Genes Chromosomes Cancer, 43, 45-53. 
KOZU, T., MIYOSHI, H., SHIMIZU, K., MASEKI, N., KANEKO, Y., ASOU, H., 
KAMADA, N. & OHKI, M. 1993. Junctions of the AML1/MTG8(ETO) fusion 
are constant in t(8;21) acute myeloid leukemia detected by reverse 
transcription polymerase chain reaction. Blood, 82, 1270-6. 
KREJCI, O., WUNDERLICH, M., GEIGER, H., CHOU, F. S., SCHLEIMER, D., 
JANSEN, M., ANDREASSEN, P. R. & MULLOY, J. C. 2008. p53 signaling in 
response to increased DNA damage sensitizes AML1-ETO cells to stress-
induced death. Blood, 111, 2190-9. 
KUO, M. H. & ALLIS, C. D. 1999. In vivo cross-linking and immunoprecipitation for 
studying dynamic Protein:DNA associations in a chromatin environment. 
Methods, 19, 425-33. 
KUWATSUKA, Y., MIYAMURA, K., SUZUKI, R., KASAI, M., MARUTA, A., 
OGAWA, H., TANOSAKI, R., TAKAHASHI, S., KODA, K., YAGO, K., 
ATSUTA, Y., YOSHIDA, T., SAKAMAKI, H. & KODERA, Y. 2009. 
Hematopoietic stem cell transplantation for core binding factor acute 
myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. 
Blood, 113, 2096-103. 
KWOK, C., ZEISIG, B. B., QIU, J., DONG, S. & SO, C. W. 2009. Transforming 
activity of AML1-ETO is independent of CBFbeta and ETO interaction but 
requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S 
A, 106, 2853-8. 
LAFIURA, K. M., EDWARDS, H., TAUB, J. W., MATHERLY, L. H., FONTANA, J. 
A., MOHAMED, A. N., RAVINDRANATH, Y. & GE, Y. 2008. Identification 
and characterization of novel AML1-ETO fusion transcripts in pediatric 
t(8;21) acute myeloid leukemia: a report from the Children's Oncology 
Group. Oncogene, 27, 4933-42. 
LASA, A., NOMDEDEU, J. F., CARNICER, M. J., LLORENTE, A. & SIERRA, J. 
2002. ETO sequence may be dispensable in some AML1-ETO leukemias. 
Blood, 100, 4243-4. 
LATAGLIATA, R., BONGARZONI, V., CARMOSINO, I., MENGARELLI, A., 
BRECCIA, M., BORZA, P. A., D'ANDREA, M., D'ELIA, G. M., MECAROCCI, 
S., MORANO, S. G., PETTI, M. C., MANDELLI, F. & ALIMENA, G. 2006. 
Acute myelogenous leukemia in elderly patients not eligible for intensive 
chemotherapy: the dark side of the moon. Ann Oncol, 17, 281-5. 
LEE, C. & ROY, M. 2004. Analysis of alternative splicing with microarrays: 
successes and challenges. Genome Biol, 5, 231. 
LEE, T. L., SHYU, Y. C., HSU, T. Y. & SHEN, C. K. 2008. Itch regulates p45/NF-
E2 in vivo by Lys63-linked ubiquitination. Biochem Biophys Res Commun, 
375, 326-30. 
LEVANON, D., GLUSMAN, G., BANGSOW, T., BEN-ASHER, E., MALE, D. A., 
AVIDAN, N., BANGSOW, C., HATTORI, M., TAYLOR, T. D., TAUDIEN, S., 
BLECHSCHMIDT, K., SHIMIZU, N., ROSENTHAL, A., SAKAKI, Y., 
LANCET, D. & GRONER, Y. 2001. Architecture and anatomy of the 
  References 
 228 
genomic locus encoding the human leukemia-associated transcription factor 
RUNX1/AML1. Gene, 262, 23-33. 
LEVANON, D., GOLDSTEIN, R. E., BERNSTEIN, Y., TANG, H., GOLDENBERG, 
D., STIFANI, S., PAROUSH, Z. & GRONER, Y. 1998. Transcriptional 
repression by AML1 and LEF-1 is mediated by the TLE/Groucho 
corepressors. Proc Natl Acad Sci U S A, 95, 11590-5. 
LEY, T. J., DING, L., WALTER, M. J., MCLELLAN, M. D., LAMPRECHT, T., 
LARSON, D. E., KANDOTH, C., PAYTON, J. E., BATY, J., WELCH, J., 
HARRIS, C. C., LICHTI, C. F., TOWNSEND, R. R., FULTON, R. S., 
DOOLING, D. J., KOBOLDT, D. C., SCHMIDT, H., ZHANG, Q., OSBORNE, 
J. R., LIN, L., O'LAUGHLIN, M., MCMICHAEL, J. F., DELEHAUNTY, K. D., 
MCGRATH, S. D., FULTON, L. A., MAGRINI, V. J., VICKERY, T. L., 
HUNDAL, J., COOK, L. L., CONYERS, J. J., SWIFT, G. W., REED, J. P., 
ALLDREDGE, P. A., WYLIE, T., WALKER, J., KALICKI, J., WATSON, M. 
A., HEATH, S., SHANNON, W. D., VARGHESE, N., NAGARAJAN, R., 
WESTERVELT, P., TOMASSON, M. H., LINK, D. C., GRAUBERT, T. A., 
DIPERSIO, J. F., MARDIS, E. R. & WILSON, R. K. 2010. DNMT3A 
mutations in acute myeloid leukemia. N Engl J Med, 363, 2424-33. 
LI, J. & WANG, C. Y. 2008. TBL1-TBLR1 and beta-catenin recruit each other to 
Wnt target-gene promoter for transcription activation and oncogenesis. Nat 
Cell Biol, 10, 160-9. 
LICHT, J. D. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of 
t(8;21) AML. Oncogene, 20, 5660-79. 
LINGGI, B., MULLER-TIDOW, C., VAN DE LOCHT, L., HU, M., NIP, J., SERVE, 
H., BERDEL, W. E., VAN DER REIJDEN, B., QUELLE, D. E., ROWLEY, J. 
D., CLEVELAND, J., JANSEN, J. H., PANDOLFI, P. P. & HIEBERT, S. W. 
2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the 
transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. 
Nat Med, 8, 743-50. 
LIU, P., TARLE, S. A., HAJRA, A., CLAXTON, D. F., MARLTON, P., FREEDMAN, 
M., SICILIANO, M. J. & COLLINS, F. S. 1993. Fusion between transcription 
factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid 
leukemia. Science, 261, 1041-4. 
LIU, S., SHEN, T., HUYNH, L., KLISOVIC, M. I., RUSH, L. J., FORD, J. L., YU, J., 
BECKNELL, B., LI, Y., LIU, C., VUKOSAVLJEVIC, T., WHITMAN, S. P., 
CHANG, K. S., BYRD, J. C., PERROTTI, D., PLASS, C. & MARCUCCI, G. 
2005. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute 
myeloid leukemia. Cancer Res, 65, 1277-84. 
LIU, W. M. & ZHANG, X. A. 2006. KAI1/CD82, a tumor metastasis suppressor. 
Cancer Lett, 240, 183-94. 
LIU, Y., CHENEY, M. D., GAUDET, J. J., CHRUSZCZ, M., LUKASIK, S. M., 
SUGIYAMA, D., LARY, J., COLE, J., DAUTER, Z., MINOR, W., SPECK, N. 
A. & BUSHWELLER, J. H. 2006. The tetramer structure of the Nervy 
homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer 
Cell, 9, 249-60. 
  References 
 229 
LOOK, A. T. 1997. Oncogenic transcription factors in the human acute leukemias. 
Science, 278, 1059-64. 
LU, J., MARUYAMA, M., SATAKE, M., BAE, S. C., OGAWA, E., KAGOSHIMA, H., 
SHIGESADA, K. & ITO, Y. 1995. Subcellular localization of the alpha and 
beta subunits of the acute myeloid leukemia-linked transcription factor 
PEBP2/CBF. Mol Cell Biol, 15, 1651-61. 
LUCK, S. C., RUSS, A. C., DU, J., GAIDZIK, V., SCHLENK, R. F., POLLACK, J. 
R., DOHNER, K., DOHNER, H. & BULLINGER, L. 2010. KIT mutations 
confer a distinct gene expression signature in core binding factor leukaemia. 
Br J Haematol, 148, 925-37. 
LUTTERBACH, B. & HIEBERT, S. W. 2000. Role of the transcription factor AML-1 
in acute leukemia and hematopoietic differentiation. Gene, 245, 223-35. 
LUTTERBACH, B., WESTENDORF, J. J., LINGGI, B., ISAAC, S., SETO, E. & 
HIEBERT, S. W. 2000. A mechanism of repression by acute myeloid 
leukemia-1, the target of multiple chromosomal translocations in acute 
leukemia. J Biol Chem, 275, 651-6. 
LUTTERBACH, B., WESTENDORF, J. J., LINGGI, B., PATTEN, A., MONIWA, M., 
DAVIE, J. R., HUYNH, K. D., BARDWELL, V. J., LAVINSKY, R. M., 
ROSENFELD, M. G., GLASS, C., SETO, E. & HIEBERT, S. W. 1998. ETO, 
a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 
corepressors. Mol Cell Biol, 18, 7176-84. 
MAO, S., FRANK, R. C., ZHANG, J., MIYAZAKI, Y. & NIMER, S. D. 1999. 
Functional and physical interactions between AML1 proteins and an ETS 
protein, MEF: implications for the pathogenesis of t(8;21)-positive 
leukemias. Mol Cell Biol, 19, 3635-44. 
MARCUCCI, G., MROZEK, K., RUPPERT, A. S., MAHARRY, K., KOLITZ, J. E., 
MOORE, J. O., MAYER, R. J., PETTENATI, M. J., POWELL, B. L., 
EDWARDS, C. G., STERLING, L. J., VARDIMAN, J. W., SCHIFFER, C. A., 
CARROLL, A. J., LARSON, R. A. & BLOOMFIELD, C. D. 2005. Prognostic 
factors and outcome of core binding factor acute myeloid leukemia patients 
with t(8;21) differ from those of patients with inv(16): a Cancer and 
Leukemia Group B study. J Clin Oncol, 23, 5705-17. 
MARDIS, E. R. 2007. ChIP-seq: welcome to the new frontier. Nat Methods, 4, 613-
4. 
MARKOVA, J., MICHKOVA, P., BURCKOVA, K., BREZINOVA, J., MICHALOVA, 
K., DOHNALOVA, A., MAALOUFOVA, J. S., SOUKUP, P., VITEK, A., 
CETKOVSKY, P. & SCHWARZ, J. 2011. Prognostic impact of DNMT3A 
mutations in patients with intermediate cytogenetic risk profile acute myeloid 
leukemia. Eur J Haematol. 
MATOZAKI, S., NAKAGAWA, T., KAWAGUCHI, R., AOZAKI, R., TSUTSUMI, M., 
MURAYAMA, T., KOIZUMI, T., NISHIMURA, R., ISOBE, T. & CHIHARA, K. 
1995. Establishment of a myeloid leukaemic cell line (SKNO-1) from a 
patient with t(8;21) who acquired monosomy 17 during disease progression. 
Br J Haematol, 89, 805-11. 
MEAD, A. J., LINCH, D. C., HILLS, R. K., WHEATLEY, K., BURNETT, A. K. & 
GALE, R. E. 2007. FLT3 tyrosine kinase domain mutations are biologically 
  References 
 230 
distinct from and have a significantly more favorable prognosis than FLT3 
internal tandem duplications in patients with acute myeloid leukemia. Blood, 
110, 1262-70. 
MELEN, K., KESKINEN, P., RONNI, T., SARENEVA, T., LOUNATMAA, K. & 
JULKUNEN, I. 1996. Human MxB protein, an interferon-alpha-inducible 
GTPase, contains a nuclear targeting signal and is localized in the 
heterochromatin region beneath the nuclear envelope. J Biol Chem, 271, 
23478-86. 
METZELER, K. H., BECKER, H., MAHARRY, K., RADMACHER, M. D., 
KOHLSCHMIDT, J., MROZEK, K., NICOLET, D., WHITMAN, S. P., WU, Y. 
Z., SCHWIND, S., POWELL, B. L., CARTER, T. H., WETZLER, M., 
MOORE, J. O., KOLITZ, J. E., BAER, M. R., CARROLL, A. J., LARSON, R. 
A., CALIGIURI, M. A., MARCUCCI, G. & BLOOMFIELD, C. D. 2011. ASXL1 
mutations identify a high-risk subgroup of older patients with primary 
cytogenetically normal AML within the ELN "favorable" genetic category. 
Blood. 
MEYERS, S., DOWNING, J. R. & HIEBERT, S. W. 1993. Identification of AML-1 
and the (8;21) translocation protein (AML-1/ETO) as sequence-specific 
DNA-binding proteins: the runt homology domain is required for DNA 
binding and protein-protein interactions. Mol Cell Biol, 13, 6336-45. 
MEYERS, S., LENNY, N. & HIEBERT, S. W. 1995. The t(8;21) fusion protein 
interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol, 
15, 1974-82. 
MILLIGAN, D. W., GRIMWADE, D., CULLIS, J. O., BOND, L., SWIRSKY, D., 
CRADDOCK, C., KELL, J., HOMEWOOD, J., CAMPBELL, K., MCGINLEY, 
S., WHEATLEY, K. & JACKSON, G. 2006. Guidelines on the management 
of acute myeloid leukaemia in adults. Br J Haematol, 135, 450-74. 
MIYAMOTO, T., NAGAFUJI, K., AKASHI, K., HARADA, M., KYO, T., AKASHI, T., 
TAKENAKA, K., MIZUNO, S., GONDO, H., OKAMURA, T., DOHY, H. & 
NIHO, Y. 1996. Persistence of multipotent progenitors expressing 
AML1/ETO transcripts in long-term remission patients with t(8;21) acute 
myelogenous leukemia. Blood, 87, 4789-96. 
MIYAMOTO, T., WEISSMAN, I. L. & AKASHI, K. 2000. AML1/ETO-expressing 
nonleukemic stem cells in acute myelogenous leukemia with 8;21 
chromosomal translocation. Proc Natl Acad Sci U S A, 97, 7521-6. 
MIYOSHI, H., KOZU, T., SHIMIZU, K., ENOMOTO, K., MASEKI, N., KANEKO, Y., 
KAMADA, N. & OHKI, M. 1993. The t(8;21) translocation in acute myeloid 
leukemia results in production of an AML1-MTG8 fusion transcript. Embo J, 
12, 2715-21. 
MIYOSHI, H., OHIRA, M., SHIMIZU, K., MITANI, K., HIRAI, H., IMAI, T., 
YOKOYAMA, K., SOEDA, E. & OHKI, M. 1995. Alternative splicing and 
genomic structure of the AML1 gene involved in acute myeloid leukemia. 
Nucleic Acids Res, 23, 2762-9. 
MIYOSHI, H., SHIMIZU, K., KOZU, T., MASEKI, N., KANEKO, Y. & OHKI, M. 
1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are 
  References 
 231 
clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci 
U S A, 88, 10431-4. 
MONIZ, S., MATOS, P. & JORDAN, P. 2008. WNK2 modulates MEK1 activity 
through the Rho GTPase pathway. Cell Signal, 20, 1762-8. 
MONIZ, S., VERISSIMO, F., MATOS, P., BRAZAO, R., SILVA, E., KOTELEVETS, 
L., CHASTRE, E., GESPACH, C. & JORDAN, P. 2007. Protein kinase 
WNK2 inhibits cell proliferation by negatively modulating the activation of 
MEK1/ERK1/2. Oncogene, 26, 6071-81. 
MULLER-TIDOW, C., STEFFEN, B., CAUVET, T., TICKENBROCK, L., JI, P., 
DIEDERICHS, S., SARGIN, B., KOHLER, G., STELLJES, M., PUCCETTI, 
E., RUTHARDT, M., DEVOS, S., HIEBERT, S. W., KOEFFLER, H. P., 
BERDEL, W. E. & SERVE, H. 2004. Translocation products in acute 
myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. 
Mol Cell Biol, 24, 2890-904. 
MULLOY, J. C., CAMMENGA, J., BERGUIDO, F. J., WU, K., ZHOU, P., 
COMENZO, R. L., JHANWAR, S., MOORE, M. A. & NIMER, S. D. 2003. 
Maintaining the self-renewal and differentiation potential of human CD34+ 
hematopoietic cells using a single genetic element. Blood, 102, 4369-76. 
MULLOY, J. C., CAMMENGA, J., MACKENZIE, K. L., BERGUIDO, F. J., MOORE, 
M. A. & NIMER, S. D. 2002. The AML1-ETO fusion protein promotes the 
expansion of human hematopoietic stem cells. Blood, 99, 15-23. 
MULLOY, J. C., JANKOVIC, V., WUNDERLICH, M., DELWEL, R., CAMMENGA, 
J., KREJCI, O., ZHAO, H., VALK, P. J., LOWENBERG, B. & NIMER, S. D. 
2005. AML1-ETO fusion protein up-regulates TRKA mRNA expression in 
human CD34+ cells, allowing nerve growth factor-induced expansion. Proc 
Natl Acad Sci U S A, 102, 4016-21. 
MUNUGALAVADLA, V., DORE, L. C., TAN, B. L., HONG, L., VISHNU, M., WEISS, 
M. J. & KAPUR, R. 2005. Repression of c-kit and its downstream substrates 
by GATA-1 inhibits cell proliferation during erythroid maturation. Mol Cell 
Biol, 25, 6747-59. 
NIMER, S. D. & MOORE, M. A. 2004. Effects of the leukemia-associated AML1-
ETO protein on hematopoietic stem and progenitor cells. Oncogene, 23, 
4249-54. 
NISHIDA, S., HOSEN, N., SHIRAKATA, T., KANATO, K., YANAGIHARA, M., 
NAKATSUKA, S., HOSHIDA, Y., NAKAZAWA, T., HARADA, Y., TATSUMI, 
N., TSUBOI, A., KAWAKAMI, M., OKA, Y., OJI, Y., AOZASA, K., KAWASE, 
I. & SUGIYAMA, H. 2006. AML1-ETO rapidly induces acute myeloblastic 
leukemia in cooperation with the Wilms tumor gene, WT1. Blood, 107, 3303-
12. 
NISSON, P. E., WATKINS, P. C. & SACCHI, N. 1992. Transcriptionally active 
chimeric gene derived from the fusion of the AML1 gene and a novel gene 
on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet, 63, 
81-8. 
NORTH, T., GU, T. L., STACY, T., WANG, Q., HOWARD, L., BINDER, M., 
MARIN-PADILLA, M. & SPECK, N. A. 1999. Cbfa2 is required for the 
formation of intra-aortic hematopoietic clusters. Development, 126, 2563-75. 
  References 
 232 
NUCIFORA, G., BEGY, C. R., ERICKSON, P., DRABKIN, H. A. & ROWLEY, J. D. 
1993. The 3;21 translocation in myelodysplasia results in a fusion transcript 
between the AML1 gene and the gene for EAP, a highly conserved protein 
associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad 
Sci U S A, 90, 7784-8. 
O'CONNELL, R. M., RAO, D. S., CHAUDHURI, A. A., BOLDIN, M. P., TAGANOV, 
K. D., NICOLL, J., PAQUETTE, R. L. & BALTIMORE, D. 2008. Sustained 
expression of microRNA-155 in hematopoietic stem cells causes a 
myeloproliferative disorder. J Exp Med, 205, 585-94. 
ODAKA, Y., MALLY, A., ELLIOTT, L. T. & MEYERS, S. 2000. Nuclear import and 
subnuclear localization of the proto-oncoprotein ETO (MTG8). Oncogene, 
19, 3584-97. 
OGAWA, E., INUZUKA, M., MARUYAMA, M., SATAKE, M., NAITO-FUJIMOTO, 
M., ITO, Y. & SHIGESADA, K. 1993. Molecular cloning and characterization 
of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related 
DNA binding protein PEBP2 alpha. Virology, 194, 314-31. 
OKUDA, T., CAI, Z., YANG, S., LENNY, N., LYU, C. J., VAN DEURSEN, J. M., 
HARADA, H. & DOWNING, J. R. 1998. Expression of a knocked-in AML1-
ETO leukemia gene inhibits the establishment of normal definitive 
hematopoiesis and directly generates dysplastic hematopoietic progenitors. 
Blood, 91, 3134-43. 
OKUDA, T., TAKEDA, K., FUJITA, Y., NISHIMURA, M., YAGYU, S., YOSHIDA, 
M., AKIRA, S., DOWNING, J. R. & ABE, T. 2000. Biological characteristics 
of the leukemia-associated transcriptional factor AML1 disclosed by 
hematopoietic rescue of AML1-deficient embryonic stem cells by using a 
knock-in strategy. Mol Cell Biol, 20, 319-28. 
OKUDA, T., VAN DEURSEN, J., HIEBERT, S. W., GROSVELD, G. & DOWNING, 
J. R. 1996. AML1, the target of multiple chromosomal translocations in 
human leukemia, is essential for normal fetal liver hematopoiesis. Cell, 84, 
321-30. 
OKUMURA, A. J., PETERSON, L. F., OKUMURA, F., BOYAPATI, A. & ZHANG, D. 
E. 2008. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated 
AML1/RUNX1 DNA-binding sequences to differentially regulate gene 
expression. Blood, 112, 1392-401. 
OKUMURA, F., MATSUNAGA, Y., KATAYAMA, Y., NAKAYAMA, K. I. & 
HATAKEYAMA, S. TRIM8 modulates STAT3 activity through negative 
regulation of PIAS3. J Cell Sci, 123, 2238-45. 
OWEN, C., BARNETT, M. & FITZGIBBON, J. 2008. Familial myelodysplasia and 
acute myeloid leukaemia--a review. Br J Haematol, 140, 123-32. 
PARDALI, E., XIE, X. Q., TSAPOGAS, P., ITOH, S., ARVANITIDIS, K., HELDIN, 
C. H., TEN DIJKE, P., GRUNDSTROM, T. & SIDERAS, P. 2000. Smad and 
AML proteins synergistically confer transforming growth factor beta1 
responsiveness to human germ-line IgA genes. J Biol Chem, 275, 3552-60. 
PASCHKA, P. 2008. Core binding factor acute myeloid leukemia. Semin Oncol, 35, 
410-7. 
  References 
 233 
PASCHKA, P., DU, J., SCHLENK, R. F., BULLINGER , L., GAIDZIK, V. I., 
CORBACIOGLU, A., BENNER, A., ZUCKNICK, M., STEGELMANN, F., 
SPÄTH, D., KAYSER, S., SCHLEGELBERGER, B., KRAUTER, J., 
GANSER, A., DÖHNER, H. & DÖHNER, K. 2009. Mutations in the Fms-
Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor 
Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the 
German-Austrian AML Study Group (AMLSG). Blood (ASH Annual Meeting 
Abstracts), 114. 
PASCHKA, P., MARCUCCI, G., RUPPERT, A. S., MROZEK, K., CHEN, H., 
KITTLES, R. A., VUKOSAVLJEVIC, T., PERROTTI, D., VARDIMAN, J. W., 
CARROLL, A. J., KOLITZ, J. E., LARSON, R. A., BLOOMFIELD, C. D., 
CANCER & LEUKEMIA GROUP, B. 2006. Adverse prognostic significance 
of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a 
Cancer and Leukemia Group B Study. J Clin Oncol, 24, 3904-11. 
PASCHKA, P., RADMACHER, M. D., MARCUCCI, G., RUPPERT, A. S., 
VUKOSAVLJEVIC, T., WHITMAN, S. P., MROZEK, K., LIU, C., R. A. 
LARSON, R. A. & BLOOMFIELD, C. D. 2007. Outcome prediction in adult 
core binding factor (CBF) acute myeloid leukemia (AML) with gene 
expression profiling: A Cancer and Leukemia Group B (CALGB) study. 
ASCO MEETING ABSTRACTS. 
PELLEGRINI, S., CENSINI, S., GUIDOTTI, S., IACOPETTI, P., ROCCHI, M., 
BIANCHI, M., COVACCI, A. & GABRIELLI, F. 2002. A human short-chain 
dehydrogenase/reductase gene: structure, chromosomal localization, tissue 
expression and subcellular localization of its product. Biochim Biophys Acta, 
1574, 215-22. 
PETERSON, L. F., BOYAPATI, A., AHN, E. Y., BIGGS, J. R., OKUMURA, A. J., 
LO, M. C., YAN, M. & ZHANG, D. E. 2007a. Acute myeloid leukemia with 
the 8q22;21q22 translocation: secondary mutational events and alternative 
t(8;21) transcripts. Blood, 110, 799-805. 
PETERSON, L. F., YAN, M. & ZHANG, D. E. 2007b. The p21Waf1 pathway is 
involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-
ETO. Blood, 109, 4392-8. 
PETERSON, L. F. & ZHANG, D. E. 2004. The 8;21 translocation in 
leukemogenesis. Oncogene, 23, 4255-62. 
PETROVICK, M. S., HIEBERT, S. W., FRIEDMAN, A. D., HETHERINGTON, C. J., 
TENEN, D. G. & ZHANG, D. E. 1998. Multiple functional domains of AML1: 
PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell 
Biol, 18, 3915-25. 
PHAN, V. T., SHULTZ, D. B., TRUONG, B. T., BLAKE, T. J., BROWN, A. L., 
GONDA, T. J., LE BEAU, M. M. & KOGAN, S. C. 2003. Cooperation of 
cytokine signaling with chimeric transcription factors in leukemogenesis: 
PML-retinoic acid receptor alpha blocks growth factor-mediated 
differentiation. Mol Cell Biol, 23, 4573-85. 
  References 
 234 
REUTHER, G. W., LAMBERT, Q. T., CALIGIURI, M. A. & DER, C. J. 2000. 
Identification and characterization of an activating TrkA deletion mutation in 
acute myeloid leukemia. Mol Cell Biol, 20, 8655-66. 
RHOADES, K. L., HETHERINGTON, C. J., HARAKAWA, N., YERGEAU, D. A., 
ZHOU, L., LIU, L. Q., LITTLE, M. T., TENEN, D. G. & ZHANG, D. E. 2000. 
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible 
transgenic mouse model. Blood, 96, 2108-15. 
RHOADES, K. L., HETHERINGTON, C. J., ROWLEY, J. D., HIEBERT, S. W., 
NUCIFORA, G., TENEN, D. G. & ZHANG, D. E. 1996. Synergistic up-
regulation of the myeloid-specific promoter for the macrophage colony-
stimulating factor receptor by AML1 and the t(8;21) fusion protein may 
contribute to leukemogenesis. Proc Natl Acad Sci U S A, 93, 11895-900. 
ROBB, L., TARRANT, J., GROOM, J., IBRAHIM, M., LI, R., BOROBAKAS, B. & 
WRIGHT, M. D. 2001. Molecular characterisation of mouse and human 
TSSC6: evidence that TSSC6 is a genuine member of the tetraspanin 
superfamily and is expressed specifically in haematopoietic organs. Biochim 
Biophys Acta, 1522, 31-41. 
ROSENBAUER, F., KOSCHMIEDER, S., STEIDL, U. & TENEN, D. G. 2005. Effect 
of transcription-factor concentrations on leukemic stem cells. Blood, 106, 
1519-24. 
ROSENBAUER, F., WAGNER, K., KUTOK, J. L., IWASAKI, H., LE BEAU, M. M., 
OKUNO, Y., AKASHI, K., FIERING, S. & TENEN, D. G. 2004. Acute 
myeloid leukemia induced by graded reduction of a lineage-specific 
transcription factor, PU.1. Nat Genet, 36, 624-30. 
ROUDAIA, L., CHENEY, M. D., MANUYLOVA, E., CHEN, W., MORROW, M., 
PARK, S., LEE, C. T., KAUR, P., WILLIAMS, O., BUSHWELLER, J. H. & 
SPECK, N. A. 2009. CBFbeta is critical for AML1-ETO and TEL-AML1 
activity. Blood, 113, 3070-9. 
ROWLEY, J. D. 1973. Identificaton of a translocation with quinacrine fluorescence 
in a patient with acute leukemia. Ann Genet, 16, 109-12. 
RUCKER, F. G., SANDER, S., DOHNER, K., DOHNER, H., POLLACK, J. R. & 
BULLINGER, L. 2006. Molecular profiling reveals myeloid leukemia cell 
lines to be faithful model systems characterized by distinct genomic 
aberrations. Leukemia, 20, 994-1001. 
SALOMON-NGUYEN, F., BUSSON-LE CONIAT, M., LAFAGE POCHITALOFF, 
M., MOZZICONACCI, J., BERGER, R. & BERNARD, O. A. 2000. AML1-
MTG16 fusion gene in therapy-related acute leukemia with 
t(16;21)(q24;q22): two new cases. Leukemia, 14, 1704-5. 
SCHESSL, C., RAWAT, V. P., CUSAN, M., DESHPANDE, A., KOHL, T. M., 
ROSTEN, P. M., SPIEKERMANN, K., HUMPHRIES, R. K., SCHNITTGER, 
S., KERN, W., HIDDEMANN, W., QUINTANILLA-MARTINEZ, L., 
BOHLANDER, S. K., FEURING-BUSKE, M. & BUSKE, C. 2005. The AML1-
ETO fusion gene and the FLT3 length mutation collaborate in inducing acute 
leukemia in mice. J Clin Invest, 115, 2159-68. 
SCHLENK, R. F., BENNER, A., KRAUTER, J., BUCHNER, T., SAUERLAND, C., 
EHNINGER, G., SCHAICH, M., MOHR, B., NIEDERWIESER, D., KRAHL, 
  References 
 235 
R., PASOLD, R., DOHNER, K., GANSER, A., DOHNER, H. & HEIL, G. 
2004. Individual patient data-based meta-analysis of patients aged 16 to 60 
years with core binding factor acute myeloid leukemia: a survey of the 
German Acute Myeloid Leukemia Intergroup. J Clin Oncol, 22, 3741-50. 
SCHLENK, R. F., PASQUINI, M. C., PEREZ, W. S., ZHANG, M. J., KRAUTER, J., 
ANTIN, J. H., BASHEY, A., BOLWELL, B. J., BUCHNER, T., CAHN, J. Y., 
CAIRO, M. S., COPELAN, E. A., CUTLER, C. S., DOHNER, H., GALE, R. 
P., ILHAN, O., LAZARUS, H. M., LIESVELD, J. L., LITZOW, M. R., MARKS, 
D. I., MAZIARZ, R. T., MCCARTHY, P. L., NIMER, S. D., SIERRA, J., 
TALLMAN, M. S., WEISDORF, D. J., HOROWITZ, M. M. & GANSER, A. 
2008. HLA-identical sibling allogeneic transplants versus chemotherapy in 
acute myelogenous leukemia with t(8;21) in first complete remission: 
collaborative study between the German AML Intergroup and CIBMTR. Biol 
Blood Marrow Transplant, 14, 187-96. 
SCHLESSINGER, K., HALL, A. & TOLWINSKI, N. 2009. Wnt signaling pathways 
meet Rho GTPases. Genes Dev, 23, 265-77. 
SCHNITTGER, S., HAFERLACH, C., ULKE, M., ALPERMANN, T., KERN, W. & 
HAFERLACH, T. 2010. IDH1 mutations are detected in 6.6% of 1414 AML 
patients and are associated with intermediate risk karyotype and 
unfavorable prognosis in adults younger than 60 years and unmutated 
NPM1 status. Blood, 116, 5486-96. 
SCHWIEGER, M., LOHLER, J., FRIEL, J., SCHELLER, M., HORAK, I. & 
STOCKING, C. 2002. AML1-ETO inhibits maturation of multiple 
lymphohematopoietic lineages and induces myeloblast transformation in 
synergy with ICSBP deficiency. J Exp Med, 196, 1227-40. 
SCOTT, L. M., MUELLER, L. & COLLINS, S. J. 1996. E3, a hematopoietic-specific 
transcript directly regulated by the retinoic acid receptor alpha. Blood, 88, 
2517-30. 
SHANKAR, D. B., CHENG, J. C. & SAKAMOTO, K. M. 2005. Role of cyclic AMP 
response element binding protein in human leukemias. Cancer, 104, 1819-
24. 
SHAPIRO, M. B. & SENAPATHY, P. 1987. RNA splice junctions of different 
classes of eukaryotes: sequence statistics and functional implications in 
gene expression. Nucleic Acids Res, 15, 7155-74. 
SHIMADA, H., ICHIKAWA, H., NAKAMURA, S., KATSU, R., IWASA, M., 
KITABAYASHI, I. & OHKI, M. 2000. Analysis of genes under the 
downstream control of the t(8;21) fusion protein AML1-MTG8: 
overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell 
proliferation in response to G-CSF. Blood, 96, 655-63. 
SHIMIZU, K., KITABAYASHI, I., KAMADA, N., ABE, T., MASEKI, N., SUZUKAWA, 
K. & OHKI, M. 2000. AML1-MTG8 leukemic protein induces the expression 
of granulocyte colony-stimulating factor (G-CSF) receptor through the up-
regulation of CCAAT/enhancer binding protein epsilon. Blood, 96, 288-96. 
SHIMIZU, R., KUROHA, T., OHNEDA, O., PAN, X., OHNEDA, K., TAKAHASHI, 
S., PHILIPSEN, S. & YAMAMOTO, M. 2004. Leukemogenesis caused by 
incapacitated GATA-1 function. Mol Cell Biol, 24, 10814-25. 
  References 
 236 
SLOVAK, M. L., KOPECKY, K. J., CASSILETH, P. A., HARRINGTON, D. H., 
THEIL, K. S., MOHAMED, A., PAIETTA, E., WILLMAN, C. L., HEAD, D. R., 
ROWE, J. M., FORMAN, S. J. & APPELBAUM, F. R. 2000. Karyotypic 
analysis predicts outcome of preremission and postremission therapy in 
adult acute myeloid leukemia: a Southwest Oncology Group/Eastern 
Cooperative Oncology Group Study. Blood, 96, 4075-83. 
SMITH, M. L., ARCH, R., SMITH, L. L., BAINTON, N., NEAT, M., TAYLOR, C., 
BONNET, D., CAVENAGH, J. D., ANDREW LISTER, T. & FITZGIBBON, J. 
2005. Development of a human acute myeloid leukaemia screening panel 
and consequent identification of novel gene mutation in FLT3 and CCND3. 
Br J Haematol, 128, 318-23. 
SMITH, S. C. & THEODORESCU, D. 2009. Learning therapeutic lessons from 
metastasis suppressor proteins. Nat Rev Cancer, 9, 253-64. 
SROCZYNSKA, P., LANCRIN, C., KOUSKOFF, V. & LACAUD, G. 2009. The 
differential activities of Runx1 promoters define milestones during embryonic 
hematopoiesis. Blood, 114, 5279-89. 
STAMATOPOULOS, B., MEULEMAN, N., HAIBE-KAINS, B., SAUSSOY, P., VAN 
DEN NESTE, E., MICHAUX, L., HEIMANN, P., MARTIAT, P., BRON, D. & 
LAGNEAUX, L. 2009. microRNA-29c and microRNA-223 down-regulation 
has in vivo significance in chronic lymphocytic leukemia and improves 
disease risk stratification. Blood, 113, 5237-45. 
TAKAHASHI, S. 2011. Current findings for recurring mutations in acute myeloid 
leukemia. J Hematol Oncol, 4, 36. 
TAKAKURA, N., WATANABE, T., SUENOBU, S., YAMADA, Y., NODA, T., ITO, Y., 
SATAKE, M. & SUDA, T. 2000. A role for hematopoietic stem cells in 
promoting angiogenesis. Cell, 102, 199-209. 
TAKUWA, Y. 2002. Subtype-specific differential regulation of Rho family G proteins 
and cell migration by the Edg family sphingosine-1-phosphate receptors. 
Biochim Biophys Acta, 1582, 112-20. 
TANAKA, K., TANAKA, T., KUROKAWA, M., IMAI, Y., OGAWA, S., MITANI, K., 
YAZAKI, Y. & HIRAI, H. 1998. The AML1/ETO(MTG8) and AML1/Evi-1 
leukemia-associated chimeric oncoproteins accumulate 
PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1. 
Blood, 91, 1688-99. 
TANAKA, Y., WATANABE, T., CHIBA, N., NIKI, M., KUROIWA, Y., NISHIHIRA, T., 
SATOMI, S., ITO, Y. & SATAKE, M. 1997. The protooncogene product, 
PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity 
with cytoskeletal structures. Oncogene, 15, 677-83. 
TASKESEN, E., BULLINGER, L., CORBACIOGLU, A., SANDERS, M. A., 
ERPELINCK, C. A., WOUTERS, B. J., VAN DER POEL-VAN DE 
LUYTGAARDE, S. C., DAMM, F., KRAUTER, J., GANSER, A., SCHLENK, 
R. F., LOWENBERG, B., DELWEL, R., DOHNER, H., VALK, P. J. & 
DOHNER, K. Prognostic impact, concurrent genetic mutations, and gene 
expression features of AML with CEBPA mutations in a cohort of 1182 
cytogenetically normal AML patients: further evidence for CEBPA double 
mutant AML as a distinctive disease entity. Blood, 117, 2469-75. 
  References 
 237 
TIGHE, J. E. & CALABI, F. 1994. Alternative, out-of-frame runt/MTG8 transcripts 
are encoded by the derivative (8) chromosome in the t(8;21) of acute 
myeloid leukemia M2. Blood, 84, 2115-21. 
TONKS, A., PEARN, L., TONKS, A. J., PEARCE, L., HOY, T., PHILLIPS, S., 
FISHER, J., DOWNING, J. R., BURNETT, A. K. & DARLEY, R. L. 2003. The 
AML1-ETO fusion gene promotes extensive self-renewal of human primary 
erythroid cells. Blood, 101, 624-32. 
UNOKI, M., NISHIDATE, T. & NAKAMURA, Y. 2004. ICBP90, an E2F-1 target, 
recruits HDAC1 and binds to methyl-CpG through its SRA domain. 
Oncogene, 23, 7601-10. 
VAN DE LOCHT, L. T., SMETSERS, T. F., WITTEBOL, S., RAYMAKERS, R. A. & 
MENSINK, E. J. 1994. Molecular diversity in AML1/ETO fusion transcripts in 
patients with t(8;21) positive acute myeloid leukaemia. Leukemia, 8, 1780-4. 
VANGALA, R. K., HEISS-NEUMANN, M. S., RANGATIA, J. S., SINGH, S. M., 
SCHOCH, C., TENEN, D. G., HIDDEMANN, W. & BEHRE, G. 2003. The 
myeloid master regulator transcription factor PU.1 is inactivated by AML1-
ETO in t(8;21) myeloid leukemia. Blood, 101, 270-7. 
VARDIMAN, J. W., THIELE, J., ARBER, D. A., BRUNNING, R. D., BOROWITZ, M. 
J., PORWIT, A., HARRIS, N. L., LE BEAU, M. M., HELLSTROM-
LINDBERG, E., TEFFERI, A. & BLOOMFIELD, C. D. 2009. The 2008 
revision of the World Health Organization (WHO) classification of myeloid 
neoplasms and acute leukemia: rationale and important changes. Blood, 
114, 937-51. 
VASSEN, L., KHANDANPOUR, C., EBELING, P., VAN DER REIJDEN, B. A., 
JANSEN, J. H., MAHLMANN, S., DUHRSEN, U. & MOROY, T. 2009. 
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are 
highly expressed in patients with acute and chronic leukemia. Int J Hematol, 
89, 422-30. 
VIRAPPANE, P., GALE, R., HILLS, R., KAKKAS, I., SUMMERS, K., STEVENS, J., 
ALLEN, C., GREEN, C., QUENTMEIER, H., DREXLER, H., BURNETT, A., 
LINCH, D., BONNET, D., LISTER, T. A. & FITZGIBBON, J. 2008. Mutation 
of the Wilms' tumor 1 gene is a poor prognostic factor associated with 
chemotherapy resistance in normal karyotype acute myeloid leukemia: the 
United Kingdom Medical Research Council Adult Leukaemia Working Party. 
J Clin Oncol, 26, 5429-35. 
WANG, J., HOSHINO, T., REDNER, R. L., KAJIGAYA, S. & LIU, J. M. 1998. ETO, 
fusion partner in t(8;21) acute myeloid leukemia, represses transcription by 
interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad 
Sci U S A, 95, 10860-5. 
WANG, J., SAUNTHARARAJAH, Y., REDNER, R. L. & LIU, J. M. 1999. Inhibitors 
of histone deacetylase relieve ETO-mediated repression and induce 
differentiation of AML1-ETO leukemia cells. Cancer Res, 59, 2766-9. 
WANG, Q., STACY, T., BINDER, M., MARIN-PADILLA, M., SHARPE, A. H. & 
SPECK, N. A. 1996a. Disruption of the Cbfa2 gene causes necrosis and 
hemorrhaging in the central nervous system and blocks definitive 
hematopoiesis. Proc Natl Acad Sci U S A, 93, 3444-9. 
  References 
 238 
WANG, Q., STACY, T., MILLER, J. D., LEWIS, A. F., GU, T. L., HUANG, X., 
BUSHWELLER, J. H., BORIES, J. C., ALT, F. W., RYAN, G., LIU, P. P., 
WYNSHAW-BORIS, A., BINDER, M., MARIN-PADILLA, M., SHARPE, A. H. 
& SPECK, N. A. 1996b. The CBFbeta subunit is essential for CBFalpha2 
(AML1) function in vivo. Cell, 87, 697-708. 
WANG, S., WANG, Q., CRUTE, B. E., MELNIKOVA, I. N., KELLER, S. R. & 
SPECK, N. A. 1993. Cloning and characterization of subunits of the T-cell 
receptor and murine leukemia virus enhancer core-binding factor. Mol Cell 
Biol, 13, 3324-39. 
WANG, S. W. & SPECK, N. A. 1992. Purification of core-binding factor, a protein 
that binds the conserved core site in murine leukemia virus enhancers. Mol 
Cell Biol, 12, 89-102. 
WANG, Y. Y., ZHOU, G. B., YIN, T., CHEN, B., SHI, J. Y., LIANG, W. X., JIN, X. 
L., YOU, J. H., YANG, G., SHEN, Z. X., CHEN, J., XIONG, S. M., CHEN, G. 
Q., XU, F., LIU, Y. W., CHEN, Z. & CHEN, S. J. 2005. AML1-ETO and C-
KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise 
leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A, 102, 
1104-9. 
WARREN, A. J., BRAVO, J., WILLIAMS, R. L. & RABBITTS, T. H. 2000. Structural 
basis for the heterodimeric interaction between the acute leukaemia-
associated transcription factors AML1 and CBFbeta. Embo J, 19, 3004-15. 
WESTENDORF, J. J., YAMAMOTO, C. M., LENNY, N., DOWNING, J. R., 
SELSTED, M. E. & HIEBERT, S. W. 1998. The t(8;21) fusion product, AML-
1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent 
transcription, and blocks granulocytic differentiation. Mol Cell Biol, 18, 322-
33. 
WICHMANN, C., CHEN, L., HEINRICH, M., BAUS, D., PFITZNER, E., ZORNIG, 
M., OTTMANN, O. G. & GREZ, M. 2007. Targeting the oligomerization 
domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-
positive leukemic cells. Cancer Res, 67, 2280-9. 
WIEMELS, J. L., XIAO, Z., BUFFLER, P. A., MAIA, A. T., MA, X., DICKS, B. M., 
SMITH, M. T., ZHANG, L., FEUSNER, J., WIENCKE, J., PRITCHARD-
JONES, K., KEMPSKI, H. & GREAVES, M. 2002. In utero origin of t(8;21) 
AML1-ETO translocations in childhood acute myeloid leukemia. Blood, 99, 
3801-5. 
WOLFORD, J. K. & PROCHAZKA, M. 1998. Structure and expression of the 
human MTG8/ETO gene. Gene, 212, 103-9. 
WOO, H. N., HONG, G. S., JUN, J. I., CHO, D. H., CHOI, H. W., LEE, H. J., 
CHUNG, C. W., KIM, I. K., JO, D. G., PYO, J. O., BERTIN, J. & JUNG, Y. K. 
2004. Inhibition of Bcl10-mediated activation of NF-kappa B by BinCARD, a 
Bcl10-interacting CARD protein. FEBS Lett, 578, 239-44. 
YAGI, R., CHEN, L. F., SHIGESADA, K., MURAKAMI, Y. & ITO, Y. 1999. A WW 
domain-containing yes-associated protein (YAP) is a novel transcriptional 
co-activator. Embo J, 18, 2551-62. 
YAN, M., BUREL, S. A., PETERSON, L. F., KANBE, E., IWASAKI, H., BOYAPATI, 
A., HINES, R., AKASHI, K. & ZHANG, D. E. 2004. Deletion of an AML1-
  References 
 239 
ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia 
development. Proc Natl Acad Sci U S A, 101, 17186-91. 
YAN, M., KANBE, E., PETERSON, L. F., BOYAPATI, A., MIAO, Y., WANG, Y., 
CHEN, I. M., CHEN, Z., ROWLEY, J. D., WILLMAN, C. L. & ZHANG, D. E. 
2006. A previously unidentified alternatively spliced isoform of t(8;21) 
transcript promotes leukemogenesis. Nat Med, 12, 945-9. 
YERGEAU, D. A., HETHERINGTON, C. J., WANG, Q., ZHANG, P., SHARPE, A. 
H., BINDER, M., MARIN-PADILLA, M., TENEN, D. G., SPECK, N. A. & 
ZHANG, D. E. 1997. Embryonic lethality and impairment of haematopoiesis 
in mice heterozygous for an AML1-ETO fusion gene. Nat Genet, 15, 303-6. 
YEYATI, P. L., SHAKNOVICH, R., BOTERASHVILI, S., LI, J., BALL, H. J., 
WAXMAN, S., NASON-BURCHENAL, K., DMITROVSKY, E., ZELENT, A. & 
LICHT, J. D. 1999. Leukemia translocation protein PLZF inhibits cell growth 
and expression of cyclin A. Oncogene, 18, 925-34. 
YIN, C. C., CORTES, J., BARKOH, B., HAYES, K., KANTARJIAN, H. & JONES, D. 
2006. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of 
blast transformation associated with hydroxyurea or antimetabolite therapy. 
Cancer, 106, 1730-8. 
YUAN, Y., ZHOU, L., MIYAMOTO, T., IWASAKI, H., HARAKAWA, N., 
HETHERINGTON, C. J., BUREL, S. A., LAGASSE, E., WEISSMAN, I. L., 
AKASHI, K. & ZHANG, D. E. 2001. AML1-ETO expression is directly 
involved in the development of acute myeloid leukemia in the presence of 
additional mutations. Proc Natl Acad Sci U S A, 98, 10398-403. 
ZENG, C., VAN WIJNEN, A. J., STEIN, J. L., MEYERS, S., SUN, W., SHOPLAND, 
L., LAWRENCE, J. B., PENMAN, S., LIAN, J. B., STEIN, G. S. & HIEBERT, 
S. W. 1997. Identification of a nuclear matrix targeting signal in the leukemia 
and bone-related AML/CBF-alpha transcription factors. Proc Natl Acad Sci 
U S A, 94, 6746-51. 
ZHANG, D. E., HETHERINGTON, C. J., MEYERS, S., RHOADES, K. L., LARSON, 
C. J., CHEN, H. M., HIEBERT, S. W. & TENEN, D. G. 1996. CCAAT 
enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically 
activate the macrophage colony-stimulating factor receptor promoter. Mol 
Cell Biol, 16, 1231-40. 
ZHANG, J., HUG, B. A., HUANG, E. Y., CHEN, C. W., GELMETTI, V., 
MACCARANA, M., MINUCCI, S., PELICCI, P. G. & LAZAR, M. A. 2001. 
Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell 
Biol, 21, 156-63. 
ZHANG, J., KALKUM, M., YAMAMURA, S., CHAIT, B. T. & ROEDER, R. G. 2004. 
E protein silencing by the leukemogenic AML1-ETO fusion protein. Science, 
305, 1286-9. 
ZHANG, Y., STRISSEL, P., STRICK, R., CHEN, J., NUCIFORA, G., LE BEAU, M. 
M., LARSON, R. A. & ROWLEY, J. D. 2002. Genomic DNA breakpoints in 
AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and 
DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A, 
99, 3070-5. 
  References 
 240 
ZHANG, Y. E. 2009. Non-Smad pathways in TGF-beta signaling. Cell Res, 19, 
128-39. 
 
 
 
Appendix A   Exon Arrays 
 241 
Appendix A 
 
Gene Lists derived from Exon Arrays 
 
Appendix A   Exon Arrays 
 242 
Table 30 Gene List of 448 differentially expressed genes with FDR p<0.05 and FC +/-1 using the Core 
metaprobeset file on the Human Exon 1.0 ST array. 
GENE 
SYMBOL 
GO BIOLOGICAL 
PROCESS 
GO CELLULAR 
COMPONENT 
GO MOLECULAR 
FUNCTION 
p-VALUE FOLD-
CHANGE  
MEIS1 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
4.30E-06 -21.7739 
HOXA9 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
7.75E-06 -14.269 
CPNE8    4.92E-06 -13.8429 
SLC40A1 ion transport  cytoplasm  iron ion 
transmembrane 
transporter 
activity  
5.93E-05 -9.27787 
KIAA0125    1.68E-06 -9.23424 
CAPG protein complex 
assembly  
nucleus  actin binding  8.71E-06 -7.37208 
C1orf150    2.27E-06 -7.3061 
ANGPT1 angiogenesis  extracellular 
region  
receptor binding  0.00035529 -6.64078 
HOXA5 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00010866
9 
-6.48519 
LAT2 immune response  plasma 
membrane  
protein binding  2.80E-10 -6.46607 
NRG4  extracellular 
region  
growth factor 
activity  
1.57E-05 -6.3083 
PLXNC1 cell adhesion  intracellular  receptor activity  2.44E-06 -5.87562 
KIAA0125    5.81E-08 -5.72191 
PBX3 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00051959
2 
-5.61075 
COL4A5  extracellular 
region  
extracellular 
matrix structural 
constituent  
0.00015335
4 
-5.18577 
TSPAN2  membrane   0.00077091
2 
-5.16152 
WBP5   protein binding  2.77E-05 -5.08686 
hCG_1645
516 
regulation of 
transcription, 
DNA-dependent  
 DNA binding  6.39E-07 -5.04596 
HOXB3 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00046102
4 
-4.92716 
LTBP1 biological_process  extracellular 
region  
transforming 
growth factor beta 
receptor activity  
0.00048890
4 
-4.92319 
HOXB6 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00011744
9 
-4.90793 
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CTSW proteolysis   cysteine-type 
endopeptidase 
activity  
1.36E-05 -4.80151 
TSPAN32 cell-cell signaling  membrane  molecular function  6.02E-12 -4.58844 
NGFRAP1 apoptosis  nucleus  protein binding  9.85E-06 -4.53085 
SPNS3 lipid transport  membrane   8.97E-08 -4.40062 
MED12L transcription  nucleus  transcription 
regulator activity  
8.66E-06 -4.38581 
HOXB2 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
7.82E-05 -4.27036 
MPP7  tight junction  protein binding  7.15E-06 -4.18498 
BTBD11  membrane  DNA binding  0.00016181
7 
-4.13874 
UGCGL2 protein amino acid 
glycosylation  
endoplasmic 
reticulum  
UDP-glucose: 
glycoprotein 
glucosyltransferas
e activity 
0.00019626
5 
-3.99205 
HNRPLL mRNA processing  nucleus  nucleotide binding  1.59E-05 -3.90223 
HOXB8 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00118619 -3.78397 
EMR1 cell adhesion  plasma 
membrane  
G-protein coupled 
receptor activity  
6.08E-05 -3.78063 
SLC44A1 transport  membrane  choline 
transmembrane 
transporter 
activity  
4.46E-05 -3.75674 
HOXB5 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00100033 -3.72638 
    0.00054972
5 
-3.50534 
HOXA7 negative 
regulation of 
transcription from 
RNA polymer 
nucleus  transcription 
factor activity  
0.00010689
5 
-3.49503 
SCHIP1 Biological process  cellular_compo
nent  
molecular_functio
n  
0.00047093
8 
-3.41816 
LGALS1 regulation of 
apoptosis  
extracellular 
space  
signal transducer 
activity  
0.00040846
3 
-3.41033 
HOXA4 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription 
factor activity  
0.00080110
1 
-3.4083 
SSX2IP cell adhesion  nucleus  protein binding  1.35E-07 -3.36613 
SELPLG cell adhesion  membrane 
fraction  
receptor binding  1.91E-05 -3.3538 
HOXA2 negative 
regulation of 
transcription from 
RNA polymer 
nucleus  transcription 
factor activity  
0.00038998
2 
-3.28137 
GFI1B regulation of 
transcription 
intracellular   DNA binding  4.59E-06 -3.22941 
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during G1 phase 
of mitoti 
HOXA3 blood vessel 
remodeling  
nucleus  transcription 
factor activity  
0.00032962
9 
-3.17032 
CAT response to 
reactive oxygen 
species  
mitochondrion  aminoacylase 
activity  
2.30E-06 -3.15249 
CXCL2 chemotaxis  extracellular 
region  
chemokine 
activity  
0.00044428
4 
-3.14042 
CYP7B1 lipid metabolic 
process  
endoplasmic 
reticulum  
monooxygenase 
activity  
0.00060780
8 
-3.09312 
SDPR  cytoplasm  phosphatidylserin
e binding  
3.32E-05 -3.09288 
PTPN22 protein amino acid 
dephosphorylation  
cytoplasm  protein tyrosine 
phosphatase 
activity  
2.40E-05 -3.08947 
LSP1 cell motion  plasma 
membrane  
actin binding  0.00027309
5 
-3.07237 
ADCY7 cAMP biosynthetic 
process  
plasma 
membrane  
magnesium ion 
binding  
5.93E-06 -3.02996 
NFIL3 transcription  nucleus  transcription 
factor activity  
3.16E-05 -2.99889 
JAG1 angiogenesis  extracellular 
region  
Notch binding  0.00014994
6 
-2.99747 
CMAH biological_process  cytoplasm  electron carrier 
activity  
3.64E-05 -2.96105 
ALCAM cell adhesion  membrane  receptor binding  0.00106233 -2.95225 
C1orf162  membrane   0.00038703
8 
-2.94159 
PDGFD cell proliferation  extracellular 
region  
growth factor 
activity  
0.00043073
4 
-2.93266 
CD300A immune response  plasma 
membrane  
receptor activity  8.87E-05 -2.92134 
C5orf53  extracellular 
region  
 0.00015467
4 
-2.88712 
SLC46A3  membrane   0.00041774
1 
-2.85646 
C11orf21  cytoplasm   1.05E-07 -2.83386 
PRKCD protein amino acid 
phosphorylation  
nucleus  nucleotide binding  1.13E-05 -2.75581 
KCNK17 ion transport  membrane  voltage-gated ion 
channel activity  
0.00055536
8 
-2.75185 
ABCA1 transport  membrane 
fraction  
nucleotide binding  6.77E-05 -2.7176 
C15orf39    3.18E-09 -2.70099 
LST1 cell 
morphogenesis  
Golgi 
membrane  
molecular_functio
n  
8.74E-05 -2.69105 
CPEB2 regulation of 
translation  
cytoplasm  nucleotide binding  0.00015539
3 
-2.6822 
BST2 humoral immune 
response  
Golgi apparatus  signal transducer 
activity  
0.00109661 -2.68131 
RECK negative peripheral to serine-type 5.03E-05 -2.66901 
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regulation of cell 
cycle  
membrane of 
membrane 
fraction  
endopeptidase 
inhibitor activity  
MAP7 microtubule 
cytoskeleton 
organization  
cytoplasm  structural 
molecule activity  
0.00027893
4 
-2.66847 
FUT7 protein amino acid 
glycosylation  
Golgi apparatus  transferase 
activity, 
transferring 
glycosyl groups  
0.00035261 -2.65019 
TRIM8 biological_proces  cellular_compo
nent  
protein binding  2.65E-06 -2.62267 
AGPAT9 metabolic process  endoplasmic 
reticulum  
1-acylglycerol-3-
phosphate O-
acyltransferase 
activity 
0.00044955
3 
-2.60573 
CAPRIN2 negative 
regulation of cell 
growth  
cytoplasm   3.83E-06 -2.59902 
NIPA1  membrane   9.20E-05 -2.54478 
ITGB7 cell adhesion  integrin 
complex  
magnesium ion 
binding  
0.00110695 -2.54408 
NFE2 nucleosome 
disassembly  
nucleus  transcription 
factor activity  
1.23E-05 -2.53148 
GABARAP
L1 
 intracellular  protein binding  6.77E-06 -2.52939 
SASH3 positive regulation 
of immunoglobulin 
production  
nucleus   1.71E-06 -2.52829 
HOXB4 negative 
regulation of 
transcription from 
RNA polymer 
nucleus  transcription 
factor activity  
0.00079158
1 
-2.52815 
GPR114 neuropeptide 
signaling pathway  
plasma 
membrane  
G-protein coupled 
receptor activity  
3.57E-06 -2.49612 
NCRNA001
73 
   0.00053368
6 
-2.4669 
SLA  cytoplasm  SH3 0.00100925 -2.44588 
C10orf54  membrane  receptor activity  0.00116098 -2.44222 
ECOP    0.00011170
1 
-2.43758 
GBGT1 carbohydrate 
metabolic process  
Golgi 
membrane  
transferase 
activity, 
transferring 
hexosyl groups  
8.19E-05 -2.43647 
GCLM cysteine metabolic 
process  
soluble fraction  glutamate-
cysteine ligase 
activity  
2.10E-05 -2.42582 
BEX2 multicellular 
organismal 
development  
nucleus   0.00069911
3 
-2.38314 
ATXN1 RNA processing  nucleus  RNA binding  0.00027941
4 
-2.38013 
Appendix A   Exon Arrays 
 246 
CTSD autophagic 
vacuole formation  
extracellular 
region  
aspartic-type 
endopeptidase 
activity  
0.00010198
4 
-2.36187 
ITGAX cell adhesion  integrin 
complex  
magnesium ion 
binding  
2.95E-05 -2.36 
FLJ11710    0.00107503 -2.35173 
LAPTM5 transport  lysosomal 
membrane  
 1.29E-05 -2.34841 
    0.00049644
8 
-2.31836 
TBC1D8B regulation of Rab 
GTPase activity  
intracellular  GTPase activator 
activity  
3.22E-05 -2.29215 
ADARB1 mRNA processing  intracellular  double-stranded 
RNA binding  
5.73E-05 -2.24964 
ELL2 transcription  nucleus  RNA polymerase 
II transcription 
factor activity  
0.00096895
6 
-2.23995 
TPM1 positive regulation 
of heart rate by 
epinephrine  
stress fiber  actin binding  3.70E-05 -2.22996 
C9orf89 negative 
regulation of I-
kappaB kinase 
nucleus  CARD domain 
binding  
1.03E-06 -2.1954 
SH2D3C JNK cascade  intracellular  SH3 8.18E-06 -2.18833 
CCND3 positive regulation 
of protein amino 
acid phosphoryla 
cyclin-
dependent 
protein kinase 
holoenzyme 
complex  
protein binding  0.00028401
6 
-2.17201 
GPR132 G1 plasma 
membrane  
receptor activity  0.00040856
1 
-2.16618 
LPXN protein complex 
assembly  
cytoplasm  zinc ion binding  0.00011802
8 
-2.16546 
CD82  plasma 
membrane  
protein binding  0.00018067
7 
-2.15598 
PLCL1 lipid metabolic 
process  
cytoplasm  phosphoinositide 
phospholipase C 
activity  
0.00080790
5 
-2.13828 
KIAA0513  cytoplasm   3.33E-06 -2.12616 
SYTL4 transport  plasma 
membrane  
transporter 
activity  
0.00090419
3 
-2.11296 
ELF4 natural killer cell 
proliferation  
nucleus  transcription 
factor activity  
1.03E-05 -2.08202 
ABCA7 transport  Golgi 
membrane  
nucleotide binding  2.56E-06 -2.06555 
C9orf95 pyridine nucleotide 
biosynthetic 
process  
 nucleotide binding  0.00103088 -2.03839 
NINJ1 cell adhesion  membrane  protein binding  6.61E-05 -2.03284 
GAS2L3 cell cycle arrest  glycosylphosph
atidylinositol-N-
acetylglucosam
inyltran 
protein binding  0.00093272
4 
-2.03145 
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C1orf217    0.0004546 -2.02643 
MAP2K6 activation of 
MAPK activity  
 nucleotide binding  0.00026200
6 
-2.0132 
C17orf91    0.00060445
5 
-2.00719 
BBS2 sperm axoneme 
assembly  
cytoplasm  protein binding  6.43E-05 -1.99647 
GNB5 signal transduction  nucleus  GTPase activity  0.00014155
5 
-1.98786 
WDFY4  membrane  binding  0.00026396
3 
-1.96759 
CYP4V2 visual perception  endoplasmic 
reticulum  
monooxygenase 
activity  
0.00027313
1 
-1.96286 
PPM1M protein amino acid 
dephosphorylation  
nucleus  magnesium ion 
binding  
0.00072551
3 
-1.94834 
AIF1 response to stress  nucleus  calcium ion 
binding  
0.00068417
7 
-1.93043 
BTG2 DNA repair  nucleus  protein binding  0.00032677
5 
-1.92795 
C11orf63    0.00049046
9 
-1.91537 
TMEM65  membrane   0.00047554
9 
-1.91292 
RAB24 autophagy  late endosome  nucleotide binding  0.00017169
3 
-1.90865 
SRXN1 response to 
oxidative stress  
cytoplasm  nucleotide binding  0.00098230
9 
-1.89357 
HEBP1 circadian rhythm  cytoplasm  binding  0.00049608
6 
-1.89158 
ICAM2 cell-cell adhesion  plasma 
membrane  
integrin binding  0.00028206
2 
-1.88933 
BLOC1S1 melanosome 
organization  
cytosol  protein binding  0.00043062
5 
-1.87382 
SLC22A20 ion transport  membrane   0.00032834
7 
-1.87361 
CD97 cell motion  extracellular 
region  
G-protein coupled 
receptor activity  
0.00020392
7 
-1.86541 
MVP protein transport  nucleus  protein binding  0.00020111
5 
-1.86042 
SLC24A6 ion transport  plasma 
membrane  
calcium ion 
binding  
3.35E-05 -1.84444 
RMND5B    0.00017581
6 
-1.84332 
WDFY4  membrane  binding  0.00106092 -1.83932 
ARHGAP2
2 
angiogenesis  intracellular  GTPase activator 
activity  
0.00012819
9 
-1.83507 
MTMR1 dephosphorylation  cellular_compo
nent  
protein tyrosine 
phosphatase 
activity  
0.00024838
3 
-1.82994 
FNBP1 endocytosis  cytoplasm  lipid binding  2.02E-05 -1.82357 
SYTL1 intracellular 
protein transport  
soluble fraction  Rab GTPase 
binding  
7.97E-05 -1.82339 
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SKIL transcription from 
RNA polymerase 
II promoter  
nucleus  nucleotide binding  0.00091316
8 
-1.82193 
PARVG cell adhesion  cytoplasm  actin binding  3.96E-06 -1.81451 
DNMT3B DNA methylation  nucleus  DNA binding  0.00100801 -1.8027 
CNNM1 ion transport  plasma 
membrane  
 0.00061714
8 
-1.7961 
C20orf197    0.00124074 -1.79484 
TGFB1 skeletal system 
development  
extracellular 
region  
type II 
transforming 
growth factor beta 
receptor bind 
2.76E-05 -1.79352 
PLBD2 lipid catabolic 
process  
lysosomal 
lumen  
hydrolase activity  0.00053748
8 
-1.79336 
MBP immune response  plasma 
membrane  
structural 
constituent of 
myelin sheath  
6.41E-05 -1.77519 
IDE proteolysis  extracellular 
space  
metalloendopepti
dase activity  
5.87E-05 -1.76771 
EIF4A1 translation  cytosol  nucleotide binding  0.00063027
7 
-1.75197 
CDRT4    0.00075149
1 
-1.75144 
MYO7B  cytoskeleton  nucleotide binding  0.00097968
6 
-1.74874 
SH3BP2 signal transduction   SH3 0.00054876
6 
-1.72992 
ACP2 skeletal system 
development  
lysosomal 
membrane  
phosphotyrosine 
binding  
0.00017887
4 
-1.70914 
DPEP2 proteolysis  membrane  peptidase activity  2.22E-05 -1.69009 
OPHN1 substrate-bound 
cell migration, cell 
extension  
intracellular  actin binding  0.00033065
2 
-1.68806 
CCDC122    1.80E-05 -1.67325 
VAV1 phagocytosis  intracellular  transcription 
factor activity  
5.22E-05 -1.66865 
SMAD3 negative 
regulation of 
transcription from 
RNA polymer 
intracellular  double-stranded 
DNA binding  
0.00026227
3 
-1.65456 
OR2G3 signal transduction  plasma 
membrane  
receptor activity  0.00093124
1 
-1.64773 
AMPD3 purine base 
metabolic process  
 AMP deaminase 
activity  
0.00034953
4 
-1.6454 
SIPA1 cytoskeleton 
organization  
intracellular  GTPase activator 
activity  
2.70E-06 -1.6328 
CEBPA  urea cycle   nucleus  RNA polymerase 
II transcription 
factor activity, 
enha 
0.00071064
9 
-1.62943 
TALDO1 carbohydrate 
metabolic process  
cytoplasm  transaldolase 
activity  
8.10E-05 -1.62352 
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GARNL4 regulation of small 
GTPase mediated 
signal transducti 
intracellular  GTPase activator 
activity  
0.00068165
4 
-1.61798 
PLCB2 phospholipid 
metabolic process  
 phosphoinositide 
phospholipase C 
activity  
0.00053408
8 
-1.61757 
SPON2 immune response  extracellular 
region  
protein binding  0.00011811
4 
-1.61712 
NUP210 protein transport  nucleus  protein binding  0.00022354
3 
-1.61167 
PPCDC coenzyme A 
biosynthetic 
process  
 phosphopantothe
noylcysteine 
decarboxylase 
activity  
4.65E-05 -1.58971 
NINJ2 cell adhesion  integral to 
plasma 
membrane  
protein binding  0.00037842
9 
-1.58717 
VCL cell motion  cytoplasm  actin binding  0.00044513
1 
-1.58274 
LRRC49  cytoplasm  protein binding  0.00043092
3 
-1.56565 
SLC25A28 ion transport  mitochondrion  binding  0.00027886
7 
-1.5616 
ZNF133 transcription  intracellular  transcription 
factor activity  
0.00053971 -1.55992 
SEMA4D anti-apoptosis  membrane  receptor activity  0.00049174
8 
-1.52265 
C14orf83  membrane   2.89E-05 -1.51411 
STK10 protein amino acid 
phosphorylation  
 nucleotide binding  3.62E-06 -1.51347 
FGD3 regulation of cell 
shape  
ruffle  guanyl-nucleotide 
exchange factor 
activity  
0.00037683 -1.50351 
ENKUR  cilium  calmodulin 
binding  
0.00022718
5 
-1.4962 
RIPK3 protein 
modification 
process  
intracellular  nucleotide binding  0.00013849
2 
-1.49389 
GPT2 biosynthetic 
process  
 L-alanine:2-
oxoglutarate 
aminotransferase 
activity 
0.00071871
4 
-1.47947 
SERGEF signal transduction  nucleus  guanyl-nucleotide 
exchange factor 
activity  
0.00112327 -1.46573 
LTB4R2 chemotaxis  membrane 
fraction  
leukotriene B4 
receptor activity  
0.00120594 -1.4653 
CLNK immune response  intracellular  SH3 0.00026334
7 
-1.46473 
PTPN6 protein amino acid 
dephosphorylation  
nucleus  protein tyrosine 
phosphatase 
activity  
0.00053509
4 
-1.46037 
AACS lipid metabolic cytoplasm  ligase activity  0.00074441 -1.45965 
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process  7 
PI4KA phosphatidylinosit
ol biosynthetic 
process  
Golgi-
associated 
vesicle  
1-
phosphatidylinosit
ol 4-kinase 
activity  
0.00114092 -1.4591 
TRABD    0.00014540
1 
-1.45805 
SH3GLB2  cytoplasm  protein binding  0.00065121
2 
-1.45739 
GPR107  membrane   0.00093797 -1.45449 
RGS14 regulation of G-
protein coupled 
receptor protein 
sign 
membrane  receptor signaling 
protein activity  
0.00016773
2 
-1.45232 
ANKMY1   zinc ion binding  0.00044075 -1.44591 
NDNL2 regulation of 
transcription, 
DNA-dependent  
nucleus  protein binding  0.00042686
6 
-1.44225 
TMBIM4  membrane  protein binding  0.00011066
7 
-1.43443 
FLJ37396  membrane   0.00123062 -1.43338 
GRK6 protein amino acid 
phosphorylation  
membrane  nucleotide binding  2.27E-05 -1.43099 
CDK9 transcription  nucleus  nucleotide binding  0.00015557
4 
-1.43001 
TM2D3  membrane   0.00012749
1 
-1.42315 
REEP6  membrane   0.00121025 -1.42281 
KLC1 axon cargo 
transport  
cytoplasm  microtubule motor 
activity  
0.00038707
1 
-1.41655 
SH3BP1 signal transduction  intracellular  GTPase activator 
activity  
0.00118531 -1.40241 
TSLP  extracellular 
region  
cytokine activity  0.00085544
1 
-1.40176 
NUDT13   hydrolase activity  0.00033758
2 
-1.38994 
PSD4 regulation of ARF 
protein signal 
transduction  
intracellular  ARF guanyl-
nucleotide 
exchange factor 
activity  
0.00031228
8 
-1.37548 
C12orf59  membrane   0.00069524 -1.35451 
GFER spermatogenesis  cellular_compo
nent  
protein binding  0.00080958
2 
-1.34615 
TICAM1  apoptosis  cytosol  signal transducer 
activity  
0.00056860
5 
-1.34504 
CCDC84    0.00041333 -1.34298 
HTT urea cycle  soluble fraction  transcription 
corepressor 
activity  
0.00082696
9 
-1.33302 
ELMOD3 phagocytosis  cytoskeleton   0.00087833
1 
-1.33282 
UBAC2  membrane   0.00115142 -1.32839 
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FAM78A    0.00040379 -1.32732 
DEF6  nucleus   3.01E-06 -1.30322 
HPS1 lysosome 
organization  
membrane 
fraction  
protein 
dimerization 
activity  
5.66E-06 -1.25301 
TOP3A DNA topological 
change  
nucleus  DNA 
topoisomerase 
type I activity  
0.00017297
2 
1.22896 
DDX56 rRNA processing  nucleus  nucleotide binding  0.00120209 1.30068 
USP10 ubiquitin-
dependent protein 
catabolic process  
 ubiquitin 
thiolesterase 
activity  
0.00085000
3 
1.33409 
NECAB3 protein secretion  Golgi cis 
cisterna  
calcium ion 
binding  
0.00024576
1 
1.33518 
YTHDF2 humoral immune 
response  
  0.00057162
3 
1.33732 
RAB40C small GTPase 
mediated signal 
transduction  
plasma 
membrane  
nucleotide binding  0.00023237
4 
1.33889 
AHCTF1 transcription  nucleus  DNA binding  0.00090155
6 
1.35375 
TPO response to 
oxidative stress  
cytoplasm  iodide peroxidase 
activity  
0.00087567
1 
1.36082 
CCNG2 cell cycle 
checkpoint  
cytoplasm   0.00121933 1.37762 
LPCAT4 metabolic process  endoplasmic 
reticulum  
1-acylglycerol-3-
phosphate O-
acyltransferase 
activity 
0.00095470
2 
1.38109 
C20orf4   protein binding  0.00023398
8 
1.38656 
C7orf68 response to stress  cellular_compo
nent  
molecular_functio
n  
0.00047319
3 
1.39432 
CTNNB1 negative 
regulation of 
transcription from 
RNA polymer 
membrane 
fraction  
chromatin binding  0.00114135 1.39591 
DKFZp451
A211 
   0.0011624 1.39641 
TMEM11 signal transduction  integral to 
plasma 
membrane  
G-protein coupled 
receptor activity  
0.00048581
5 
1.39782 
LMBR1  membrane  receptor activity  0.00083940
8 
1.40494 
WIPF1 protein complex 
assembly  
cytoplasm  actin binding  0.00096310
8 
1.40696 
CDH26 cell adhesion  plasma 
membrane  
calcium ion 
binding  
0.00037851
6 
1.40968 
C8orf41  nucleus   0.00010168
1 
1.42226 
MGAT5 protein amino acid 
N-linked 
glycosylation  
Golgi 
membrane  
transferase 
activity, 
transferring 
7.83E-05 1.42842 
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glycosyl groups  
NR2F6 transcription  nucleus  transcription 
factor activity  
5.89E-05 1.43035 
TMEM41A  membrane   3.45E-05 1.4413 
SCGB3A1 negative 
regulation of cell 
growth  
extracellular 
region  
cytokine activity  0.00114653 1.44361 
BLMH proteolysis  soluble fraction  aminopeptidase 
activity  
0.00024046 1.44732 
RPS6KA4 regulation of 
transcription, 
DNA-dependent  
nucleus  nucleotide binding  6.78E-06 1.44786 
TBC1D14 regulation of Rab 
GTPase activity  
intracellular  GTPase activator 
activity  
0.00036896
6 
1.45898 
ZC3H3   nucleic acid 
binding  
0.00048886
7 
1.46274 
C1orf96    0.00067468
5 
1.4632 
ZNF662 transcription  intracellular  DNA binding  0.00036817
2 
1.46757 
CLN6 ganglioside 
metabolic process  
endoplasmic 
reticulum  
protein 
homodimerization 
activity  
0.00106363 1.47062 
PARD6G cell cycle  cytoplasm  protein binding  0.00020785
6 
1.47234 
GNG7 behavioral fear 
response  
heterotrimeric 
G-protein 
complex  
signal transducer 
activity  
0.00028704
3 
1.4755 
ZNF280B transcription  intracellular  DNA binding  0.00097827
3 
1.48491 
LSM14B    0.00072241
1 
1.48495 
KIAA1383    0.00071962
8 
1.48661 
CRBN RNA processing  cytoplasm  ATP-dependent 
peptidase activity  
0.00033715
8 
1.48972 
LOC43991
4 
   0.00034692
4 
1.4901 
C11orf84    0.00036749 1.49155 
CCND1 G1 cyclin-
dependent 
protein kinase 
holoenzyme 
complex  
protein kinase 
activity  
0.00098167
3 
1.49296 
ATF4 gluconeogenesis  nucleus  transcription 
factor activity  
0.00048602
3 
1.49855 
FMNL2 cellular 
component 
organization  
cytoplasm  actin binding  0.0011962 1.50194 
MEST mesoderm 
development  
Golgi apparatus  catalytic activity  0.00058647
6 
1.50222 
DOK1 cell surface 
receptor linked 
 insulin receptor 
binding  
0.00095430
8 
1.503 
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signal transduction  
IPO7 protein import into 
nucleus, docking  
soluble fraction  small GTPase 
regulator activity  
0.00013722
9 
1.50949 
PLXND1 signal transduction  intracellular  receptor activity  0.00080774
4 
1.52517 
LRP5 gastrulation with 
mouth forming 
second  
mitochondrion  receptor activity  0.00089286
6 
1.52563 
KDM4B transcription  nucleus  nucleic acid 
binding  
0.00031177 1.52597 
NT5C2 nucleotide 
metabolic process  
cytoplasm  nucleotide binding  0.00054041
2 
1.52624 
SRrp35 assembly of 
spliceosomal tri-
snRNP  
nucleus  nucleotide binding  1.16E-05 1.52657 
L2HGDH cellular protein 
metabolic process  
mitochondrion  oxidoreductase 
activity  
0.00020690
4 
1.53355 
PLAU proteolysis  extracellular 
region  
serine-type 
endopeptidase 
activity  
0.00025410
2 
1.53373 
F11R inflammatory 
response  
plasma 
membrane  
protein binding  0.0011187 1.53788 
MIXL1 endoderm 
formation  
nucleus  transcription 
factor activity  
0.00055259
7 
1.54255 
SYNGR1  integral to plasma membrane  0.00039048
9 
1.54497 
CMTM7 chemotaxis  extracellular 
space  
cytokine activity  0.00015648
6 
1.5485 
RNF219   protein binding  0.00083857
2 
1.56961 
NBL1 negative 
regulation of cell 
cycle  
extracellular 
region  
 0.00030432
8 
1.57059 
SHB angiogenesis  cytoplasm  SH3 0.00094556
4 
1.57328 
LPO response to 
oxidative stress  
extracellular 
region  
peroxidase activity  8.88E-05 1.57529 
RAB43 small GTPase 
mediated signal 
transduction  
plasma 
membrane  
nucleotide binding  0.00025538
1 
1.57679 
TTC28   binding  0.00103917 1.58417 
CORO6    0.0010704 1.59034 
CRBN RNA processing  cytoplasm  ATP-dependent 
peptidase activity  
0.00098672
8 
1.60102 
GALNT1 protein amino acid 
O-linked 
glycosylation via 
serine  
extracellular 
region  
polypeptide N-
acetylgalactosami
nyltransferase 
activit 
0.00079425
8 
1.60304 
SCMH1 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription factor 
activity  
0.00037107
8 
1.60737 
PITPNM2 transport  intracellular  calcium ion 
binding  
0.00064189
9 
1.60756 
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FAM129A negative 
regulation of 
protein amino acid 
phosphoryla 
cytoplasm  molecular_functio
n  
0.00035230
7 
1.6113 
TRIM47  intracellular  protein binding  0.00043128 1.61221 
SYNGAP1 signal transduction  intracellular  GTPase activator 
activity  
0.0009485 1.6126 
PDE4B signal transduction  soluble fraction  3',5'-cyclic-AMP 
phosphodiesteras
e activity  
0.00027940
5 
1.61386 
TGFBRAP
1 
signal transduction  cytoplasm  transforming 
growth factor beta 
receptor binding  
0.00017788
3 
1.62448 
FLT4 protein amino acid 
phosphorylation  
integral to 
plasma 
membrane  
nucleotide binding  0.00017965
9 
1.63524 
AGPAT2 phosphatidic acid 
biosynthetic 
process  
endoplasmic 
reticulum  
1-acylglycerol-3-
phosphate O-
acyltransferase 
activity 
0.00014942
8 
1.63595 
GALNT2 immunoglobulin 
biosynthetic 
process  
extracellular 
region  
polypeptide N-
acetylgalactosami
nyltransferase 
activit 
1.42E-06 1.638 
NR3C1 regulation of 
gluconeogenesis  
intracellular  transcription factor 
activity  
0.00051590
3 
1.6431 
C12orf42    0.00107498 1.65198 
TNFRSF10
D 
apoptosis  membrane  transmembrane 
receptor activity  
4.09E-05 1.66791 
HK2 glucose metabolic 
process  
mitochondrion  nucleotide binding  5.47E-05 1.67684 
RAB44 small GTPase 
mediated signal 
transduction  
plasma 
membrane  
nucleotide binding  0.00099527
6 
1.67714 
TEX2 sphingolipid 
metabolic process  
membrane  molecular_functio
n  
0.00115724 1.6788 
C2orf65    0.00033847
1 
1.68211 
LOC93622    0.00092914
5 
1.68785 
HYAL2 carbohydrate 
metabolic process  
lysosome  hyalurononglucos
aminidase activity  
0.00029949
6 
1.68874 
PLCB3 intracellular 
signaling cascade  
insoluble 
fraction  
phosphoinositide 
phospholipase C 
activity  
8.09E-05 1.6904 
ALAS1 heme biosynthetic 
process  
mitochondrion  5-aminolevulinate 
synthase activity  
0.00087058
9 
1.69236 
MARCKSL
1 
positive regulation 
of cell proliferation  
plasma 
membrane  
calmodulin binding  0.0012456 1.69944 
PAFAH2 lipid catabolic 
process  
cytoplasm  1-alkyl-2-
acetylglycerophos
phocholine 
esterase activi 
2.31E-06 1.71182 
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GIPC3   protein binding  0.00019705
9 
1.7134 
PGAM5  nucleus   7.39E-05 1.71411 
SLC5A3 inositol metabolic 
process  
integral to 
plasma 
membrane  
transporter activity  0.00085338
6 
1.72229 
PKN3 protein amino acid 
phosphorylation  
intracellular  nucleotide binding  0.00115968 1.7251 
GNPTAB cell differentiation  nucleus  UDP-N-
acetylglucosamine
-lysosomal-
enzyme N-
acetylgluc 
9.45E-05 1.73182 
MMP28 proteolysis  extracellular 
region  
metalloendopeptid
ase activity  
0.00012852
8 
1.73511 
ZHX2 negative 
regulation of 
transcription from 
RNA polymer 
intracellular  transcription factor 
activity  
0.00022665
6 
1.75381 
PLEKHG2 regulation of Rho 
protein signal 
transduction  
intracellular  guanyl-nucleotide 
exchange factor 
activity  
8.15E-05 1.76193 
WEE1 protein amino acid 
phosphorylation  
nucleus  nucleotide binding  1.13E-05 1.76233 
TRIO protein amino acid 
phosphorylation  
intracellular  nucleotide binding  0.00020660
9 
1.79003 
SYTL2 intracellular 
protein transport  
membrane 
fraction  
Rab GTPase 
binding  
0.00064487 1.79181 
NEDD4 protein 
modification 
process  
ubiquitin ligase 
complex  
ubiquitin-protein 
ligase activity  
0.00092050
8 
1.81864 
ACADSB lipid metabolic 
process  
mitochondrion  acyl-CoA 
dehydrogenase 
activity  
0.00086194
5 
1.82738 
DAGLB lipid catabolic 
process  
plasma 
membrane  
triacylglycerol 
lipase activity  
4.87E-05 1.83607 
PXMP2  peroxisome  protein binding  0.00093277 1.85357 
RASSF8 signal transduction    4.49E-05 1.8545 
FNDC3B  endoplasmic 
reticulum  
 0.00071065
4 
1.85746 
DISC1 biological_process  cellular_compo
nent  
protein binding  8.70E-06 1.85893 
RGS9 intracellular 
signaling cascade  
heterotrimeric 
G-protein 
complex  
signal transducer 
activity  
0.00084729
8 
1.88556 
SHANK1 cytoskeletal 
anchoring at 
plasma membrane  
intracellular  protein binding  1.27E-05 1.89216 
CKB creatine metabolic 
process  
cytoplasm  nucleotide binding  0.00030676
5 
1.89245 
ZMYM1  nucleus  zinc ion binding  0.00111921 1.89854 
AP1B1 intracellular 
protein transport  
Golgi 
apparatus  
transporter activity  0.00032424
9 
1.90275 
Appendix A   Exon Arrays 
 256 
EPN2 endocytosis  cytoplasm  lipid binding  3.93E-06 1.90633 
BAIAP3 neurotransmitter 
secretion  
 protein C-terminus 
binding  
0.00065751
1 
1.91359 
HOMER3 protein targeting  cytoplasm  protein binding  0.00011675
6 
1.92102 
RRAGD  nucleus  nucleotide binding  0.00031415
5 
1.92733 
P2RY2 cellular ion 
homeostasis  
plasma 
membrane  
receptor activity  0.00104812 1.93398 
AIF1L  focal adhesion  calcium ion 
binding  
0.00078229
5 
1.93842 
C8orf56    0.00116542 1.93973 
ZNF440 transcription  intracellular  DNA binding  0.00078767 1.95459 
DLL3 skeletal system 
development  
membrane  Notch binding  0.00036366
7 
1.97945 
TRAF3IP2 intracellular 
signaling cascade  
cellular_compo
nent  
 9.85E-05 1.98066 
EVC2  membrane   0.00024081
6 
1.98619 
EGFL7 angiogenesis  extracellular 
region  
calcium ion 
binding  
0.00010015
6 
2.02239 
BCAT1 G1 cytoplasm  branched-chain-
amino-acid 
transaminase 
activity  
6.87E-05 2.04554 
FLJ46020    0.00057356
6 
2.05882 
PDGFC activation of 
transmembrane 
receptor protein 
tyrosine 
extracellular 
region  
platelet-derived 
growth factor 
receptor binding  
7.67E-05 2.07071 
KIFAP3 protein complex 
assembly  
endoplasmic 
reticulum  
protein binding  0.00103572 2.07599 
GLT25D1 lipopolysaccharide 
biosynthetic 
process  
endoplasmic 
reticulum  
transferase 
activity, 
transferring 
glycosyl groups  
0.00029838
9 
2.0786 
NTNG2  multicellular 
organismal 
development  
proteinaceous 
extracellular 
matrix  
molecular_functio
n  
0.00046959
3 
2.08723 
IFRG15    0.0007004 2.09089 
ITGB4 cell 
communication  
integrin 
complex  
receptor activity  1.64E-06 2.11938 
SPRY1 ureteric bud 
development  
cytoplasm  protein binding  0.00053793
1 
2.12373 
RCBTB1 transcription  nucleus  protein binding  1.98E-05 2.13903 
KIAA1841    0.00115897 2.14592 
MPL cell surface 
receptor linked 
signal transduction  
plasma 
membrane  
cytokine receptor 
activity  
0.00112164 2.15246 
CPNE7 lipid metabolic 
process  
 transporter activity  0.00019641 2.17656 
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DNM1 receptor-mediated 
endocytosis  
cytoplasm  nucleotide binding  0.00062269 2.17671 
STX2 cytokinesis  membrane 
fraction  
SNARE binding  0.00028982 2.19314 
LRP3 receptor-mediated 
endocytosis  
coated pit  receptor activity  0.00034296
4 
2.20438 
SLC22A16 ion transport  plasma 
membrane  
carnitine 
transporter activity  
3.94E-05 2.20807 
PRELID2    0.00043608
4 
2.22485 
JUP cell-cell adhesion  membrane 
fraction  
cytoskeletal 
protein binding  
0.00021049
5 
2.22614 
CIITA regulation of 
transcription, 
DNA-dependent  
nucleus  nucleotide binding  0.00016764
5 
2.22787 
SCML2 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription factor 
activity  
0.0011144 2.25451 
RELL1  plasma 
membrane  
 2.44E-07 2.25629 
PXK protein amino acid 
phosphorylation  
cytoplasm  nucleotide binding  0.00020481
4 
2.29579 
LASS4 regulation of 
transcription, 
DNA-dependent  
nucleus  transcription factor 
activity  
5.65E-05 2.31841 
GFI1 regulation of 
transcription of G1 
intracellular  DNA binding  0.00075696
1 
2.32281 
Sep-11 cell cycle  stress fiber  nucleotide binding  2.48E-06 2.33785 
KCNH8 two-component 
signal transduction 
system 
(phosphorela 
membrane  two-component 
sensor activity  
0.00022938
5 
2.34888 
HSPG2 cell adhesion  extracellular 
region  
protein binding  3.40E-05 2.3495 
C6orf150    0.00020420
9 
2.36238 
SLCO4A1 ion transport  membrane  transporter activity  6.59E-05 2.36246 
CCL28 chemotaxis  extracellular 
region  
chemokine activity  0.00083507
8 
2.37549 
SLC25A1 transport  mitochondrion  transporter activity  5.56E-06 2.37864 
ADRA2C activation of 
MAPK activity  
endosome  receptor activity  0.00014470
5 
2.40161 
TRERF1 transcription  intracellular  transcription factor 
activity  
0.00100373 2.40251 
LAMB2 cell adhesion  extracellular 
region  
structural 
molecule activity  
0.00069986
3 
2.41525 
ADCY9 cAMP biosynthetic 
process  
integral to 
plasma 
membrane  
magnesium ion 
binding  
0.0012008 2.42547 
ZNF555 transcription  intracellular  DNA binding  0.00085738
5 
2.42594 
TPSD1 proteolysis  extracellular 
region  
serine-type 
endopeptidase 
0.00028833
1 
2.44257 
Appendix A   Exon Arrays 
 258 
activity  
C11orf9 regulation of 
transcription  
membrane  transcription factor 
activity  
0.00010740
8 
2.46749 
NF-E4 transcription  nucleus   0.00032886
9 
2.46976 
TBXA2R signal transduction  plasma 
membrane  
receptor activity  2.22E-05 2.51593 
ST6GALNA
C2 
protein amino acid 
glycosylation  
Golgi 
membrane  
sialyltransferase 
activity  
7.42E-06 2.52625 
HS3ST3B1 heparan sulfate 
proteoglycan 
biosynthetic 
process, en 
Golgi 
membrane  
sulfotransferase 
activity  
0.00105888 2.54211 
ALS2 endosome 
organization  
ruffle  guanyl-nucleotide 
exchange factor 
activity  
0.00087913
2 
2.56021 
RPSAP58 translational 
elongation  
intracellular  structural 
constituent of 
ribosome  
5.41E-05 2.58299 
TLR2 response to 
molecule of fungal 
origin  
plasma 
membrane  
lipopolysaccharide 
receptor activity  
0.00074762
9 
2.60807 
TBL1X transcription  nucleus   5.34E-05 2.61725 
UNQ6490  extracellular 
region  
 0.00012772
4 
2.62828 
SMAGP  plasma 
membrane  
 2.02E-07 2.65315 
DNAH8 ciliary or flagellar 
motility  
cytoplasm  nucleotide binding  0.00039247
1 
2.66548 
PLCG1 intracellular 
signaling cascade  
cellular_compo
nent  
phosphoinositide 
phospholipase C 
activity  
9.50E-05 2.73251 
GRK5 protein amino acid 
phosphorylation  
soluble fraction  nucleotide binding  6.30E-05 2.74553 
FLNB cytoskeletal 
anchoring at 
plasma membrane  
nucleus  actin binding  0.00020704
2 
2.74964 
HOMER2 metabotropic 
glutamate receptor 
signaling pathway  
cytoplasm  actin binding  5.86E-08 2.77109 
CDCA7 transcription  nucleus   0.00014406
4 
2.84763 
CORO2A intracellular 
signaling cascade  
 actin binding  4.93E-05 2.88715 
UBASH3B  nucleus   6.87E-05 2.89231 
TMEM136  membrane   0.00070043 2.92113 
FGFR1 MAPKKK cascade  membrane 
fraction  
nucleotide binding  1.46E-08 2.96314 
CAV2 vesicle fusion  Golgi 
membrane  
protein binding  0.00101907 2.98291 
FBXL13 modification-
dependent protein 
catabolic process  
  0.00082235
9 
3.0095 
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SERPINB1
0 
 nucleus  serine-type 
endopeptidase 
inhibitor activity  
0.00108965 3.01633 
SCCPDH oxidation 
reduction  
 binding  7.46E-05 3.01881 
AADAT biosynthetic 
process  
mitochondrion  kynurenine-
oxoglutarate 
transaminase 
activity  
2.10E-05 3.05775 
UHRF1 DNA repair  nucleus  transcription factor 
activity  
0.00039198
9 
3.08633 
SLC45A3 transport  membrane   0.00118312 3.17098 
TNFRSF21 apoptosis  cytoplasm  receptor activity  2.68E-07 3.21 
MFAP4 cell adhesion  microfibril  molecular_functio
n  
0.00042281
4 
3.2451 
KIT myeloid leukocyte 
differentiation  
extracellular 
space  
nucleotide binding  0.00050724
2 
3.28286 
STK32B protein amino acid 
phosphorylation  
 nucleotide binding  3.14E-06 3.42717 
GNAI1 signal transduction  intracellular  nucleotide binding  3.71E-06 3.50149 
ITM2C  Golgi 
apparatus  
 0.00057172
4 
3.5228 
TM6SF1 biological_process  membrane  molecular_functio
n  
1.68E-05 3.52511 
SERPINB9 anti-apoptosis  cytoplasm  serine-type 
endopeptidase 
inhibitor activity  
2.69E-06 3.53143 
NT5DC3   magnesium ion 
binding  
3.70E-05 3.57121 
GATM creatine 
biosynthetic 
process  
cytoplasm  glycine 
amidinotransferas
e activity  
4.18E-05 3.58058 
NCALD vesicle-mediated 
transport  
intracellular  actin binding  5.90E-05 3.64514 
MTSS1 cell motion  ruffle  actin monomer 
binding  
6.99E-05 3.70334 
CACNA2D
2 
ion transport  membrane  voltage-gated ion 
channel activity  
2.54E-05 3.70803 
PRTN3 proteolysis  cellular_compo
nent  
serine-type 
endopeptidase 
activity  
0.00020143
6 
3.72313 
PTGR1 leukotriene 
metabolic process  
cytoplasm  alcohol 
dehydrogenase 
activity  
2.40E-05 3.74584 
HIST1H2B
M 
nucleosome 
assembly  
nucleosome  DNA binding  0.00026267
3 
4.04628 
PALM cell motion  plasma 
membrane  
 2.11E-10 4.13068 
PSD3 regulation of ARF 
protein signal 
transduction  
intracellular  ARF guanyl-
nucleotide 
exchange factor 
activity  
8.30E-05 4.19546 
ITGA9 cell adhesion  integrin receptor activity  0.00019521 4.19728 
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complex  2 
HAL histidine catabolic 
process  
soluble fraction  histidine 
ammonia-lyase 
activity  
0.00041280
7 
4.2152 
EPCAM  plasma 
membrane  
 0.00014148
2 
4.40028 
VEGFA angiogenesis  extracellular 
region  
fibronectin binding  5.76E-07 4.51368 
FBLN5 cell adhesion  extracellular 
region  
integrin binding  0.00123704 4.63839 
PSD3 regulation of ARF 
protein signal 
transduction  
intracellular  ARF guanyl-
nucleotide 
exchange factor 
activity  
4.92E-06 4.69641 
MAN1A1 metabolic process  Golgi 
membrane  
mannosyl-
oligosaccharide 
1,2-alpha-
mannosidase 
activi 
4.53E-07 4.82998 
HPGD lipid metabolic 
process  
nucleus  prostaglandin E 
receptor activity  
0.00060708
5 
4.97399 
GPM6B multicellular 
organismal 
development  
nucleus  molecular_functio
n  
3.99E-05 5.69264 
SLC18A2 response to 
amphetamine  
membrane 
fraction  
monoamine 
transmembrane 
transporter activity  
0.00018365
9 
5.71725 
CEACAM4  membrane   0.00016687 6.22054 
C21orf109    0.00018988
7 
6.35642 
CAV1 inactivation of 
MAPK activity  
Golgi 
membrane  
structural 
molecule activity  
2.84E-06 7.22331 
SIPA1L2 regulation of small 
GTPase mediated 
signal transducti 
intracellular  GTPase activator 
activity  
2.24E-07 7.2642 
BAALC  cytoplasm   1.17E-06 7.54201 
PGDS prostaglandin 
biosynthetic 
process  
cytoplasm  prostaglandin-D 
synthase activity  
0.00112342 7.61551 
SLCO5A1 transport  membrane  transporter activity  7.45E-08 7.67319 
ELANE proteolysis  extracellular 
region  
serine-type 
endopeptidase 
activity  
3.64E-05 9.34343 
CLEC5A immune response  integral to 
plasma 
membrane  
binding  6.95E-07 9.50729 
IL5RA signal transduction  extracellular 
space  
receptor activity  1.56E-06 13.5298 
TRH signal transduction  extracellular 
region  
neuropeptide 
hormone activity  
3.44E-06 13.7637 
ROBO1 chemotaxis  integral to 
plasma 
membrane  
receptor activity  1.37E-08 15.0037 
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CD200  plasma 
membrane  
 3.72E-07 15.3419 
POU4F1 suckling behavior  nucleus  transcription factor 
activity  
6.23E-07 17.1116 
RUNX1T1 generation of 
precursor 
metabolites and 
energy  
nucleus  transcription factor 
activity  
8.66E-15 17.166 
MPO anti-apoptosis  extracellular 
space  
chromatin binding  1.75E-05 18.4828 
PRAME   protein binding  7.77E-05 18.5729 
TSPAN7 protein amino acid 
N-linked 
glycosylation  
plasma 
membrane  
 7.91E-06 20.0498 
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Cloning of pMSCV-AML1-ETO6a-GFP 
 
A pMSCV-AML1-ETO-GFP (pMiG-A-E) vector was obtained (courtesy of 
D.Gascoyne). The vector was digested with enzymes MfeI and BamH1 (NEB), 
which only cut the AML1-ETO sequence once each, on either side of exon 6 (Figure 
65). This gives rise to a fragment of approximately 800 bp, which is discarded 
(Figure 66). The linearised vector, now containing sticky ends, was obtained while 
the approximate 700bp insert was discarded. 
 
 
Figure 64 Part of Sequence of ETO highlighting exon 6 and the digestion sites BamH1 and Mfe1 
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Figure 65 Agarose Gel of a Restriction Digest of pMiG -A-E with enzymes BamH1, Mfe1 and a double 
digest (DD). Buffer 4 (5ul) (NEB), DNA (3ug) enzyme 1.5ul each enzyme and water to make upto 50ul was 
mixed and incubated in a water bath at 37C for 3 hours. There is linearisation of vector with the Mfe1 and 
BamH1 enzymes. The double digest results in a smaller linearised vector, which is retained, and the 
appearance of an approximately 800bp insert, which is discarded. 
 
 
Using the same enzymes, the previously cloned TA TOPO vector containing the 
ETO exon 6a transcript was digested. On this occasion the resulting insert was kept 
as this contains the 6a exon. However, the TA TOPO vector has an extra BamH1 
digest site leading to 2 inserts with the double digest. The larger insert contains the 
new exon and this was cut out from the gel and the smaller insert and vector 
discarded (Figures 67 & 68). 
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Figure 66 Agarose Gel of Restriction Digestion of TaTOPO vector containing exon 6a with BamH1 and Mfe1 
and a double digest (DD). Digestion was performed in same conditions as above. There is an extra BamHI 
digest site in this vector leading to an extra fragment. Consequently the DD has two inserts in addition to the 
vector, which are seen more clearly on the figure below. 
 
 
Figure 67 Agarose Gel of a Restriction Digestion of TaTOPO vector containing exon 6a with a double digest, 
highlighting the vector and both inserts. The larger insert at approximately 850bp was excised from the gel. 
 
The pMiG-A-E vector minus the 700bp fragment was ligated to the insert from the 
second digest containing the exon 6a to obtain a pMiG-A-E6a plasmid. Ligation was 
performed with vector to insert ratios of 1:1, 1:2 and vector alone. The products were 
cloned, 12 colonies selected and minipreps made. The plasmids were checked by 
digesting with BamH1 and MfeI before use for functional assays. 
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Cloning of pMSCV AML1-ETO-ires hCD2 
The pMiG A-E was obtained and digested with restriction enzymes ECoR1 and Sal1 
(NEB). This results in a vector and 2 inserts, one containing the ires-GFP and the 
other a small part of the AML1-ETO coding region. (Figure 69 & 70) The vector is 
retained.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68 Schematic representation of the pMiGA/E vector with coding region and ires region and highlighting 
the digestion points. 
Figure 69 Agarose Gel of Restriction Digestion of pMiGA/E vector with ECoR1 and Sal1 and a double digest 
(DD). Digestion was performed in Buffer D (4ul) (NEB), DNA (1ul), enzymes (1ul each) and water to make up 
to 40ul were mixed and digested at 37c for 3 hours. The double digest has two inserts in addition to the vector. 
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Next a pMSCV-ireshCD2 vector was obtained. The vector was digested with ECoR1 
followed by a partial digest with Sal1 to obtain the vector and the ireshCD2 insert 
(Figure 71& 72). On this occasion the vector is discarded but the insert containing 
the ires is retained.  
 
 
 
 
 
 
 
 
 
 
Figure 71 Buffer H (NEB) (4ul), DNA (2ug), ECoR1 (1ul) and water to make to 40ul were mixed and 
incubated at 37C for a total of 2 hours. After 60, 90 and 105 minutes 0.5ul of Sal1 was added to produce a 
partial digests 1,2 and 3 respectively. 
Figure 70 Schematic representation of the pMSCV-ireshCD2 vector highlighting the digestion points. 
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The vector from the first digest and the insert from the second digest (sample 3) 
were ligated. A pMihC-A-E vector that is incomplete, lacking a small piece of 
approximately 500bp of AML1-ETO coding region, is obtained. Plasmids were 
checked with further digests for verification and the correct plasmids used (Figure 
73). 
 
 
 
 
 
 
 
 
 
 
The next aim was to re-insert the missing approximately 500bp insert into this new 
vector to complete the AML1-ETO coding region. The new vector was digested with 
ECoR1 to linearise the vector and treated with alkaline phosphotase to stop re-
annealing (Figure 74). Then the original pMiG-A-E was digested with ECoR1 and 
the 500bp fragment was obtained as previously described. The vector and the 
500bp fragment were ligated. 
Figure 72 Schematic of newly formed vector and the digestion break points. Digestion with Sal1 should give an 
approximately 1500bp band and vector, with Bgl1 a 3000bp band and vector and with ECoR1 a linearised 
vector. 
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To check ligation and correct orientation of the 500bp insert a series of digests were 
performed and the appropriate colonies were selected (Figure 75). 
 
 
 
 
 
 
 
 
Figure 73 Buffer ECor1 (4ul), DNA (1ug), ECoR1 (5ul) and water to make upto 40ul were mixed and 
incubated for 2 hours at 37C, heat inactivated at 65C for 5 minutes and incubated at 37C for a further 15 
minutes after adding 1ul (1unit/ul) of alkaline phosphotase. 
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Figure 74 Schematic representation of the size of digests expected. BGLII should give approximately 
1700bp and not 1200bp digest; with SmaI 2050bp and not 1550bp if the insert is in the correct orientation.  
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Appendix C 
Gene Lists derived from ChIp-Seq Experiments 
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Table 31 Gene List of 338 genes which bind AML1-ETO showing the gene name; chromosome location; the 
total number of reads located in the binding site for the input sample and the test sample; and the p value 
derived from the comparison of input and test sample.  
GENE  CHROMOSOME INPUT CHIP P-VALUE 
MX2 21 121 776 0 
CDH23 10 74 651 0 
TRIM8 10 125 714 0 
CCND3 6 141 1123 0 
PTCH1 9 77 576 0 
STAB1 3 99 974 0 
PRKCD 3 129 709 0 
HCCA2 11 71 636 0 
RPS6KA1 1 126 1011 0 
INPP5A 10 74 617 0 
GFOD1 6 110 693 0 
ZBTB16 11 56 459 0 
NEK8 17 88 602 0 
MAP2K2 19 29 420 0 
BAHCC1 17 117 936 0 
USP20 9 30 356 9.81E-45 
SH3BP5 3 70 482 7.26E-43 
KIAA0427 18 83 519 1.89E-42 
LOC374443 12 29 338 3.63E-42 
FAM129B 9 22 310 3.92E-42 
PTTG1IP 21 80 507 5.35E-42 
GALNT6 12 104 567 1.50E-40 
BCL3 19 86 512 4.44E-40 
ADCY4 14 72 470 4.70E-40 
HIP1 7 69 459 8.93E-40 
LMNA 1 108 564 1.48E-38 
SULF2 20 71 452 8.99E-38 
LAPTM5 1 108 558 1.01E-37 
C6orf103 6 64 417 1.13E-35 
HNRNPM 19 99 517 1.74E-35 
CXXC5 5 177 711 2.07E-34 
PPP4R1L 20 72 431 3.54E-34 
CYP51A1 7 88 474 9.30E-34 
GLIPR2 9 70 419 2.86E-33 
KIAA0652 11 56 376 3.93E-33 
VAV1 19 95 485 1.38E-32 
JMJD6 17 84 452 3.09E-32 
GRK7 3 165 661 5.52E-32 
GNB5 15 110 520 7.40E-32 
TADA3 3 98 485 1.80E-31 
ACSL1 4 71 407 4.40E-31 
RASSF2 20 73 411 7.87E-31 
TPM4 19 63 374 1.19E-29 
RAI1 17 77 414 1.21E-29 
EEPD1 7 54 347 1.29E-29 
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RARA 17 173 659 1.72E-29 
LAT2 7 43 306 1.60E-28 
HSH2D 19 32 269 2.47E-28 
MSI2 17 105 473 1.90E-27 
SLC2A1 1 120 507 6.61E-27 
SH3BP2 4 67 364 1.53E-26 
TSPAN32 11 103 460 1.90E-26 
ZFYVE28 4 98 446 2.59E-26 
KIAA0182 16 75 384 3.13E-26 
NHSL2 X 14 190 5.31E-26 
ALDH16A1 19 50 310 7.87E-26 
RASSF5 1 119 494 1.27E-25 
C5orf56 5 121 497 2.21E-25 
ABCG1 21 33 254 2.53E-25 
GPR114 16 99 437 7.84E-25 
TOX2 20 77 377 1.55E-24 
CD276 15 75 371 1.87E-24 
TBC1D14 4 120 486 2.33E-24 
SPNS3 17 38 263 3.20E-24 
SMG6 17 154 561 1.43E-23 
MBP 18 171 599 2.15E-23 
STARD9 15 20 198 2.35E-23 
PKIB 6 80 376 2.44E-23 
MAX 14 66 337 3.74E-23 
FNTB 14 66 337 3.74E-23 
IL21R 16 55 305 5.82E-23 
CCDC135 16 48 283 1.09E-22 
TK2 16 134 504 1.68E-22 
LOC100130987 11 84 380 1.69E-22 
IL17RA 22 101 423 1.86E-22 
SORBS1 10 68 335 3.87E-22 
ADORA2A 22 92 396 6.34E-22 
C22orf45 22 92 396 6.34E-22 
MGAT1 5 198 646 6.38E-22 
COL23A1 5 52 287 1.33E-21 
SIK3 11 152 538 1.41E-21 
CNIH3 1 82 365 3.07E-21 
SIPA1L3 19 82 362 7.39E-21 
LST1 6 100 407 8.11E-21 
CD82 11 109 429 8.32E-21 
EP400NL 12 77 348 1.02E-20 
SPN 16 79 353 1.08E-20 
RALGDS 9 115 442 1.26E-20 
LHX6 9 104 414 1.77E-20 
PI16 6 73 334 2.98E-20 
FAM82A2 15 81 353 4.81E-20 
RNF166 16 92 379 7.80E-20 
SERINC5 5 46 256 1.36E-19 
FBRSL1 12 135 480 1.38E-19 
HSPG2 1 70 319 2.54E-19 
FUT7 9 93 376 3.56E-19 
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C9orf139 9 93 376 3.56E-19 
MAD1L1 7 23 183 4.42E-19 
IL1RN 2 36 221 1.05E-18 
LMAN2 5 44 244 1.10E-18 
ZMIZ1 10 46 248 1.88E-18 
PTPRE 10 72 317 2.10E-18 
UNC13D 17 90 362 2.19E-18 
GAS7 17 47 250 2.43E-18 
FOXN3 14 56 274 2.92E-18 
CUGBP2 10 14 147 3.03E-18 
CDC42BPB 14 73 317 4.41E-18 
ADCY8 8 6 114 4.63E-18 
XYLT1 16 41 231 4.85E-18 
LCP2 5 75 320 8.01E-18 
BPI 20 43 235 8.41E-18 
MYO1D 17 12 137 8.67E-18 
DCC 18 9 125 9.86E-18 
MTMR4 17 202 609 1.47E-17 
PLD3 19 64 288 2.49E-17 
GRID1 10 19 159 2.61E-17 
TBPL1 6 38 217 2.96E-17 
RUNX1 21 108 395 3.33E-17 
LOC100128822 7 40 222 3.74E-17 
AGTRAP 1 80 327 3.78E-17 
ERICH1 8 51 252 4.19E-17 
CRTC1 19 128 440 4.73E-17 
TEC 4 56 264 6.32E-17 
XKR6 8 16 145 1.14E-16 
TSEN54 17 119 415 1.36E-16 
AHI1 6 38 212 1.57E-16 
AKAP13 15 200 593 1.68E-16 
KIAA0513 16 81 324 1.70E-16 
SLC43A2 17 73 304 1.80E-16 
PLCB1 20 15 139 3.07E-16 
ZC3H3 8 82 323 4.35E-16 
RIN2 20 68 288 4.81E-16 
FOXK2 17 84 327 5.48E-16 
PNPLA7 9 20 154 6.05E-16 
EFHD2 1 87 333 7.62E-16 
SAPS3 11 78 308 1.80E-15 
ZNRF1 16 13 126 3.28E-15 
CHST11 12 128 420 5.31E-15 
PDE4DIP 1 24 159 9.55E-15 
LOC153684 5 127 414 1.26E-14 
CDA 1 29 173 1.30E-14 
SMOX 20 31 178 1.70E-14 
TRAP1 16 16 132 1.74E-14 
PCSK6 15 118 392 1.93E-14 
HIVEP3 1 6 95 1.97E-14 
FAM155A 13 8 103 2.05E-14 
EMILIN1 2 65 267 2.17E-14 
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SYT2 1 27 163 5.41E-14 
DLG2 11 9 104 6.68E-14 
FGGY 1 7 96 7.43E-14 
PTPRC 1 54 235 7.54E-14 
MTSS1 8 4 83 8.35E-14 
UBE2V1 20 120 389 1.08E-13 
TMEM189-UBE2V1 20 120 389 1.08E-13 
TTC7A 2 112 371 1.11E-13 
PFKM 12 10 104 3.02E-13 
DFFB 1 89 314 3.33E-13 
RERE 1 9 100 3.47E-13 
ZSWIM6 5 37 185 3.99E-13 
LMTK2 7 27 157 4.19E-13 
CCDC109B 4 19 133 4.36E-13 
ERGIC1 5 22 142 4.63E-13 
EFHC2 X 4 79 5.00E-13 
SYNJ2 6 49 215 6.24E-13 
DEDD2 19 68 262 6.28E-13 
TRPM2 21 111 361 6.68E-13 
CLMN 14 50 217 7.31E-13 
OSBPL5 11 113 365 7.40E-13 
TSPAN16 19 65 254 7.68E-13 
RAB3D 19 65 254 7.68E-13 
CABLES1 18 11 105 8.44E-13 
NTNG2 9 43 198 9.80E-13 
CACNA1C 12 28 157 1.09E-12 
GRAP2 22 165 475 1.19E-12 
PRR5 22 23 142 1.31E-12 
HTT 4 45 202 1.40E-12 
TNS3 7 3 72 1.48E-12 
ARAP1 11 135 410 1.48E-12 
TFEB 6 100 332 1.84E-12 
AGPAT3 21 21 135 1.90E-12 
C18orf45 18 15 116 2.16E-12 
SYN3 22 97 323 3.11E-12 
ADARB2 10 10 98 3.38E-12 
BDNF 11 35 172 4.35E-12 
C9orf89 9 99 326 4.41E-12 
PPAP2B 1 44 195 5.16E-12 
FAM73B 9 74 268 5.36E-12 
KIAA1949 6 76 272 6.35E-12 
HHEX 10 93 310 7.93E-12 
ZNF718 4 14 109 8.89E-12 
PPCDC 15 15 112 9.61E-12 
UHRF1 19 18 121 1.09E-11 
HVCN1 12 40 182 1.15E-11 
DNAJB12 10 92 306 1.20E-11 
RAB11FIP4 17 7 83 1.77E-11 
ALK 2 17 115 3.14E-11 
SH3BP5L 1 8 85 3.56E-11 
PIP5K1C 19 71 252 5.18E-11 
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LARS2 3 5 72 6.89E-11 
RAPGEF1 9 53 208 7.39E-11 
MAPK1 22 81 273 8.24E-11 
MED26 19 17 112 9.19E-11 
ZNF444 19 15 105 1.26E-10 
OR9Q1 11 20 120 1.26E-10 
ATP2B4 1 3 62 1.36E-10 
NCOR2 12 57 215 1.48E-10 
ACVR1B 12 79 266 1.48E-10 
PDE3A 12 2 57 1.58E-10 
EFNB2 13 73 251 2.06E-10 
TNFRSF4 1 64 230 2.18E-10 
STAT3 17 31 148 2.74E-10 
NFAM1 22 67 236 2.77E-10 
AKNA 9 7 76 3.17E-10 
ARHGEF2 1 12 93 3.22E-10 
INPP5B 1 46 185 3.74E-10 
C20orf26 20 1 50 3.76E-10 
FAM125B 9 119 349 3.93E-10 
ARHGAP26 5 15 101 5.36E-10 
SMAD3 15 60 217 5.52E-10 
MAP1LC3B2 12 71 242 6.02E-10 
ZFHX3 16 21 118 6.55E-10 
PI4KA 22 20 115 6.91E-10 
WFS1 4 39 165 7.89E-10 
PGCP 8 8 77 8.93E-10 
TNFRSF1A 12 9 80 1.06E-09 
EVL 14 7 73 1.08E-09 
BDNFOS 11 7 73 1.08E-09 
FLJ43663 7 17 105 1.08E-09 
LOC651250 17 15 99 1.10E-09 
TRIP4 15 40 166 1.21E-09 
UBASH3B 11 38 161 1.21E-09 
LOC285045 2 6 69 1.24E-09 
FLJ45079 17 101 305 1.25E-09 
PCSK5 9 1 47 1.56E-09 
RIN3 14 21 115 1.78E-09 
C2orf18 2 69 232 2.23E-09 
PID1 2 2 51 2.49E-09 
TTYH3 7 87 271 2.76E-09 
SYK 9 13 89 4.49E-09 
TMEM104 17 52 190 4.56E-09 
LUZP1 1 40 161 4.89E-09 
PACSIN2 22 23 117 5.55E-09 
SDC3 1 58 203 5.77E-09 
BCL2 18 35 148 5.82E-09 
GPR149 3 8 72 6.45E-09 
CDC27 17 13 88 6.45E-09 
TSNAX-DISC1 1 24 119 6.92E-09 
ZNF804B 7 0 38 6.92E-09 
HFM1 1 2 48 9.79E-09 
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DUSP10 1 168 429 1.72E-08 
SCFD2 4 4 55 1.83E-08 
WDR81 17 15 91 1.83E-08 
TRPM1 15 14 88 1.87E-08 
OGG1 3 124 339 2.15E-08 
ANKRD33B 5 73 231 2.20E-08 
ATP9B 18 3 50 2.80E-08 
VIM 10 142 373 3.42E-08 
C12orf5 12 52 182 3.43E-08 
WASF1 6 15 89 3.65E-08 
PARN 16 7 64 3.95E-08 
LOC100216545 7 136 360 4.01E-08 
SASH3 X 22 108 4.09E-08 
FGD3 9 4 53 4.28E-08 
KIAA1797 9 3 49 4.34E-08 
CLCN7 16 13 82 5.47E-08 
MYH9 22 13 82 5.47E-08 
PI4KB 1 65 208 7.44E-08 
SIPA1 11 118 320 7.47E-08 
AR X 0 33 8.20E-08 
GSN 9 28 121 8.82E-08 
SENP5 3 2 43 9.44E-08 
SNAPC3 9 56 186 1.18E-07 
RAP1GDS1 4 20 98 1.77E-07 
UMODL1 21 137 353 1.93E-07 
CARD9 9 76 227 2.16E-07 
POLR1A 2 21 100 2.17E-07 
ARHGEF6 X 13 78 2.20E-07 
MIA 19 79 232 2.89E-07 
ETV6 12 83 240 3.17E-07 
KCNJ12 17 20 96 3.31E-07 
ZMYND10 3 90 254 3.61E-07 
RASSF1 3 90 254 3.61E-07 
KLF9 9 7 58 4.09E-07 
KLF13 15 88 249 4.25E-07 
NRD1 1 78 227 5.22E-07 
SLC43A3 11 108 289 5.25E-07 
FAM53B 10 120 313 5.45E-07 
MAN1A1 6 297 650 5.97E-07 
NFATC1 18 32 124 6.03E-07 
LIMS1 2 86 243 6.10E-07 
ZCCHC14 16 20 94 6.15E-07 
AXIN1 16 62 191 7.64E-07 
CD9 12 7 56 8.81E-07 
SH3GL1 19 5 49 1.01E-06 
TTLL4 2 13 73 1.21E-06 
MOBKL2A 19 58 180 1.27E-06 
INPP5D 2 7 55 1.29E-06 
CTNND1 11 74 214 1.32E-06 
ARID5A 2 89 245 1.38E-06 
STAT5B 17 5 48 1.51E-06 
Appendix C   ChIP-Seq 
 278 
ATP2A3 17 19 88 1.74E-06 
THRAP3 1 1 32 1.81E-06 
DOK7 4 4 44 1.85E-06 
PCBD2 5 30 115 1.88E-06 
DNAJC15 13 10 63 1.97E-06 
SPI1 11 10 63 1.97E-06 
DYNC1LI2 16 9 60 1.99E-06 
MADD 11 23 97 2.45E-06 
CDKL4 2 60 181 2.62E-06 
CCDC113 16 2 35 3.37E-06 
CNN2 19 65 190 3.70E-06 
CASK X 1 30 4.59E-06 
NBPF1 1 7 51 5.79E-06 
DUSP3 17 62 181 6.41E-06 
PWP2 21 47 147 9.54E-06 
FSTL3 19 50 153 1.07E-05 
TBC1D1 4 5 43 1.09E-05 
DUS2L 16 0 23 1.15E-05 
TMEM120B 12 1 28 1.16E-05 
LSM4 19 8 52 1.21E-05 
PRODH2 19 64 182 1.23E-05 
DHCR24 1 4 39 1.42E-05 
ZNF445 3 5 42 1.61E-05 
DHRS12 13 9 54 1.66E-05 
WIPF1 2 11 59 2.04E-05 
DNMT3L 21 5 41 2.36E-05 
RNF44 5 50 149 2.53E-05 
LOC285456 4 3 34 2.64E-05 
CEP63 3 1 25 4.60E-05 
KIAA1539 9 94 235 4.83E-05 
FAM117A 17 26 90 0.000110188 
ZNF595 4 105 244 0.000318889 
SOLH 16 5 33 0.000474549 
TSNAX 1 4 29 0.000697853 
C19orf45 19 12 50 0.000755817 
PDPR 16 85 200 0.000769034 
KIAA1012 18 0 12 0.00264936 
PMF1 1 45 114 0.00311452 
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Table 32 Gene List of top 186 genes generated from analysis of samples 2 & 3 only in order of p-value.  
 
GENE SYMBOL CHROMOSOME PEAKS INPUT  PEAKS CHIP p-VALUE  
 
RGSL1 1 44 701 0 
DOCK6 19 23 346 0 
MX2 21 121 776 0 
RHBDF2 17 156 783 0 
CDH23 10 74 651 0 
CALR 19 76 690 0 
TRIM8 10 125 714 0 
CCND3 6 141 1123 0 
MYEOV 11 195 1172 0 
PTCH1 9 77 576 0 
STAB1 3 99 974 0 
PRKCD 3 129 709 0 
HCCA2 11 71 636 0 
RPS6KA1 1 126 1011 0 
BLK 8 42 500 0 
INPP5A 10 74 617 0 
GFOD1 6 110 693 0 
ZBTB16 11 56 459 0 
NEK8 17 88 602 0 
MAP2K2 19 29 420 0 
BAHCC1 17 117 936 0 
RPS9 19 84 983 0 
USP20 9 30 356 9.81E-45 
LMO2 11 141 697 2.10E-44 
WNT10A 2 110 605 1.54E-43 
SH3BP5 3 70 482 7.26E-43 
KIAA0427 18 83 519 1.89E-42 
LOC374443 12 29 338 3.63E-42 
FAM129B 9 22 310 3.92E-42 
PTTG1IP 21 80 507 5.35E-42 
GPR97 16 171 755 1.17E-41 
GALNT6 12 104 567 1.50E-40 
BCL3 19 86 512 4.44E-40 
ADCY4 14 72 470 4.70E-40 
TESC 12 102 557 6.24E-40 
HIP1 7 69 459 8.93E-40 
LMNA 1 108 564 1.48E-38 
SULF2 20 71 452 8.99E-38 
LAPTM5 1 108 558 1.01E-37 
MPG 16 35 333 2.12E-37 
IQCD 12 75 461 2.52E-37 
ADRBK1 11 133 611 7.73E-36 
C6orf103 6 64 417 1.13E-35 
HNRNPM 19 99 517 1.74E-35 
SDK2 17 31 304 7.24E-35 
CXXC5 5 177 711 2.07E-34 
PPP4R1L 20 72 431 3.54E-34 
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ZFPM2 8 23 270 4.16E-34 
CYP51A1 7 88 474 9.30E-34 
GLIPR2 9 70 419 2.86E-33 
DIS3L2 2 92 481 3.55E-33 
KIAA0652 11 56 376 3.93E-33 
VAV1 19 95 485 1.38E-32 
MCF2L 13 88 465 1.71E-32 
MYO1C 17 57 374 2.37E-32 
JMJD6 17 84 452 3.09E-32 
GRK7 3 165 661 5.52E-32 
GNB5 15 110 520 7.40E-32 
TADA3 3 98 485 1.80E-31 
ACSL1 4 71 407 4.40E-31 
RASSF2 20 73 411 7.87E-31 
SLC35F3 1 23 251 1.02E-30 
SBF1 22 67 391 1.95E-30 
ATP10A 15 66 385 5.54E-30 
MNAT1 14 57 358 6.50E-30 
DMWD 19 105 492 6.51E-30 
TPM4 19 63 374 1.19E-29 
RAI1 17 77 414 1.21E-29 
EEPD1 7 54 347 1.29E-29 
RARA 17 173 659 1.72E-29 
GRK5 10 140 572 9.86E-29 
LAT2 7 43 306 1.60E-28 
HSH2D 19 32 269 2.47E-28 
ANXA11 10 61 357 5.24E-28 
ANXA6 5 11 187 8.46E-28 
GFI1B 9 57 343 1.15E-27 
BIN1 2 81 410 1.51E-27 
MSI2 17 105 473 1.90E-27 
SLC2A1 1 120 507 6.61E-27 
LFNG 7 165 617 6.65E-27 
DIP2C 10 63 354 9.86E-27 
FXYD2 11 19 213 1.22E-26 
CBFA2T3 16 45 300 1.31E-26 
MIR548H2 12 17 205 1.42E-26 
RFX4 12 17 205 1.42E-26 
ADC 1 100 453 1.52E-26 
SH3BP2 4 67 364 1.53E-26 
IQGAP2 5 221 743 1.77E-26 
C11orf21 11 103 460 1.90E-26 
TSPAN32 11 103 460 1.90E-26 
ZFYVE28 4 98 446 2.59E-26 
KIAA0182 16 75 384 3.13E-26 
GHDC 17 105 462 4.78E-26 
NHSL2 X 14 190 5.31E-26 
LTC4S 5 66 357 6.01E-26 
CCDC88B 11 80 395 7.09E-26 
ALDH16A1 19 50 310 7.87E-26 
PADI2 1 49 307 7.91E-26 
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RASSF5 1 119 494 1.27E-25 
LOC257358 5 149 567 1.42E-25 
C5orf56 5 121 497 2.21E-25 
ABCG1 21 33 254 2.53E-25 
WDR1 4 249 793 3.22E-25 
DLGAP2 8 16 193 4.16E-25 
MUC16 19 6 150 4.20E-25 
DNMT3A 2 45 290 4.49E-25 
KCNMA1 10 47 295 6.41E-25 
GPR114 16 99 437 7.84E-25 
SYTL4 X 10 167 7.94E-25 
KRT80 12 47 294 9.08E-25 
KIRREL 1 7 153 9.63E-25 
GAB2 11 14 183 1.02E-24 
C14orf106 14 32 247 1.02E-24 
TOX2 20 77 377 1.55E-24 
CD276 15 75 371 1.87E-24 
SGMS1 10 22 211 2.28E-24 
TBC1D14 4 120 486 2.33E-24 
TNFRSF14 1 77 375 2.87E-24 
DAB1 1 8 155 3.14E-24 
STAC 3 8 155 3.14E-24 
SPNS3 17 38 263 3.20E-24 
GNAO1 16 12 171 5.40E-24 
PPM1L 3 27 226 5.52E-24 
CDH4 20 7 149 5.82E-24 
SFXN3 10 52 302 8.99E-24 
SMG6 17 154 561 1.43E-23 
ILDR2 1 24 213 1.62E-23 
RAD52 12 51 297 1.83E-23 
MBP 18 171 599 2.15E-23 
ALS2CR12 2 72 355 2.19E-23 
STARD9 15 20 198 2.35E-23 
DYM 18 80 376 2.44E-23 
PKIB 6 80 376 2.44E-23 
C7orf50 7 40 263 2.90E-23 
MAX 14 66 337 3.74E-23 
FNTB 14 66 337 3.74E-23 
PEBP4 8 56 309 3.96E-23 
IL21R 16 55 305 5.82E-23 
UNC5B 10 14 173 6.81E-23 
CCDC135 16 48 283 1.09E-22 
CSRNP1 3 152 547 1.49E-22 
NAV2 11 12 163 1.63E-22 
TK2 16 134 504 1.68E-22 
LOC100130987 11 84 380 1.69E-22 
IL17RA 22 101 423 1.86E-22 
MTUS2 13 2 115 2.14E-22 
DMGDH 5 14 170 2.38E-22 
IL6R 1 40 257 2.41E-22 
MOBKL2B 9 20 191 3.81E-22 
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SORBS1 10 68 335 3.87E-22 
DYSF 2 7 139 5.12E-22 
WNK2 9 20 190 5.66E-22 
OLFM4 13 6 134 5.96E-22 
RELT 11 145 525 6.11E-22 
ADORA2A 22 92 396 6.34E-22 
C22orf45 22 92 396 6.34E-22 
MGAT1 5 198 646 6.38E-22 
CSMD2 1 8 143 6.39E-22 
INTS1 7 59 308 8.39E-22 
C9orf3 9 54 294 8.55E-22 
STK32C 10 30 222 1.01E-21 
CCDC86 11 16 174 1.04E-21 
TGFB2 1 25 205 1.30E-21 
COL23A1 5 52 287 1.33E-21 
SIK3 11 152 538 1.41E-21 
AIM1 6 114 447 1.73E-21 
ANK1 8 9 145 1.78E-21 
LOC284805 20 42 257 1.93E-21 
CUX1 7 83 369 2.02E-21 
CLIC5 6 44 262 2.61E-21 
CNIH3 1 82 365 3.07E-21 
RNF152 18 8 139 3.71E-21 
DCLK1 13 20 185 4.06E-21 
MIR548F5 13 20 185 4.06E-21 
LOC146336 16 52 283 4.97E-21 
LNPEP 5 174 583 5.17E-21 
SHISA6 17 8 138 5.76E-21 
TYROBP 19 184 605 5.85E-21 
HCST 19 184 605 5.85E-21 
SIPA1L3 19 82 362 7.39E-21 
ITGAE 17 55 290 7.78E-21 
LST1 6 100 407 8.11E-21 
CD82 11 109 429 8.32E-21 
PRMT7 16 54 287 8.35E-21 
C20orf94 20 22 190 8.50E-21 
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Table 33 Significant processes as detected by GeneGo generated from the definitive gene list of the above186 
genes  
 
 NAME p-VALUE NETWORK 
OBJECTS 
1 Reproduction_FSH-beta signaling pathway 1.17E-05 10/159 
2 Apoptosis_Anti-Apoptosis mediated by external 
signals via MAPK and JAK/STAT 
6.78E-04 8/170 
3 Signal transduction_CREM pathway 8.48E-04 6/98 
4 Signal transduction_WNT signaling 8.84E-04 8/177 
5 Signal transduction_NOTCH signaling 1.41E-03 9/236 
6 Cell cycle_G1-S Growth factor regulation 1.65E-03 8/195 
7 Cell cycle_G2-M 2.26E-03 8/205 
8 Development_Hedgehog signaling 2.27E-03 9/253 
9 Cell adhesion_Platelet aggregation 3.28E-03 7/171 
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Mixtures, Solutions, Buffers & Primers 
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I. Common Methods 
cDNA Synthesis 
Component Volume x1 Rxn 
(for 100ng RNA) 
Volume x1 Rxn  
(for 2ug RNA) 
DW 10.5µl Up to 12µl 
5x Synthesis Buffer 6µl 6uµl 
dNTP, 2.5 µM 10µl 10uµl 
Random hexamers, 50 µm 1.5µl 1.5uµl 
RT 1µl 2µl 
RNA 1µg/µl 100ng 
RT-PCR Master Mix 
Component Volume x1 Rxn 
10x PCR Buffer 10.5µl 
dNTP, 2.5uM 4µl 
Forward Primer, 20uM 2µl 
Reverse Primer, 20 uM 2uµl 
Taq Polymerase 0.3µl 
DW 35.7µl 
cDNA 1µl 
RQ-PCR - SYBR Protocol 
Components Volume x1 Rxn 
Universal Mastermix 12.5µl 
Gene Assay Mix 1.25µl 
DW 10.25µl 
cDNA 1µlµ 
Total 25ul 
RQ-PCR- Protocol for Specific Probes 
Components Volume x1 Rxn 
Universal Mastermix 12.5 
Forward Primer 2.5µl 
Reverse Primer 2.5µl 
Probe (FAM) 2.5µl 
DW 4µl 
cDNA 1µl 
Total 25µl 
Appendix D   Materials & Methods 
 286 
II. Exon Array Protocols 
Step C RiboMinus Probe Hybridization 
Component Volume x1Rxn(1µg/µl 
sample concentration) 
Volume x 1Rxn 
(0.31µg/ul-1µg/µl) 
Total RNA/Poly-A RNA Controls 
Mix 
3.0ul Up to 5.2µl 
Ribominus Probe, 100pmol/ul 0.8µl 0.8µl 
Hybridization buffer with Betaine 20µl 30µl 
Total 23.8µl 36.0µl 
First-cycle, First-Strand Master mix 
Component Volume in 1 Rxn 
5x 1st strand Buffer 2µl 
DTT 1µl 
dNTP Mix, 10mM 0.5µl 
RNase Inhibitor 0.5µl 
SuperScript II 1µl 
Total Volume 5µl 
First-Cycle, Second-Strand cDNA Synthesis 
Component Volume in 1Rxn 
RNase-free Water 4.8µl 
MgCl2, 17.5mM 4.0µl 
dNTP Mix, mM 0.4µl 
DNA Polymerase I 0.6µl 
RNase H 0.2µl 
Total Volume 10µl 
First-Cycle, IVT Master Mix 
Component Volume in 1 Rxn 
10x IVT Buffer 5µl 
IVT NTP Mix 20µl 
IVT Enzyme Mix 5µl 
Total Volume 30µl 
Second-Cycle, cRNA/Random Primers Mix 
Component Volume in 1 Rxn 
cRNA 10ug Variable 
Random Primers (3ug/ul) 1.5µl 
RNase-free water Up to 8µl 
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Total Volume 8µl 
Second-Cycle, First Strand Master Mix 
Component Volume in 1 Rxn 
5x 1st strand Buffer 4µl 
DTT, 0.1mM 2µl 
dNTP+dUTP, 10mM 1.25µl 
SuperScript II 4.75µl 
Total Volume 12µl 
Fragmentation Master Mix 
Component Volume in 1 Rxn 
Single-Stranded DNA 5.5gµ 
10x cDNA Fragmentation Buffer 4.8lµ 
UDG 10U/uL 1lµ 
APE 1, 1000 U/uL 1lµ 
RNase-free Water Up to 48lµ 
Total Volume 48lµ 
Labelling Reaction 
Component Volume in 1 Rxn 
Fragmented Single-Stranded DNA 45lµ 
5x TdT Buffer 12µl 
TdT 2µl 
DNA Labelling Reagent, 5mM 1µl 
Total Volume 60µl 
Hybridisation master mix 
Fragmented and Labelled DNA 60µl 
Control Oligonucleotide B2 3.7µl 
20x Eukaryotic Hybridization Controls 11µl 
Herring Sperm DNA (10mg.ml) 2.2µl 
Acetylated BSA (50mg/ml) 2.2µl 
2x Hybridisation Buffer 110µl 
DMSO 15.4µl 
RNase free Water Upto 220µl 
Total 220µl 
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III. Alternative Transcripts 
Restriction Digestion 
Components Volumes Volumes 
Distilled Water 5.5µl Upto 40µl 
10x Buffer 1µl 4µl 
DNA 3µl 2µg 
Enzyme 0.5µl 1µl 
Total 10µl 40µl 
Ligation Protocol 
Components Volume 
Distilled Water 13µl 
Buffer x10 2µl 
DNA (Insert) 2µl 
Vector 2µl 
Enzyme 1µl 
Total 20µl 
 
Wizard Plus SV Cell Lysis Solution 
0.2M NaOH 
1% SDS 
 
Wizard Plus SV Cell Resuspension Solution 
50mM Tris-HCl (pH 7.5) 
10mM EDTA 
100ug/ml RNase A 
 
Wizard Plus SV Neutralization Solution 
4.09M guanidine hydrochloride 
0.759M potassium acetate 
2.12M glacial acetic acid 
final pH 4.2 
 
Wizard Plus SV Column Wash Solution 
162.8mM potassium acetate 
22.6mM Tris-HCL (pH 7.5) 
0.109mM EDTA (pH 8.0) 
 
Buffer D (Promega) 
6mM Tris-HCl 
6mM MgCl2 
150mM NaCl 
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1mM Dithiothreitol 
pH 7.9 @37C 
 
Buffer H (Promega) 
90mM Tris-HCl 
10mM MgCl2 
50mM NaCl 
pH 7.5 @37C 
 
Buffer 1 (New England Biolabs) 
10mM bis-Tris-Propane-HCl 
10mM MgCl2 
1mM Dithiothreitol 
pH 7.0 @ 25C 
 
Buffer 4 (New England Biolabs) 
50 mM potassium acetate 
20 mM Tris-acetate 
10 mM Magnesium Acetate 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
 
TBE Buffer (x10) 
Tris 107.81 g/l 
EDTA  5.8 g/l 
Boric acid 55.0 g/L 
 
TAE Buffer (x50) 
242g Tris 
57.1 ml acetic acid 
100ml 0.5M EDTA 
made up to 1000ml water 
 
T4 DNA Ligase Buffer (New England Biolabs) 
50 mM Tris-HCl 
10 mM MgCl2 
1 mM ATP 
10 mM Dithiothreitol 
pH 7.5 @ 25°C 
 
TBS-T 
Tris pH 10ml 
NaCl 30ml 
Triton X-100 0.5 ml 
Made up to 500ml 
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Running Buffer 
50ml NuPageR Buffer (x20) 
100ml Methanol 
made upto 1L 
 
Blocking Buffer 
Marvel TM 4% (ie. 2g in 50ml) 
TBS-T 
 
Antibodies for Western Blots 
Goat IgG α-ETO (Santa Cruz Biotech) 
Rabbit IgG α-AML1 (Calbiochem) 
Rabbit IgG GAPDH (Cell Signalling) 
 
Primers 
 
AML EXON 4 CTACCGCAGCCATGAAGAACC 
 
ETO EXON 3 AGAGGAAGGCCCATTGCTGAA 
 
ETO Exon 9a CCATCGATCCTCATATGACCCAGGACAGC 
 
ETO Exon 6a ACTGGACTGGGAATCAAGAGACCTG 
 
Real Time 6a Primer Forward 
 
TGATTCCCAGTCCAGTGCTCTT 
Real Time 6a Primer Reverse  
 
GAGTGCAAAGGCTCTCTGTCAAA 
Primer 6a Probe (Dye FAM, 
Quencher Tamara) 
CACTACACCACAATGCCAGTAAGAACCAAAGA
AAA 
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IV. ChIP-Sequencing  
Lysis Buffer 
Distilled Water 8.3 (for 10ml) 
10%SDS 1ml 
0.5M EDTA 200ul 
1M Tris pH8.0 500ul 
200ul PMSF (1mM) 5ul/ml 
Aprotinin A1153  1ug/ml 1ul/ml 
Leupetin L2884 (1ug/ml) 1ul/ml 
Dilution Buffer 
Distilled Water 18.7 (for 20ml) 
10%SDS 20ul 
Triton X-100 200ul 
0.5M EDTA 80ul 
5M NaCl 600ul 
1M Tris pH 8.0 400ul 
200ul PMSF (1mM) 5ul/ml 
Aprotinin A1153  1ug/ml 1ul/ml 
Leupetin L2884 (1ug/ml) 1ul/ml 
Wash Buffer 1 
Distilled Water 18.72ml (for 20ml) 
10% SDS 200ul 
Triton X100 200ul 
0.5M EDTA 80ul 
5M NaCl 600ul 
1MTris pH 8.0 200ul 
Wash Buffer 2 
Distilled Water 17.32 (for 20ml) 
10% SDS 200ul 
Triton X-100 200ul 
0.5M EDTA 80ul 
5M NaCl 2ml 
1Mtris pH 8.0 200ul 
Wash Buffer 3 
Distilled Water 14.56ml (for 20ml) 
1M LiCl 5ml 
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NP40 200ul 
Deoxycholic acid 200mg 
0.5M EDTA 40ul 
1M Tris pH 8.0 200ul 
 
Elution Buffer  
1% SDS and 1M NaHCO3 (for 10ml solution 0.084g of NaHCO3) 
Antibodies 
Goat IgG α-ETO (Santa Cruz Biotech) 
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Abbreviations 
 
AML Acute Myeloid Leukaemia 
AML1 Acute Myeloid Leukaemia 1 
AMP Adenosine Monophosphate 
AP-1 proximal activator protein 
APE1 apurinic/apyrimidinic endonuclease 
APML Acute Promyelocytic Leukaemia 
BAALC Brain and acute leukaemia cytoplasmic protein 
BCL-2 Break-point Cluster Locus -2 
BCR-ABL Break-Point Cluster-ABL 
BSA Bovine serum albumin 
bHLH Basic Helix-Loop-Helix 
CBFα Core Binding Factor alpha 
CBF Core Binding Factor 
CBFβ Core Binding Factor beta 
CBP/ p300 CREB Binding Protein 
CDK2 Cyclin Dependent Kinase 2 
CDKN1a Cyclin Dependent Kinase inhibitor 1A 
CEBPα CCAAT/enhancer binding protein 
CML Chronic Myeloid Leukaemia 
c-Myb Cellular- myeloblastosis viral oncogene 
CR Complete Remission 
CREB  c-AMP response-element binding 
CT Cycle Threshold 
DABG Detection Abobe Bacground 
DEPC Diethylpyrocarbonate 
dNTPs Deoxynucleotide trisphosphate 
dTTP De-thymidine trisphosphate 
dUTP De-uracil trisphosphate 
DNMT DNA methyltransferase 
DW Distilled Water 
EAP Epstein Barr encoded RNA associated protein 
EAR2 Early Growth Response 2 
EDTA Ethylene diamine tetraacetic acid 
ERG v-ets erythroblastosis virus E26 oncogene like 
ETO Eight Twenty-One 
ETS v-ets erythroblastosis virus E26 oncogene homolog 
EVI1 ecotropic viral integration site 1 
EZH2 Enhancer of zeste homolog 2 
FAB French-American-British 
FCS Fetal Calf Serum 
FDR False Discovery Rate 
FLT3 fms-like tyrosine kinase receptor-3 
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fos FBJ murine osteosarcoma viral oncogene homolog 
GATA1 GATA binding protein 1 
G-CSF Granulocyte Colony Stimulating Factor 
GEP Gene expression profiling 
GFI Growth factor inhibitor 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GPS G protein pathway suppressor 1 
HAT Histone acetyle transferase 
HDAC Histone deacetylase 
HSC Haemopoietic stem cell 
HEB or TCF12 Transcription factor 12 
ICSBP Interferon Consensus Sequence-binding protein 
IgA Immunoglobulin alpha 
IDH Isocitrate dehydrogenase 
IL-3 Interleukin 3 
IR10 coronin, actin binding protein, 2A 
IRES Internal ribosme entry site 
JAK2 Janus Kinase 2 
JNK C-Jun N-terminal kinases 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene  
 homolgue 
LB medium Lysogeny broth 
LEF Lymphoid Enhancer Binding Factor 
MAD Mother against DPP 
MAPK Mitogen activated protein kinase 
M-CSF Macrophage colony-stimulating factor 
MDM murine double minute 
MDS Myelodysplasia 
MDS1 Myelodysplasia syndrome 1 
MDR-1 Mulit drug resistance 1 
MEF Myeloid ELF-1-like factor 
MLL Mixed-Lineage Leukaemia 
miR Micro RNA 
MN1 Meningioma (disrupted in balanced translocation)1 
MPD Myeloproliferative disease 
MPO Myeloperoxidase 
MRC Medical Research Council 
MTG Myeloid transforming gene 
MYND MTG8, Nervy, Deformed 
NCoR Nuclear receptor corepressor 
NF1 Neurofibromaosis type1 
NGF Nerve Growth Factor 
NHR Nervy homology region 
NMTS Nuclear matrix attachment signal 
NPM Nucleophosmin 
NTRK1 Neurotrophic tyrosine kinase, receptor, type 1 
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p53 Protein 53 
PBS Phosphate buffered saline 
PCA Principal Component Analysis 
PDGFR Platelet Derived Growth Factor Receptor 
PEBP2 Polyoma Enhancer Binding Protein 2 
PLIER Probe Logarithmic Intensity Error 
PLZF Promyelocytic leukaemia zinc finger 
RA Retinoic Acid 
RARα Retinoic Acid Receptor alpha 
Rb Retinoblastoma 
RHD Runt homology domain 
RMA Robust Multi-chip Average 
RT Reverse Transcriptase 
RUNX Runt related transcription factor 
SAP SLAM associated protein 
SMAD mothers against DPP homolog 
SMRT Silencing mediator of retinoid and thyroid hormone 
 receptor  
SWOG South-West Oncology Group 
TAE Tris/Acetate/EDTA 
T-ALL T-Lineage Acute Lymphoblastic Leukaemia 
TBE Tris/Borate/EDTA 
TBLI transducin (beta)-like 1 
TBS-T Tris Buffered Saline with Tween-20 
TCR T-cell receptor 
TdT Terminal Deoxynucleotidyl Transferase 
TEL/ETV6 ets variant 6 
TEL-PDGFR TEL-Platelet derived growth factor 
TGF Transforming Growth Factor 
TLE Transducin like enhancer 
Tris tris(hydroxymethyl)aminomethane 
TRKA Tyrosine kinase receptor 
TRPS Trichorhinophylangeal syndrome 
UDG Uracil DNA Glycosylase 
WHO World Health Organisation 
Wnt Wingless-type MMTV integration site family 
WT-1 Wilms Tumor 1 
YAP Yes associated protein 
 
 
 
 
 
 
 
